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General introduction & Outline of the thesis
General Introduction
Vulvar Squamous cell carcinoma and its premalignant lesions
Vulvar squamous cell carcinoma (SCC) accounts for approximately 3-5% of all 
gynaecological malignancies and 1% of all carcinomas in women, with an incidence 
rate of 1-2/100.000.1 In the Netherlands (16 million inhabitants) about 230 new 
patients with vulvar SCC are diagnosed annually.2 Typically, these cancers occur in 
the seventh decade when comorbidity is common. A rise in absolute numbers of 
vulvar SCC is expected because of the proportional increase in the average age of 
the population. Vulvar SCC may spread by three routes. Initial spread occurs usually 
to the inguinofemoral lymph nodes. The number of inguinofemoral lymph node 
métastasés is the most important prognostic factor. Hematogenous spread is rare 
in early stage disease, while spread by direct extension also is infrequent. Surgery 
is first choice in the treatment of patients with SCC of the vulva.3 In the second 
half of the last century overall survival figures rose from 20% to over 60% after the 
introduction of radical vulvectomy with “en bloc” bilateral inguinofemoral and pelvic 
lymphadenectomy instead of simple local excision.*5 The current surgical standard of 
care is the triple incision approach with radical wide local excision (WLE) or complete 
radical vulvectomy with uni- or bilateral inguinofemoral lymphadenectomy. The use 
of the triple incision technique has lowered treatment related morbidity.The sentinel 
lymph node (SLN) procedure is a technique for determining the status of the regional 
lymph nodes with even less treatment-related morbidity. Recently, a large multicenter 
observational study provided level 3 evidence indicating that it appears safe to omit 
inguinofemoral lymphadenectomy in case of a negative SLN.6
There are two different types of vulvar SCC with their own associated premalignant 
lesions (Figure 1). The most common type occurs in elderly women and leads to 
mostly differentiated keratinising SCC, in a background of lichen sclerosus (LS) and 
often differentiated vulvar intraepithelial neoplasia (dVIN).7 There is no association 
with high-risk Human Papillomavirus (HPV) infection. DVIN is underreported, has a 
relatively brief intraepithelial phase before progression to invasive carcinoma, and 
is a difficult histological diagnosis.8;9 The oncogenesis of LS to vulvar SCC and its 
connection with dVIN is not exactly known.
The second type ofvulvar SCC consists of mainly non-keratinising carcinomas, primarily 
affectingyounger women.This type of vulvar SCC is caused by an infection with high- 
risk HPV, predominantly HPV 16 and 18.10 This type of carcinoma is associated with 
warty and/or basaloid VIN. These HPV-associated usual VIN (uVIN) lesions are seen 
adjacent to approximately 30% of the vulvar SCCs. In the processes associated with 
both progression to invasive disease and spontaneous regression of uVIN the immune 
system seems to play an important role.11 Multicentric HPV infections affecting cervix,
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vagina and/or anus have been described; twenty-two percent of uVIN patients has a 
concurrent cervical intra epithelial neoplasia (CIN)12 and up to 71% of uVIN patients 
has a previous, concomitant or subsequent history of vaginal intraepithelial neoplasia 
(VAIN), CIN or cervical carcinoma.13'15 Despite a stable pattern in the incidence of vulvar 
SCC,16;17 the incidence of uVIN and vulvar SCC is increasing in women aged 50 years 
and younger.l6;18'21 This might be due to a higher incidence of HPV infection of the 
genital tract and/or to an increased awareness of uVIN.
Figure i: Two pathways leading to vulvar squam ous cell carcinom a
normal normal
V
usual VIN
V
SCC ^  differentiated VIN
Diagnostics
Biopsy
Vulvar biopsy is the only method to get a histopathological diagnosis when there is 
a vulvar lesion of uncertain significance, or in the presence of persisting symptoms, 
such as vulvar irritation or itching. The optimal biopsy is a punch- or small incision 
biopsy, preferably taken from the edge of the lesion, including a small piece of normal 
tissue (Figure 2). In case of a suspected malignancy, the biopsy should be taken from 
the most suspicious part of the lesion. A punch biopsy will produce a core-shaped 
specimen that is very small, but descendsthrough thefull thickness of the epithelium. 
It can be performed under local, topical anaesthesia. Infiltration anaesthesia, using 
lidocaine 1% (which may be combined with adrenalin), may be preceded by the 
application of EMLA® spray or cream, which contains lidocaine and prilocaine as a 
surface anaesthetic. Disposable punch biopsy devices are available, and a minimal 
size of 4 mm is advisable for a reliable diagnosis.
After taking the biopsy, pressure should be applied to the biopsy site, and when 
necessary for haemostasis, the wound can be closed by one or two approximating
12
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resolvable stitches or by using a silver nitrate stick. When the lesion is multifocal, the 
most divergent lesions should be biopsied to obtain the diagnoses of the entire vulvar 
area. Obtaining the right diagnosis is greatly helped by providing the pathologist with 
a description of the clinical picture and providing a differential diagnosis. When the 
results of a punch biopsy are inconclusive, an incision or excision (especially in unifocal 
lesions that cause symptoms) biopsy can be an attractive alternative. A photograph 
can be taken for consultation with other medical specialties, to note the localisations 
of the biopsies that were taken, and to document changes duringfollow  up.
Figure 2: Taking a punch biopsy.
1.The disposable punch biopsy device should be placed on the edge of the lesion with normal 
tissue. In a gentle, turning motion, the punch should be inserted in the skin.
2. After careful retraction o f the device, the skin core can be cut off, carefully holding it in position 
with a forceps to prevent crush artefacts.
Vulvoscopy
Vulvoscopy consists of careful observation, and the possible use of a 5% acetic acid 
solution on the vulvar area to facilitate examination of the vulva by the colposcope. 
It may result in identification of previously unidentified, subclinical lesions and better 
define the distribution of clinically evident disease.22 After application of acetic acid 
solution clearly demarcated, dense acetowhite areas in the epithelium and abnormal 
vascular patterns, like mosaicism and punctuation (which reflect the underlying 
capillary distribution) can be seen.22 However, acetowhitening has low sensitivity as 
a predictor of HPV infections,23:24 although it can be used to determine the extent of 
the VIN lesion. The use of acetic acid can be very painful. In conclusion, vulvoscopy 
provides limited additional information in the diagnostics of vulvar disease and the 
painful experience make that there is only a limited role for vulvoscopy. Moreover, 
performance of a biopsy remains required to establish the diagnosis.
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Psychology and sexology
The effect of vulvar lesions on quality of life is unmistakable. Many LS patients feel 
embarrassed and have sexual problems.25;26 Some psychological disturbance has 
been noted in surveys of women with LS, but this disturbance is thought to be a 
consequence rather than a cause of the disease.2*28 Patients may be embarrassed 
by the disfiguring changes that may occur and avoid sexual intimacy. Limited data 
that focus on the effect of LS on sexual function are available. A study regarding the 
impact of LS on wom en’s sexual satisfaction showed that women with LS were less 
likely to be sexually active (vaginal intercourse, oral intercourse, and masturbation) 
than controls.29 The majority of women with LS reported dyspareunia, apareunia 
and difficulty achieving orgasms and 71% of the patients with a reduced frequency 
of intercourse experienced an improvement in sexual functioning after treatment 
with topical steroids.30 Introital dyspareunia in patients with LS may be related to 
three different causes; dryness of the vulvar mucosa, posterior synechiae of the labia 
minora and rarely introital stenosis. The dryness can be treated with topical steroids 
and lubricants. The synechiae of the labia minora and the introital stenosis may 
require limited surgical intervention.31
Also the diagnosis VIN can have a great impact on the quality of life. In a review of eight 
studies on the sexual function for patients treated for VIN, only a small number of 
women had chronic vulvar pain after vulvar excision, however the majority of women 
did not return to baseline sexual function.32 The type of surgery significantly correlates 
with the magnitude of sexual difficulties, with greater sexual problems among 
those who underwent radical vulvectomy than among patients treated with wide 
local excision (WLE).33 35 However, in the study of Green et al. the sexual dysfunction 
after vulvectomy did not correlate with the extent of surgery or type of vulvectomy.36 
Not all changes in sexual functioning after cancer treatment automatically lead to 
sexual dysfunctioning. In patients treated for a gynaecological malignancy, sexual 
dysfunctioning depended on personal and social factors, and the context in which 
changes in sexual functioning occurred.37 It is likely that this mechanism can also be 
applied to patients suffering from a vulvar premalignancy.
Most studiesfocussed on surgicallytreated patients; less information is available about 
the initial effect of pain and pruritus, the two main complaints in patients with LS and 
VIN lesions. Sargeant and O’Callaghan report that patients with vulvar pain have a 
significantly worse health-related quality of life in comparison with women without 
vulvar pain. Moreover, women without vulvar pain were significantly happier in their 
relationships than those with pain. In addition, women with vulvar pain reported 
significantly higher levels of distress related to sexual activities. It is important to teach 
a couple to broaden their sexual repertoire, such that intercourse does not become the 
major part of sexual activities. Assisting couples dealing with vulvar conditions may 
lead to an increase in couple happiness and a decrease in sex-related distress.38
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In conclusion, the number of studies regarding sexuality and LS and/or VIN is very 
limited.This important aspect of care for patients with LS and/or VIN deserves clinical 
and scientific attention.
Lichen Sclerosus
History
Over the years, a variety of names and descriptions have been used for the disease that 
is currently named lichen sclerosus (LS). In 1892, Darier was the first to describe the 
histological features of the disease.39:40 Lichen sclerosus et atrophicans has been an 
often used term for a longtim e. In 1975, the removal of'et atrophicans’ was proposed 
by the Terminology Committee of the International Society for the Study of Vulvar 
Disease (ISSVD, later its name was changed to International Society for the Study of 
Vulvovaginal Disease), because not all LS is histologically atrophic.41;42
Epidemiology
LS occurs at all ages, but not in neonates and is rare in the first year of life. It has a 
bimodal peak incidence in prepubertal girls and menopausal women.43 In a study on 
the prevalence of LS in childhood, a prevalence of 1:900 was found.44 The majority 
of patients consists of women aged 50-70 years, while 5-15% of the LS patients are 
children.26 Recently, an increase in incidence in childhood LS was noted in the United 
Kingdom.44 No definite associations with ageat menarche, menopause, first pregnancy 
or sexual intercourse, number of sexual partners, number of pregnancies, education, 
smoking habits, Body Mass Index (BMI), hysterectomy, or use of oral contraceptives 
or hormone-replacement therapy have been found.40;45 However, the symptoms of 
LS can be modified by hormonal events in some wom en.46 The female to male-ratio 
is 6 :i- io : i,3940 and most reports have been on Caucasians. In young girls, the signs 
and symptoms of LS are sometimes mistaken for sexual abuse.47 However, childhood 
LS and sexual abuse are not m utually exclusive diagnoses.48 In a series of 42 cases of 
childhood LS, in 12 cases there was evidence of sexual abuse.49
The true incidence of LS is unknown and difficult to establish as the care of patients 
is fragmented: specialties treating LS include dermatology, gynaecology, urology, 
geriatrics, fam ily medicine and paediatrics, depending on the location of the disease 
and the patient’s age and the responsiveness to therapy. Furthermore, patients 
can feel embarrassed or frightened and not visit any doctor or have LS that runs 
an asymptomatic course.26;5° No recent studies of the incidence of LS in the general
15
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population are available. In 1971, Wallace calculated incidences of 1:300 to 1:1000 in 
new patients, referred to a general hospital.51 Only a limited number of studies report 
on the prevalence or incidence of LS in specific groups of patients. Among women with 
chronic vulvar symptoms 7-13% suffered from LS.52;53The rate of biopsy proven vulvar LS 
in one general gynaecology private practice was approximately 1.7% (1 in 60 women).43 
One study suggests that 1 in 30 elderly women (nursery home population) have LS.54
Aetiology
Based upon epidemiologic data, a number of mechanisms have been proposed 
to explain the cause and development of LS. As the highest incidence of LS is 
observed in patients with low oestrogen physiological states (prepubertal girls and 
postmenopausal women), hormonal factors have been suggested as a cause for 
LS. Friedrich and Kalra have shown apparent underlying abnormalities in androgen 
metabolism (defect in 5-alpha-reductase) in women with LS.27 However, neither 
oestrogens nor testosterone bring benefit in terms of treatment of symptoms or 
prophylaxis of the disease.2*55
There is a strong association of LS with autoimmune disorders. Between 21.5 and 34% 
of all patients have an autoimmune disease and up to 74% are found to have auto­
antibodies.56'58 Alopecia areata and vitiligo werethe most common associated disorders, 
but thyroid disease, pernicious anaemia, diabetes mellitus, and cicatrical pemphigoid 
were also reported.26;56;57;59 Nevertheless, no statistically significant differences in the 
natural history of LS were noticed between those patients with autoimmune disorders 
and those without associated autoimmune disorders.55 In patients with LS, the family 
history for autoimmune disease is often positive.60 There is no evidence that screening 
for autoimmune disorders in LS patients is beneficial.61 However, thorough history 
taking is important and when there are signs and symptoms of concurrent disease, 
appropriate tests should be ordered. Immunogenetic studies have demonstrated a 
significant association with HLA class II antigens, particularly DQ7.26;62This association 
was strongest in the patients with early-onset LS.60 Most HLA class 11-related diseases 
(rheumatoid arthritis, lupus erythematosus) have an immunologic basis. This 
suggested immunogenetic profile may be one of many presumed factors involved in 
LS development, extent, and risk of malignancy.62 The frequency of one of the alleles 
of the interleukini receptor antagonist (IL-1RN) gene is related to increasing disease 
severity. Thus, IL-1RN may be a candidate gene or severity factor for LS or may possibly 
be a linked marker to another, as yet undefined, gene.63 Studies by Carli et al. give 
support to the involvement of the skin immune system in pathogenesis of LS.64;65 
A genetic influence favouring LS can be derived from familial LS reports.26;55 LS has 
been reported in identical and non-identical twins,5*59 sisters, and mothers and 
daughters.60 However, no consistent genetic pattern has been determined and the 
number of case reports of familial LS is limited.
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Several infectious agents have been postulated to induce LS, but such a relationship has 
not been conclusively demonstrated.66 LS shares several clinical and histological signs 
with morphea and acrodermatitis chronica atrophicans (ACA), which both have been 
associated with Borrelia burgdorferi. Borrelia has been identified in samples of LS by 
modified silver stain,6?and using immunoperoxidase methods.68 However, polymerase 
chain reaction (PCR) assessment has yielded conflicting results, summed up by Weide 
et al.69 In Europe and Asia, borrelial DNA was detected in nine of 28 of the cases 
with LS, whereas in the United States (US) none of 48 patients was positive. Possible 
explanations are that a subset of LS is caused by a special subspecies of B. burgdorferi 
that is present in Europe and Asia but does not occur in the US, or that B. burgdorferi 
is no causal inducer of LS. Also technical differences of the detection methods might 
contribute to the difference. In some LS lesions however, B. burgdorferi might very 
well play a role as an observational study by Shelly et al. showed positive effects of 
penicillin and cephalosporin therapy on patients with LS who had responded poorly 
to treatment with potent topical corticosteroids. All patients (n=i3,four men and nine 
women) showed a significant response, evident w ithin a few weeks.70 A small study of 
only four LS patients, suggested an aetiological role of Mycobacterium because of the 
finding of acid-fast bacteria in all skin biopsies.71 Furthermore, hepatitis C (HCV) has 
been suggested because of a case-report of LS associated with chronic hepatitis C and 
the suspected but non-proven association of HCV with lichen (ruber) planus.72 
No relationship between HPV infection and LS was found in wom en55 but has been 
shown in men.7375 In a study of 23 boys (4-14 years) with penile LS, HPV-DNA was 
detected with PCR in 70%,76 although it is not clear whether there is a causal relation 
between LSand HPV. Powell et a I. compared genital carriage of HPV DNA in prepubertal 
girls with and without vulvar disease and concluded that HPVappeared to be common 
in all pre-pubertal girls, but children with LS more often carried high-risk HPV types 
and their mothers had a high incidence of abnormal cervical smears.77 
In the itch-scratch-lichen sclerosus hypothesis, LS is postulated to occur as a Köbner 
phenomenon (the occurrence of LS lesions at sites of injured skin) in women with the 
susceptible immuno-phenotype who scratch because of genital irritants/*79 Whimster 
showed that healthy skin grafted onto the vulva became affected by LS and a fu ll­
thickness graft from diseased vulva transplanted onto the thigh became normal.26This 
suggests that local dermal factors may facilitate disease expression. This hypothesis 
is supported by a recent study that showed that the use of moisturizer on LS-affected 
vulvar skin helps to prevent relapse after use of dermatocorticosteroids.80 In childhood 
LS, it has been postulated that sexual abuse could trigger LS as a Köbner effect.81
In conclusion, no cause for LS has been found. Careful history ta king remains important 
and further research is needed. When the aetiology is clarified, more specialised and 
targeted therapies can be developed and prevention might be possible.
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Histology
The classical histological features of LS include a thinned epidermis with loss of normal 
rete pegs, basal layer vacuolar changes, and paucity of melanocytes.82 Furthermore, a 
wide band of homogenised collagen belowthe dermo-epidermal junction and a band­
like lymphocytic infiltrate belowthe homogenised area are present.The dermis shows 
variable degrees of oedema.25;43;55 Oedema is a stage of LS. After oedema, hyalinisation 
and fibrosis can occur. In severe cases the subepithelial vacuolar change may progress 
to the formation of bullae.82 A certain degree of spongiosis and vacuolar degeneration 
may exist in the cells of the deepest layer. Hyperkeratosis and follicular plugging are 
highly variable, but may be marked.82 An example of the typical histology of LS can be 
found in Figure 3A.
In a recent 'Clinical Opinion’ by Jones et al., it was suggested that it should be the role 
of the pathologist to firstly diagnose LS, then place it into one of the following three 
categories: atrophic (classic) LS, LS with histological evidence of epidermal thickening, 
and LS with dVIN.83
Recently, Regauer et al. have introduced a hypothesis describing early LS as a separate 
entity. The histological features that they describe as belonging to early LS are quite 
subtle, and often more prominent in the adnexal structures than in interfollicular skin. 
Biopsy specimens of early LS rarely display all features that they describe as typical for 
early LS.84 So far, no studies following this concept have been described, and up till 
now there has been little debate about the concept of early LS.85 Regauer’s criteria 
have not gained any acceptance and have no pathogenetic basis.
Clinical characteristics
LS runs a relapsing and remitting course and there is a poor correlation between the 
extent of the clinical signs and the symptoms.50 At least one third of patients may 
be asymptomatic.43 Complications, most often encountered in severe cases of LS, are 
secondary infection, adhesion of the clitoral hood with formation of a smegmatic 
pseudocyst and narrowing of the introitus, which can make intercourse impossible 
and micturition difficult.40
Next to the genital form of LS, in 11-20% of the patients, extra-genital manifestation of 
the disease is present.86;87Thesecan be found on the trunk and neck, upper legs, a round 
the wrists and on the head. Extragenital LS consists of white papules and atrophic 
maculae. Sporadically, an oral form of LS, without genital or cutaneous manifestations, 
is described, which consists of asymptomatic white macular lesions.88;89 Most extra­
genital manifestations of LS are asymptomatic, however some rare cases of severe 
itching of the scalp have been described.86
18
General introduction & Outline of the thesis
Because other dermatoses, such as lichen (ruber) planus, vitiligo, psoriasis inversa and 
oestrogen deficiency, can mimic LS, the diagnosis in adult patients should preferably 
be confirmed with a punch biopsy,25:55 performed as described earlier.
Signs
Typically, the lesions are white plaques and papules, often with areas of erythema, 
ecchymosis, hyperkeratosis, pallor, fissuring, telangiectasia, hyperpigmentation, 
bullae, excoriation, oedema and/or ulceration.The signs can vary from subtle (Figure 
4A) to very extensive (Figure 4B). In advanced LS, often there is destruction of vulvar 
architecture, w ith scarring of the clitoral prepuce, resorption of the labia minora and 
narrowing of the introitus.43 Typica I ly, there is a figure of eight-pattern in the genital 
area, as can be seen in Figure 4B. The labia minora and majora are most frequently 
affected, but the entire vulva, perineum and peri-anal area can be affected.22 In 
contrast with lichen (ruber) planus, in LS, the vaginal mucosa is usually unaffected, 
however incidental cases of vaginal LS have been reported.90 In an extensive study 
by Cooper et al., pallor and atrophy (wrinkled skin and textural change) were the 
most frequent findings in both adults and children (in 89% and 62% of patients, 
respectively). Erythema, atrophy, pallor, hyperkeratosis, and ulceration were all 
significantly more frequent in wom en but purpura was more frequent in children 
(p=o.ooi)87. An exam ple of prepubertal LS can be seen in Figure 4C.
Symptoms
Presenting symptoms of LS may include intense pruritus, soreness, pain, burning, 
dyspareunia, dryness, irritation, urinary complaints, constipation/bowel pain, 
bleedingand blistering. Painful skin fissures can occurwith or after sexual intercourse 
and defecation. Anogenital pruritus and soreness are the most frequently reported 
symptoms in both women and children. Prepubertal girls usually present with soreness 
or itching of the vulva, constipation or dysuria. The signs of LS in young girls may be 
confused with those of sexual abuse, especially because of local bleeding.40;44;87 As 
described earlier, LS and sexual abuse may coexist.
Treatment
In general, LS has no cure in adults, and lifelong treatment is required. However in 
some cases, especially prepubertal girls, LS can spontaneously resolve.2591 The reasons 
for treating LS are alleviating and m inimising symptoms and the possible prevention 
of architectural changes.25;50;8491 It is not known whether successful control of the 
disease reduces the long-term risk of malignancy,92 although a protective effect from 
malignant evolution is suggested.91
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Figure 3: Histological pictures o f lichen sclerosus, differentiated VIN, usual VIN and vulvar 
squam ous cell carcinom a.
A. In lichen sclerosus the epithelium is thinned and w ithout atypia. There is loss of rete ridges, 
a homogenous, hyalinised zone of oedema beneath the basement membrane and a bandlike 
infiltrate o f lymphocytes.
B. H&E stained slides of a differentiated VIN lesion (adjacent to squamous cell carcinoma). Nu­
clear atypia and the presence of mitotic figures in differentiated VIN are confined to the basal 
cell layers. Hyperkeratosis and dyskeratosis are present and the rete ridges are elongated.
C. H&E stained slide of a usual VIN lesion w ithout adjacent squamous cell carcinoma; atypical 
nuclei can be found throughout the entire epithelium.
D. Invasive nests o f vulvar squamous cell carcinoma (adjacent to differentiated VIN).
Figure 4: Clinical picture o f different patients w ith lichen sclerosus.
A. LS in a pre-menopausal woman showing subtle loss o f architecture and erythema.
B. Advanced stage LS in a postmenopausal woman, showing the typical ‘figure o f eight”.
C. Lichen sclerosus in a prepubertal girl.
20
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Surgery
The role of surgery for the treatment of LS is limited in the absence of dVIN or 
malignancy.25;50;93 Surgical options include vulvectomy (with or without a skin graft), 
laser ablation and cryosurgery.There is a high recurrence rate in patients with LS who 
have been treated with surgery, even iffulI thickness skin grafts have been placed.25;50;93 
Next to architectural changes due to surgery, scarring can cause additional anatomical 
changes.Therefore, surgical treatment of LS should be used as a last resort to release a 
buried clitoris, to separate fused labia or to widen a narrowed introitus. Perineoplasty 
can provide good functional results for women with introital stenosis related to LS.31 
Vaginal dilation and corticosteroids may be necessary after operation.
Medical treatment
Dermatocorticosteroids
The treatment with the best evidence of efficacy is topical ultrapotent corticosteroid 
ointment. Corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictor 
effects. Various studies show good clinical response and histological improvement 
with the use of these drugs.50;S7;91;92 The use of ultrapotent topical steroids for LS has 
now become accepted for fist-line management of LS in both children and adults. 
Recent British Association of Dermatologists (BAD) (www.bad.org.uk) guidelines 
advocate their use, and give specific guidance on length of initial treatment and on 
maintenance treatment. There have been no randomised controlled trials on the 
efficacy of corticosteroids, but evidence for efficacy comes from several small case 
series.9496 Ultrapotent topical steroids can reverse some of the histological changes 
caused by LS,849497 however there is no convincing evidence that the treatment of LS 
influences its prognosis. Cooper et al. investigated the reversibility of clinical signs 
with treatment. They stated that in some patients no signs of LS were present at 
follow-up, but there is no information on the recurrence rates after use of ultra-potent 
steroids was stopped.87
There is no universally accepted treatment schedule. In general, short-term use of an 
ultrapotent corticosteroid is followed by less frequent use of the high-potency steroid 
(or long-term use of a lower potency topical steroid).Thickened hypertrophic plaques 
may respond better to intralesional steroids, which can be given in combination with 
prilocaine.98 The side effects of topical corticosteroids are burning, irritation, dryness, 
flaking, maceration, hypopigmentation, and dermal atrophy. Maintenance therapy is 
often advised, as symptoms can recur in women who terminate therapy.50;92 Long­
term maintenance therapy of vulvar LS with a moisturising cream can maintain 
the symptom relief induced by topical corticosteroids.80 However, this study was 
performed as an open trial without the use of a control group that did not use a 
moisturizer.
21
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Testosterone
Some reports have noted that patients with LS have decreased serum levels of 
testosterone compared to age-matched controls without the disease.27 Topical 
treatment with testosterone has been used and controversy exists about its 
effectiveness." Topical testosterone can cause virilisation (clitoral enlargement, voice 
alterations), especially in hyperandrogenic women.100 In a prospective, randomised, 
double-blind evaluation of 58 cases of vulvar LS, 2% testosterone propionate 
was as effective as petrolatum101 and in several studies it was less effective than 
clobestasol.102;103 Numerous studies emphasise a lack of efficacy and report severe 
side effects of testosterone; therefore testosterone is considered to be obsolete 
nowadays.25;40;50;100
Retinoids
Retinoids are vitamins, because retinol (vitamin A) is not synthesised in the body and 
must be derived from diet. Retinoids are also considered hormones because retinol 
is transformed into molecules that bind to nuclear receptors, exhibit their activity, 
and are subsequently inactivated.Topical retinoids normalise hyperkeratinisation and 
have demonstrated significant anti-inflammatory effects. Skin diseases like psoriasis 
and related disorders, congenital disorders of kératinisation, acne, photo-aging and 
hypovitaminosis A are approved indications of retinoid treatment.104 
Retinoids appear to reduce connective tissue degeneration in LS. Although orally 
administered retinoids showed good results, use of these drugs is limited because of 
significant and potentially harmful side effects such as cheilitis, xerosis, teratogenicity, 
elevated liver enzymes, hypertriglyceridemia, abdominal pain, and alopecia.Therefore, 
retinoids should be saved for severe LS cases that are non-responsive to corticosteroid 
treatment, and consultation with a dermatologist is recommended before initiating 
therapy.2550
Tacrolimus /  pimecrolimus
Tacrolimus and pimecrolimus have an anti-inflammatory and immunomodulating 
effect and were first introduced as a new second-line treatment for atopic dermatitis. 
The main side effects are local sensation of heat and burning and therefore it is 
often discontinued by patients.55105 New research has been published on the use of 
tacrolimus and pimecrolimus for LS and reported to be successful.105 No long-term 
effects of tacrolimus and pimecrolimus use in LS patients have been investigated and 
described yet. Although tacrolimus is not genotoxic and does not interact directly 
with DNA.it may have a potential to impair local im munosurveillance. Carcinogenicity 
studies conducted with topical application of tacrolimus in mice demonstrated a 
dose-dependent development of lymphoma. At the Food and Drug Administration 
(FDA), 19 cases of tacrolimus (Protopic)-related malignancies have been reported, 
including nine lymphomas, 10 cutaneous tumours, seven of which occurred at the 
site of tacrolimus application, as well as cases of SCC, cutaneous sarcoma, malignant 
melanoma and other tum our types.Therefore the use of tacrolimus should be limited 
and preferably conducted in a well-designed study.
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Other
Various other (experimental) treatments for LS have been summed up in recent 
review articles: antimalarial agents, oral potassium para-aminobenzoate, calcipotriol, 
oxitomide and photodynamic therapy using aminolevulinic acid. However, the 
number of cases in these studies is limited and the results are inconclusive.26;50;55;105
Supportive care
Correlated complaints of LS should also be treated.Topical oestrogen is recommended 
for vaginal atrophy. In secondary infections, antibacterial- or antifungal therapy 
may be needed. Vulvodynia may be treated with xylocaine 5% (or 3%) ointment and 
antidepressants are a treatment option in unresponsive cases.2540 Nocturnal itching 
can be relieved with antihistamines like hydroxyzine hydrochloride (10-40 mg A.N.); 
the sedative effect contributes to its usefulness to relieve pruritus.
In general, and especially in patients with LS, vulvar care and hygiene is important: 
use lipid-rich neutral creams (e.g., cremor lanette) to soften the skin, no or only 
neutral soap, cotton underwear, no panty liners and scratching should be avoided. 
The use of lubricants to facilitate sexual intercourse is recommended.92 Recently, the 
results of a prospective non-randomised trial were published, showing that long­
term maintenance therapy of vulvar LS with a moisturising cream can maintain 
the symptom relief induced by topical corticosteroids.80 Written information and 
information about support groups should be offered.92
Malignant potential
There are different reasons to link LS to the development of vulvar SCC.106 First, the 
majority of vulvar SCCs has LS, squamous cell hyperplasia or dVIN in the adjacent 
epithelium. In up to 62% of cases of SCC of the vulva, LS can be found in adjacent 
areas.10*108 Furthermore, as reported in multiple case reports, patients (old and young) 
with LS may develop vulvar SCC. Third, in series of LS patients that underwent long­
time follow-up, 2-6% has been reported to develop vulvar SCC.1o8;1°9 A protective effect 
from symptom control is suspected but has not been proven.87 Neither the presence 
nor duration of symptoms nor the loss of vulvar architecture is a useful indicator of 
malignant potential in LS.87
There is an impression that itch and scratch damage (related to the duration of 
symptoms), is associated with the risk of developing vulvar SCC.78 Chronic inflammation 
seems to play an important role, but the exact pathogenesis of progression to 
malignancy has not yet been established.55 The immunogenetic profile may also 
determine (part of) the risk of malignant disease.40
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Extra-genital LS is not associated with malignancy,55 and could prove to be an 
interesting control group in the search for factors that determine the risk of 
malignant transformation in vulvar LS. Furthermore, the exact mechanism of 
malignant progression rem ainsto be elucidated.dVIN isth e possible precursor lesion 
of HPV-negative SCC but the exact pathogenesis from LS to dVIN and a subsequent 
SCC is unknown. Some authors claim a role for squamous cell hyperplasia as a next 
stage after LS in the development of HPV-negative vulvar SCC but the exact pathway 
rem ainsto be elucidated.110 Recently, high p53-expression in LS has been postulated as 
a marker for increased likelihood to progress to vulvar SCC.111;112
Differentiated Vulvar Intraepithelial Neoplasia
History
dVIN was first described in the 1960s by Abell as a highly differentiated form of vulvar 
carcinoma in situ (CIS) and designated 'intraepithelial carcinoma of simplex type’ 
to distinguish it from 'intraepithelial carcinoma of Bowen’s type’ (which nowadays 
would be called uVIN). In 1977, the term 'differentiated’was introduced to highlight the 
marked differentiated morphologic features of this entity.7 In the subsequent ISSVD 
revisions of the classification that followed, 'VIN III, severe dysplasia, differentiated 
type’ was replaced by the current term 'VIN, differentiated type’. The nomenclature of 
the WHO spoke of'carcinoma in situ (simplex type) (VIN 3)’.
Epidemiology
dVIN accounts for a small proportion (<2-5%) of all VIN lesions compared with the 
usual type.15;113 Because of a difficult clinical and histological diagnosis there probably 
is a considerable underdiagnosis. dVIN characteristically occurs in postmenopausal 
women (mean age 67 years) and is associated with LS.7 As dVIN is seldom found in an 
isolated form, some authors believe it is actually part of the adjacent vulvar SCC.114 In 
cases where dVIN is found without any sign of invasion, often the patient has been 
previously treated for vulvar SCC, and also suffers from LS,115 however also isolated 
dVIN lesions can occur in patients without a history of vulvar SCC. Isolated dVIN is 
believed to have high malignant potential. Unlike uVIN, dVIN is mostly unicentric.116
Aetiology
HPV is very uncommon in dVIN and does not play an important role in its genesis.11*116'118 
The aetiology of dVIN remains to be elucidated. Because of its high concurrence with 
LS, a causative role for LS is likely but also other factors might play a role. Squamous
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cell hyperplasia has a close relationship to dVIN. However, it is still unclear whether it 
is a direct precursor of invasive vulvar SCC.116 Squamous cell hyperplasia with atypia 
might represent a step in the carcinogenesis.119 Some have suggested a role for P53- 
alterations but a study by Regauer et al. suggested that p53-expression in LS is a sign 
of ischemic stress rather than a sign of dVIN.114
Figure 5: Clinical pictures o f differentiated VIN.
A. Differentiated VIN arising in a background o f LS.An incision biopsy was taken at the site o f the 
ellipse and showed differentiated VIN. Histological exam ination o f the excision of the entire 
lesion revealed vulvar squamous cell carcinoma, with a depth of invasion o f more than 1 mm.
B. Differentiated VIN in a patient w ho was treated by multiple excisions and a vulvectom y with 
plastic surgery because of therapy resistant lichen sclerosus.
C.The red lesion within the dotted line did not improve upon dermatocorticosteroid application 
and was removed by excision al biopsy. The histology showed differentiated VIN.
D. A close-up of the differentiated VIN lesion.
Histology
Histologically, dVIN is a more subtle lesion than uVIN and can be mistaken easily for a 
benign dermatosis or epithelial hyperplasia.The recognition of dVIN is hindered by a high 
degree of cellular differentiation combined with an absence of widespread architectural 
disarray, nuclear pleomorphism and diffuse nuclear atypia.7The atypia in dVIN lesions is 
strictly confined to the basal and parabasal layers of the epithelium, where the cells have 
abundant cytoplasm and form abortive pearls.*22 Scattered mitotic figures are common 
in the basal areas, but can extend into the upper levels of the epidermis.116 Typically, the 
epidermis isthickened and has a parakeratotic surface reaction.7The nuclei are relatively 
uniform in size and contain coarse chromatin and prominent nucleoli leading to 
paradoxical maturation abutting on the epithelial-stromal junction.The superficial layers 
ofthe epithelium have normal maturation and do not show koilocytosis. Furthermore, in 
dVIN the epithelium exhibits elongation of rete pegs.22;113;116 Intercellular bridges typically 
are very prominent, probably as a result of loss of cohesion between cells rather than 
spongiosis.7 dVIN is characterised by an increased amount of eosinophilic cytoplasm in 
dysplastic cells immediately above the basal cell layer. This is indicative of premature
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differentiation or kératinisation. At low power,the epithelium looks eosinophilic because 
of the large amount of intracytoplasmic keratin. These abnormal keratinocytes are the 
hallmark of dVIN.At higher power, nuclear changes of enlargement, pleomorphism, and 
hyperchromatism and mitoses are present.7;22;115 In the underlying or adjacent papillary 
dermis, a chronic inflammatory cell infiltrate, consisting of predominantly lymphocytes, 
plasma cells, and occasionally eosinophils, is present7 (Figure 3B).
When dVIN invadesthe dermis, nodules of enlarged eosinophilic keratinocytes appear 
to fall from the basilar epidermis orfrom  elongated rete ridges. In superficial biopsies, 
the distinction of dVIN from early invasive vulvar squamous cell carcinoma may be 
difficult.7 Immunostaining for P53 may be of value in identifying dVIN in difficult 
cases. The p53-labeling-index (Ll) of the basal cell layer in dVIN is often >90%, and P53- 
positive cells extend above the basal cell layer (suprabasilar extension) into higher 
levels of the epidermis.116
Clinical characteristics
Symptoms
Patients are, due to the underlying LS, often symptomatic with a long-lasting history 
of itching and other LS-related symptoms.116
Signs
dVIN is infrequently seen as a solitary lesion, and is more commonly identified 
adjacent to LS and/or invasive SCC. However, also a patient with dVIN that developed 
vulvar SCC without presence of LS has been described.120
It can present as an area of grey-white discoloration with a roughened surface (Figure 
5A), an ulcerative red lesion (Figure 5B), an erythematous red lesion (Figure 5C and 
D), or as an ill-defined raised white plaque. It may be difficult to distinguish from the 
often-present background of LS.116 In general, dVIN is believed to produce less bulky 
lesions than uVIN does. Yang and Hart described a series of 12 patients with lesions 
varying from 0.5-3.5 cm in greatest dimension.116
Treatment
dVIN generally requires a more extensive surgical approach than uVIN, and as dVIN 
often is unifocal, radical surgical excision is the preferred treatment. dVIN is usually 
confined to non hair-bearing areas or the external sides of atrophic labia minora, 
where vulvar reconstruction is feasible. Recurrent lesions are common and so far, 
there is no place for medical therapy.113 Follow-up of patients previously treated for 
dVIN should occur at a specialised vulvar clinic or by a vulvar specialist (a consultant 
dermatologist or gynaecologist who has had additional and educated training in 
managing vulvar disease).83
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Malignant potential
dVIN is associated with the development of keratinising SCC.113;116 The exact pathway 
of carcinogenesis has not yet been established. It is suggested that dVIN is highly 
proliferative and might be more likely to progress to an invasive SCC than LS and 
uVIN.1l6;120;121 The observation that most SCCs are dVIN-related and most VIN lesions 
without concurrent invasion are of the usual type, combined with the frequent find­
ing of dVIN adjacent to rapidly growing invasive vulvar SCC, reinforces this presump­
tion.116 Therefore, any suspicious area should be biopsied.113;116
Usual Vulvar Intraepithelial Neoplasia
History
Historically, various terms have been used to define vulvar SCC precursors. In 1912, 
Bowen described 'squamous intraepithelial lesions’ (also referred to as Bowen’s 
disease) and since then a myriad of clinical and histopathological terms have been 
employed to describe what is currently known as uVIN.113 The first series of Bowen’s 
disease of the vulva was described in 1943 by Knight et al.122 In 1965, Kaufman 
separated non-neoplastic from neoplastic vulvar lesions. He divided the precancerous 
lesions into three groups: Oueyrat’s erythroplasia, Bowenoid carcinoma in situ, and 
carcinoma simplex.113 In 1976, the ISSVD simplified the terminology: carcinoma in situ 
and vulvar atypia were replaced by Vulvar Intraepithelial Neoplasia (VIN).113 The term 
VIN first appeared in literature in 1980.
ISSVD classification
The old three-grade system of the ISSVD made a subdivision between the lesions 
according to the amount of epithelium involved by dysplasia, sim ilar to CIN lesions. 
In VIN 1 the maturation is present in the upper two-thirds of the epithelium, and the 
superficial cells contain variable but usually mild dysplasia. In VIN 2 the dysplasia 
involves the lower two-third of the epithelium, and in VIN 3 the dysplasia extends 
into the upper third of the epithelium, but not involving the full thickness.2*123 When 
the entire epithelium is involved, the lesion is classified as carcinoma in situ, which 
is gathered in VIN 3. In 2003, the ISSVD decided to abolish the three grade system 
of VIN because clinicopathological data did not appear to support the concept of a 
continuum spectrum of VIN lesions leading to vulvar carcinoma, that does exist for 
CIN and cervical carcinoma.9™ The abandonment of VIN 1 and the consolidation of 
VIN 2 and 3 into one category simply termed (high-grade) VIN, best fitted the studies 
that have been performed on grading of VIN so far.9 In Table 1 an overview o f'o ld ’
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and 'new ’ nomenclature is given. VIN as a single diagnostic category included two 
different vulvar premalignancies that have a different malignant potential.113 In the 
light of the two different types of vulvar carcinoma the VIN terminology has been 
further modified by the ISSVD, and a 2-tier classification has been suggested: VIN 
usual type and VIN differentiated type.9;124 uVIN has been divided into basaloid and 
warty subtypes.The w arty subtype was earlier described as Bowen’s disease. Basaloid 
VIN occurs in an older age group, is more likely to become invasive and less likely to 
regress.These two subtypes may be seen in a single VIN lesion and cases with mixed 
features are common.124 Both subtypes are associated with high-risk HPV types, 
especially HPV 16, often occur as multicentric genital tract neoplasia and should 
be considered as premalignant lesions.113 In clinical practice, no difference is made 
between the two uVIN lesions.
Table i: O verview  of the old and new  nom enclature of VIN lesions.
Old nom enclature New nom enclature9
V IN i no cancer precursor
, . . . . . . . .  w artyVIN
(claSSIc)VIN2/3 basaloid VIN
usual VIN (uVIN) 
 
 
mixed (warty-basaloid)
(wel ^ differentiated VIN 3 /  VIN sim plex differentiated VIN (dVIN)
Bethesda classification
Many gynaecologists and some pathologists have suggested analogous terms 
of high-and low-grade changes of the vulva as also exist for CIN lesions. In 2005, 
Medeiros et al proposed a Bethesda-like grading system of low and high-grade vulvar 
intraepithelial lesions: low grade vulvar intraepithelial lesions (LGVILS) and high grade 
vulvar intraepithelial lesions (HGVILS).118 When a Bethesda like system is applied to 
vulvar histopathology, by far most frequent lesions fitting into the LGVILS category 
are condylomata acuminata, which carry a negligible risk for malignant progression 
and require nofo llow up .lt seems inappropriate and un necessary that such lesions are 
placed in a new category of vulvar premalignant lesions.124 In our opinion a Bethesda- 
like grading system is not sufficient because no distinction is made between uVIN 
and dVIN. Because of the extensive differences in clinicopathological behaviour and 
malignant potential between uVIN and dVIN lesions,w efavourthe above-mentioned 
ISSVD classification.
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Epidemiology
The incidence of u VIN is approximately five per 100.000 women peryear and increasing 
worldwide.125 In several countries the age-adjusted incidence rates have surpassed the 
incidence rate of invasive vu lvarcarcinoma.l6;19;126;127 uVIN has a predilection for relatively 
young women, often in their 30s and 40s. Cigarette smoking is reported in about 60- 
80% of the cases.Condylomata.a history of genital herpes, and infection with Human 
Immunodefiency Virus (HIV) are particularly common in young women with uVIN.7 
Moreover, the use of immunosuppressants to prevent rejection after transplantation 
or to treat a chronic autoimmune disease increases the risk of developing uVIN. 
The increase in incidence of uVIN lesions is in concordance with the increase in HPV 
prevalence. Despite the increase in uVIN, no increase in the overall incidence of SCC of 
the vulva w asfound.l6;17 In young women an increase in SCC incidence is seen, possibly 
due to the younger age of first sexual intercourse and the increasing incidence of HPV 
infections.l6;l8'21;127 The increase of uVIN without a clear increase of vulvar carcinoma 
may have different reasons. The main reason is the more liberal use of vulvar biopsy, 
which contributed to earlier diagnosis of VIN lesions that might have been missed 
in the past. This earlier diagnosis and treatment of VIN may prevent the ultimate 
development of invasive SCC. Moreover, the malignant progression is estimated to be 
<10%, so only a limited number of uVIN lesions progress to invasive vulvar SCC.128
Aetiology
In the 1970s, zur Hausen first proposed the hypothesis that HPV, and not herpes simplex 
as previously thought, was the most likely aetiological agent for the development of 
cervical carcinoma.129;13° From laboratory studies as well as epidemiological studies it 
became clear that HPV plays a major role in the aetiology of not only CIN and cervical 
carcinoma, but of all squamous anogenital cancers (vulvar, vaginal and anal SCC).122 In 
1982, detection of HPV DNA in VIN was described for the first time.131 Only high-risk 
HPV (hr-HPV) subtypes, mainly HPV 16 and 18, are able to induce uVIN or vulvar SCC. 
The mean HPV positivity in VIN lesions is 85% (calculated from nine studies,14:15:132138 
see Table 2), and in the largest study 100% HPV positivity has been shown.14 It is 
important to know which type of VIN (uVIN or dVIN) is subject of study, which DNA 
detection method has been used and which HPVtypes are determined.The difference 
in HPV positivity between u- and dVIN is illustrated by Table 2. A possible explanation 
for the higher percentage of HPV in VIN comparable to SCC of the vulva (about 30%) 
is that SCC can have developed in both LS and dVIN as well as in uVIN.
The immune system seems to play an important role in clearance and persistence 
of the HPV infection and development of uVIN. Women infected with HIV are 
approxim atelyfourtim es more likelyto be infected with HPV.The prevalence of uVIN 
in HIV infected women was reported to range from 0,5 to 37%.139 Also women who use 
immunosuppressants to prevent rejection after transplantation, had a 10 to 30 fold
29
Chapter i
risk of cancer of the vulva, mainly caused by HPV 16 and 18, that are found at a higher 
rate in transplant patients compared with immunocompetent women.140142
Table 2: HPV positivity in VIN lesions
Study Num ber VIN lesions Test
Percentage 
HPV positive
Hoevenaars, 2008133
45 uVIN 84%
75 dVIN 0%
Van Beurden, 199515
47 x  uVIN
92%**
1 x dVIN
Hampl, 200614 183 VIN HPV 92%
Hillemanns, 2006132 30 VIN HPV 80%
H 0rd ing,igg i134 19 VIN HPV 6,11,16,18,33 79%
Lerma, 1999135
12 uVIN 
6 dVIN
HPV
HPV
42%
0%
Rufforny, 2005136 24 VIN HPV 16 79%
Ska pa, 2007137
82 uVIN HPV 99%
12 dVIN HPV 8%
Srodon, 2006138 34 VIN Hr HPV 100%
Total 186 uVIN 
290 VIN*** 
93 dVIN
89.9% 
89.8% 
1.0 %
* Hr-HPV: high risk HPV subtypes 16,18,31,33,35,39,45,51,52,56,58,59 68,73, and 82
uVIN = usual VIN
dVIN = differentiated VIN
When specified, only VIN 2/3 cases were included
** It is not mentioned whether the dVIN lesion contained HPV. The dVIN lesions were not taken 
into account in the calculation in the HPV positivity of dVIN lesions. The uVIN lesions were 
considered to be 92% HPV positive.
*** Subtype ofV IN  not specified, it is known that >90% ofVIN  lesion are of the usual type.
Histology
Histopathologically, uVIN lesions are easy to recognise. An example of the histology 
of uVIN can be found in Figure 3C. Typically, the epidermis is thickened and is 
accompanied by a surface reaction of hyperkeratosis and/or parakeratosis of the most 
superficial of cell layers.*22 The characteristic microscopic features include a w in d­
blown appearance of the epidermis that produces a disorganisation of keratinocytes, 
high nuclear-to-cytoplasmic ratio, nuclear hyperchromasia, irregularities of the
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nuclear membranes, and numerous mitotic figures at all levels of the epidermis. 
Dyskeratotic cells with dense eosinophilic cytoplasm and pyknotic nuclei probably 
representing apoptotic cells are common. Cells with a clear or vacuolated cytoplasm 
that appears to form clear halos around shrunken pyknotic nuclei corresponding to 
so-called 'koilocytes’ may be numerous. M ultipolar and abnormal mitotic figures 
are easily found. uVIN lesions characteristically are aneuploid in upper cell layers 
of the epithelium.7 The histological correlates of aneuploidy have been reported to 
be abnormal mitotic figures and nuclear enlargement with hyperchromatism and 
pleomorph ism, especially in the basal and parabasal zones. Two types of u VIN exist; in 
the warty pattern the involved epidermis has an undulating or spiked surface creating 
a warty or condylomatous appearance and there is a striking cellular pleomorphism. 
Multinucleated cells and koilocytes are common. In the basaloid pattern, the surface 
is relatively flat and non-papillamatous with a diffuse replacement of the epidermis 
by a homogenous population of small, undifferentiated keratinocytes with scanty 
cytoplasm. However, there are overlapping features of these two patterns: mixtures 
of w arty and basaloid patterns are commonly found in the same lesion.7
Clinical characteristics
Signs
uVIN lesions can have a variety of clinical appearances. The key features are raised, 
well demarcated and asymmetrical lesions. They often produce large whitish (Figure 
7) or erythematous plaques (Figure 6A); while some lesions are pigmented (Figure 6C). 
The most frequently affected sites a re the labia majora, the labia minora and posterior 
fourchette. Other, less affected sites are the clitoris, mons pubis, perineal and perianal 
areas.143 Multifocal involvement of the vulva occurs in more than 40% of cases.*143 
Multicentric intraepithelial or invasive squamous neoplasia (of the cervix, vagina or 
anus) is also common, occurring in approximately 25-66% of the uVIN patients.7;12;1415 
The multicentricity of uVIN is age-related; decreasing from 59% in women aged 20- 
34 to 10% in patients over 50 years of age.113 Multicentric uVIN are more often HPV 
positive than the unicentric uVIN lesions.15;132;134 Because of the often-concurring uVIN 
and CIN, a cervical smear should always be performed. In Figure 6 and 7, different 
appearances of uVIN are depicted: varying from white and condylomatous-like to 
brown lesions.
Symptoms
The most common presenting complaint is pruritus, present in about 60% of the 
patients. Other presenting symptoms can be pain, ulceration and dysuria.143 A 
significant proportion of patients have no specific complaints, apart from the finding 
of an abnormal vulvar area by self examination. (22%).143
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Figure 6: Clinical pictures of usual VIN.
A+B. mapping of usual VIN. In order to get information of all suspicious looking lesions (I, IV, V, VI 
and VII), and the extent of the usual VIN lesions, two normal looking areas were also biopsied 
(II and III). Six biopsies showed usual VIN and in biopsy III no abnormalities were found.
C. The brown area of biopsy-proven usual VIN (indicated by the arrow) was treated by 
laser vaporisation. The areas indicated by the asterix, were previously treated by laser 
vaporisation.
D. In the area indicated by the arrow, the upper layers of the epithelium were vaporised.
Figure 7: Clinical pictures of usual VIN w ith adjacent vulvar squam ous cell carcinom a.
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A. The patient had been treated for vulvar itching for months before she visited our outpatient clinic.
B.The left labium minus shows white, flat, warty lesions, adjacent to an ulcerative lesion that 
showed to be vulvar squamous cell carcinoma upon biopsy.
C. Because of the size o f the tum our (>4cm diameter) the patient was not eligible for the sentinel 
node study protocol and inguinofemoral lymph node dissection, combined with a wide local 
excision, was performed.
Treatment
There are several options for treatment of uVIN, with a major role for surgery. When 
a large number of treatment options exist for a particular condition, it is likely that 
none of those treatments provides an excellent solution to the problem.This seems to 
be the case considering the treatment of uVIN.144The paucity of robust evidence is of 
critical importance supporting most of the various treatments suggested for uVIN.144 
Ideally, a treatment of uVIN should address some or all of the following:144
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Exclude invasive disease at the outset
Relief of symptoms
Eradication of HPV infection
Minimal disruption of adjacent normal epithelium
Restoration of normal epithelial architecture
Reduction in the risk of malignant progression
Sustained remission
uVIN is considered as an uncommon chronic skin disorder with a high risk of recurrence 
after treatment and a risk of progression to invasive vulvar SCC. Removal has been 
standard treatment for a II suspicious and/or symptomatic lesions. Due to the recurrent 
character of uVIN, young women are at risk to require repeated treatment over a 
prolonged period of follow-up. As a consequence, they may suffer from psychosexual 
morbidity.3436This leads to the need for alternative treatment options.
Surgery as treatment for uVIN 
Cold knife surgery
In the past, extensive surgery has been performed for uVIN. During the 1970s, 
several authors addressed vulvectom y as overtreatment for uVIN.The main reasons 
to favour more limited surgery were the m utilating treatm ent for a disease with an 
increasing incidence in young women, w ith a recurrent character and the lack of 
knowledge about the biological behaviour of the disease.145 In 1984, Wolcott et al. 
reported an increase in recurrences when wide local excision (WLE) was performed 
instead of radical vulvectomy, and they found that positive surgical margins were 
a significant predictor of recurrence.146 This observation paved again the way 
towards more extensive surgery for uVIN since that time.143 Recent reports showed 
that positive surgical margins rarely predict the development of invasive disease. 
Therefore WLE, consisting of removal of all visible lesions, is the surgical technique 
of choice.145147
Laser excision, vaporisation, and Loop Electrosurgical Excision Procedure (LEEP).
Vulvar laser surgery was introduced more than a decade ago and seemed an 
appropriate treatment particularly for uVIN because of the low thermal effect on 
vulvar tissue.11*148 Laser excision combines the advantages of both surgical excision 
(high cure rate and correct diagnosis), and laser vaporisation (cosmetic and functional 
results).113 Laser vaporisation is a destructive technique and has the disadvantage of 
destroying the treated tissue, without the possibility of histological evaluation.113 In 
laser excision and vaporisation, at the end of the procedure the treated areas can be 
washed with 5% acetic acid to ensure that no residual lesion is left behind.148 Before 
treatment with laser vaporisation, invasive disease must have been excluded. Both 
treatments can be performed under local anaesthesia. When a large vulvar area is 
involved, more treatment sessions may be necessary, as treatment of a large area 
is painful. LEEP may be an alternative to laser vaporisation with the advantage of
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provision of a specimen for pathology; there is a lot of experience with this treatment 
because of its widespread use in patients with CIN.
In several studies, surgical techniques have been compared. In a review about the effect 
of surgical treatment in relation to recurrence and progression of uVIN.the recurrence 
rates in 1921 surgically treated patients have been evaluated. The recurrence rates 
were comparable with an overall recurrence rate of about 20%.147 In Figure 6 C & D,the 
effect of laser vaporisation is shown.The areas marked with an asterix were previously 
treated by laser and had the same appearance as the area indicated by the arrow in 
between. In Figure 6D the situation directly after the laser vaporisation is shown.
Medical treatment of uVIN
A lot of medical treatments have been tried to avoid surgery in patients with uVIN 
lesions. Medical treatment does not provide a specimen for histological evaluation 
and occult invasion may be missed. Therefore, mapping of the vulva is important, 
before starting any treatment to prevent missing invasive disease.
Other medical treatment options, like 5-Fluorouracil (5-FU)149, lnterferon150;151, photo 
dynamic therapy (PDT)152 and Cidofovir153 have been described, but are not discussed 
here in detail because of limited experience and results.
Imiquimod
Imiquimod (Aldara®),an imidazoquinoline amine, is classified as an immune response 
modifier. It is widely used in the treatment of genital warts with proven efficacy 
in terms of clearance of the lesions, and a lower recurrence rate compared with 
conventional surgical treatments.154'156
Analogous to high grade CIN, uVIN microenvironment is associated with a decreased 
expression of the pro-inflammatory Thi cytokines, Tumour Necrosis Factor a  (TNF 
a) and Interferon y (IFNy). Imiquimod acts by activating macrophages and thereby 
inducing secretion of these pro-inflammatory cytokines. This in turn promotes a Thi 
adaptive immune response leading to the secretion of IFNy and the up-regulation of 
cell mediated immunity.157 By inhibiting viral replication, imiquimod focuses on the 
cause of uVIN and preserves the anatomy and function of the vulva.15S;159 
Several studies evaluated the effect of imiquimod on uVIN lesions; in most study settings, 
a two to three times per week 5% dose regimen was used. After several applications most 
patients with uVIN experienced side effects, varying from irritation to burning, itching, 
and/or ulcer development. The side effects made several patients stop applying the 
imiquimod treatment. Responses were reached after six to 30 weeks of treatment.159 
In the study of Mathiesen et al., 81% of the patients reached complete remission 
and another 10% a partial remission (from VIN 3 to 1). The patients in the placebo 
group were offered imiquimod after the study period; another four out of seven had 
a complete response, two patients had a partial response. All together, 25 out of 31 
patients had a complete or partial response.160 In the study of van Seters et al. 81% 
of patients showed reduction in lesion size, whereas none of the placebo subjects 
experienced a response. Imiquimod was significantly associated with histological
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regression and viral clearance. Moreover, relief of itchiness and pain significantly 
were reduced in comparison with the placebo.Three patients progressed to invasion 
(<im m );two of them after placebo, one after imiquimod.161
In a study to the T-cell responses triggered by imiquimod application, it was 
demonstrated that these T-cell responses were unable to eliminate the virus 
completely, possibly the reservoir of HPV remaining in the vulvar epithelium is 
too large, inaccessible or not processed and presented in the appropriate way to 
the immune system. The magnitude and specificity of the T cell response had no 
correlation with clinical response to imiquimod.162
Follow up of patients treated with imiquimod is still short; long-term effects cannot 
yet be established. The results of imiquimod are promising but large randomised 
controlled trials are needed to obtain data on the long term effects. Considering the 
side effects of imiquimod, its use should be restricted to motivated patients.
Therapeutic vaccination
Two commercial vaccines against HPV (Gardasil™ and Cervarix™) are currently available 
in manycountries worldwide. Both are produced with recombinanttechnologies, consist 
of self-assembled virus-like particles (VLPs), and have shown high immunogenicity. 
They have been found to be highly efficient in preventing persistent infections and 
lesions not only from the uterine cervix, but also from the anus, vagina, and vulva. Both 
vaccines have been shown to be generally safe in the phase II and phase III randomized 
controlled trials. Gardasil™ is a quadrivalent recombinant vaccine that protects against 
HPV 6, HPV11, HPV16 and HPVi8.l63. Cervarix™ is a bivalent vaccine that protects against 
HPViôand HPV18.lt has been chosen by the Dutch govern ment for the Dutch vaccination 
programme. Cross protection for HPV31, HPV33 and HPV45 for cervical lesions has been 
described, but has not been evaluated for vulvar lesions.164
Davidson et al. compared the immune responses of patients with uVIN lesions to 
healthy volunteers. In patients with HPV 16 positive uVIN lesions, both antibody- and 
T-cell responses to the Li protein were stimulated, but not always sufficient to clear the 
lesions. E2-specific T-cell responses were rare, and possibly their absence facilitates the 
persistence of uVIN lesions.11 Because of the above-mentioned observations, therapeutic 
vaccination studies were performed in uVIN lesions to enhance T-cell mediated 
immunity in patients with uVIN lesions. Results from those studies show that after 
various schedules of vaccination, only 1 of 85 patients showed a complete response, 
23 of 85 patients had a partial response, and four patients showed progression.165'167 
Viral load diminished post vaccination,166 but the same HPV subtypes were detected 
pre- and post-vaccination,165 and in most patients the grade of uVIN lesion remained 
unchanged.165 In a combined analysis of three randomised trials a 49% reduction in 
lesion size in all high-grade uVIN was seen, irrespective of whether or not HPV DNA 
was isolated from the lesion.168 In women positive for HPV DNA, HPV 16/18 vaccination 
does not accelerate clearance of the virus and should not be used to treat prevalent 
infection.l69;17° Currently the effect of other new therapeutic HPV vaccines is tested.171
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Observation
In case of little or no complaints, some patients may not want to undergo treatment. 
Considering the relatively low malignant potential, a wait and see policy is an option.172 
Careful observation, at least every three months, is required and greatly helped by 
photographs. In our clinic, asymptomatic women who deny treatment despite a 
treatment advice, are seen in our outpatient vulvar clinic every three months. These 
patients are instructed to contact us when any abnormality occurs and we have a low 
threshold to perform a biopsy in case of suspected progression.
Malignant potential
Generally, the malignant potential of uVIN is considered to be low in comparison with 
dVIN.This opinion is mainly based on the malignant progression in treated patients. 
An example of vulvar SCC adjacent to untreated uVIN is shown in Figure 7.
The rate of invasion after various primary treatments ranges from 1.4% to 20%.143;146;173‘ 
180 In the meta-analysis of van Seters et al., 3,3% (108/3322) of patients developed 
a vulvar SCC during follow up after primary treatment,147 and in the study of Jones 
et al. 17/405 (4.2%) progression was seen after treatment.181 The rates of malignant 
transformation of uVIN are high when compared to the rates found in treated CIN 
lesions: in four studies, only 31/13969 (0.22%) patients developed invasive cervical SCC 
after treatment for CIN lesions.182185
The first study on the malignant potential in untreated VIN III lesions, showed 
malignant progression in 7/8 cases. However, in the above mentioned meta-analysis 
vulvar SCC developed in 9% (8/88) of untreated uVIN patients.147 Jones et al. described 
10/63 (15-8%) women who developed invasive disease before treatment of uVIN.181 
Advanced age, raised lesions, radiotherapy, and an immune compromised state are 
known risk factors for progression of uVIN186. No differences in progression rate could 
be found between uni-and multifocal ity.147
Two strikingly different patterns of invasive vulvar SCC in women previously treated 
for uVIN were found. In one group (2.0%), invasion occurred within seven years of 
treatment (median 2.4 years). Close examination of these cases points to progression of 
inadequately treated uVIN, as invasion occurred either at the site of previous treatment 
and/or there was histological evidence of previous positive surgical margins. In the 
second group (1.8%) invasion occurred many years after treatment of uVIN (median 13.8 
years). In all of these cases, the SCC developed at some distance from the previously 
treated uVIN lesions, thus representing'de novo’ tumours. These late-occurring SCCs 
appear to represent lesions arising in an HPV induced 'field of risk’.181 
In contrast to progression to invasive carcinoma, also spontaneous regression of 
uVIN has been described in 14 women 15-27 years of age. All women had multifocal, 
pigmented lesions.187 In the review of van Seters et al 1.2% of the patients showed 
spontaneous regression, all were younger than 35 years. In 17 patients, regression was
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related to giving birth.147 An improvement of the immune compromised state, e.g., 
by refraining from the use of immune suppressants could also lead to spontaneous 
regression of uVIN. From our own clinical experience, cessation of smoking greatly 
improves the signs and symptoms of uVIN.
Outline of the thesis
Despite all surgical advances, the morbidity of the treatment of vulvar SCC is still 
impressive. A rise in absolute numbers of vulvar SCC is expected because of the 
proportional increase in the average age of the population. Ultimately, around 
20 percent of all vulvar SCC patients will develop a recurrence, making repeated, 
mutilating surgery with or without radiotherapy necessary.
Improving the care for patients with vulvar (pre-)malignancies requires further 
understanding of the oncogenesis of vulvar SCC. In 1990, Neill et al. suggested two 
different kinds of vulvar carcinoma exist: one arising in vulvar dystrophy (currently LS) 
and another that develops after an infection with HPV, followed by VIN.188 Additional 
research led to the belief that vulvar SCC indeed develops following at least two 
different pathways.
In chapter 2 and 3, the two pathways leading to vulvar SCC are characterised by the 
differences in the presence of hr-HPV DNA and the immunohistochemical expression 
of p i6 INK4A, pi4ARF and MIB1. In chapter 4 we investigated MIBi-expression in vulvar 
tissue, in order to find an explanation for the differences in malignant potential.
The malignant potential of LS is believed to be low; 3-5% of the patients develop 
vulvar SCC. Therefore, most guidelines recommend regular follow-up. In chapter 
5 we describe the follow-up of LS patients at the departments of Gynaecology and 
Dermatology in the Radboud University Nijmegen Medical Centre. Follow-up in LS 
patients could be improved when one is able to differentiate between LS lesions 
that will progress into dVIN and/or vulvar SCC and those that remain solitary LS. In 
chapter 6 we investigated whether microvessel parameters in LS with associated 
SCC differ from the microvessel parameters in solitary LS. In chapter 7 we evaluated 
the correlation between aneuploidy and the expression of P53 with the intention to 
shed light on the potential malignant conversion of LS and dVIN towards SCC. In the 
final chapter 8, we propose future studies and hypothesis based on the results of the 
abovementioned studies, to gain further insight in the development of HPV-negative 
vulvar SCC and to improve the care for patients with vulvar disease.
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Abstract
Two separate pathways leading to vulvar carcinoma have been suggested. First, a 
human papillomavirus (HPV)-dependent pathway, where pre-malignant stages of 
vulvar cancer are the classic vulvar intraepithelial neoplasia (VIN) lesions. Second, 
an HPV-independent pathway, associated with differentiated VIN III lesions and/or 
lichen sclerosus. To obtain insight into the mechanisms underlying these pathways, 
we determined the relationship between HPV DNA and the expression of pi4ARF and 
P-i ô 'nk+a j n  non. anc| (pre)malignant vulvar lesions. Seventy-three archival samples of 
non-and (pre)neoplastic vulvar lesions were selected and tested for hr-HPV DNA using 
a broad-spectrum HPV detection/genotyping assay (SPFio-LiPA) and the expression of 
pi4ARF and pi6INK4\  The prevalence of HPV increased with the severity o fth e  classic 
VIN lesions; in VIN I no hr-HPV was detected, in VIN II 43% and in VIN III 71% of the 
samples were hr-HPV positive. Roughly the same was true for the expression of pi4ARF 
and p i6 INK4A.The simultaneous expression of pi4ARF and p i6 INK4A was highly associated 
with the presence of hr-HPV DNA. Hr-HPV was detected in only a single case of the 
differentiated VIN III lesions, whereas no expression of pi4ARF was found and i6 INK4A 
was present in only 2 cases. All 16 samples of vulvar cancer were hr-HPV DNA negative 
although in respectively 63% and 25%, pi4ARF and pi6INK4A was expressed. No relation 
was found between hr-HPV and the expression of pi4ARF and p i6 INK+A in the 20 non­
neoplastic vulvar lesions.
Our results provide further evidence that vulvar squamous cell carcinoma is a 
multifactorial disease that develops from two different pathways. First, an HPV- 
dependent pathway with a remarkable resemblance to CIN lesions and cervical 
carcinoma and second, an HPV-independent pathway in which differentiated VIN III 
lesions, which are hr-HPV-negative, may be precursors.
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Introduction
Vulvar cancer is the fourth most common gynecologic cancer. In the United States, in 
2004, 3970 new cases of vulvar cancer (4.8% of malignancies of the female genital 
tract) were diagnosed (Cancer Facts and Figures 2004, American Cancer Society). 
Cigarette smoking, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), human 
papillomavirus (HPV) infection, immunodeficiency syndromes, a previous history of 
cervical cancer, and northern European ancestry are risk factors for the development 
of vulvar carcinoma.1
The majority of vulvar malignancies are squamous cell carcinomas. It has been 
suggested that vulvar squamous cell carcinoma and its precursor lesions may 
develop following two separate pathways, based on etiological and histopathologic 
characteristics, thus suggesting a heterogeneous etiology.2'5
The first pathway leads mainly to non keratinizing (basaloid and/or warty) carcinomas 
and primarily affects younger women. In this pathway infection with high-risk human 
papillomavirus (hr-HPV), predominantly HPV 16 and 18, seems to be involved.2;3;5'7This 
type of carcinoma is associated with w arty a nd/or basaloid VIN, which is often referred 
to as “classic” or Bowenoid VIN.8'11 In a recently proposed new nomenclature, the HPV- 
positiveVIN lesions a re called VIN, usual type.12;13The HPV-positive vulvar squamous cel I 
carcinomas are supposed to have a significantly better prognosis than HPV-negative 
cancer. The second pathway is rarely associated with high-risk HPV, occurs in older 
women and leads to mostly differentiated keratinizing squamous cell carcinoma, in a 
background of non-neoplastic epithelial disorders (e.g., lichen sclerosus). Its possible 
precursor form is referred to as “sim plex” or (well-) differentiated VIN (III) and is 
often difficult to distinguish from benign vulvar lesions like lichen sclerosus, chronic 
inflammation or normal vulvar skin.8;1114The atypia in differentiated VIN III lesions is 
confined to the basal and parabasal layers o fth e  epithelium, in which the cells have 
abundant cytoplasm and form abortive pearls and the nuclei are relatively uniform 
in size and contain coarse chromatin and prominent nucleoli leading to paradoxical 
maturation abutting on the epithelial-stromal junction. The superficial layer o fth e  
epithelium has a normal maturation and does not contain koilocytosis.
It is well established that high-risk HPV infection plays an essential role in the 
carcinogenesis of tumors o fth e  anogenital tract. Cancer development is the result 
of a complex mechanism in which, among others, HPV oncogenic proteins E6 and E7 
bind host regulatory proteins, especially tumor gene products P53 and phosphorylated 
retinoblastoma protein (pRb).These changes may respectively lead to the degradation 
of P53 by the E6 oncoprotein, and to the functional inactivation of pRb through binding 
to the E7 gene product.15'17 Because ofthe loss of tumor suppressor function the release 
o fth e  transcriptional factor E2F-1 from the E2F-pRb complex may occur, allowing for 
the activation of pi6INK4A.17'19 E2F also regulates pi4ARF, creating a connection between the
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pRb and p53 tumor suppressor pathways.20 22 The INK4A/ARF gene encodes the proteins 
pi6INK4Aand pi4ARF. Pi6INK4Ais a cyclin-dependent kinase (CDK) inhibitor that regulates the 
activity of CDK-4 and -6 . Pi4ARF mediates P53 activation by inhibiting MDM2-mediated 
degradation of P53 and is induced by hyperproliferative signals such as E2F, c-myc and 
ras. Over-expression of pi6INK4Ain cervical intraepithelial neoplasia (CIN) and cervical 
carcinomas with high-risk HPV infection has recently been extensively reported.l6;l8;23'26 
Little is known aboutthe expression of pi4ARF in CIN with only a few reports sofar.l6;27The 
relationship between the presence of HPV DNA and the expression of both pi4ARF and 
pi6'NK4Ajn vu |var lesions has not been studied until now, which is of interest because both 
proteins are encoded by the same transcription factor and their pathways are activated 
through HPV oncogenic proteins as well as by several other factors (i.e. P53, c-myc, ras).
This study was designed to evaluate whetherthe presence or absence of high-risk HPV 
combined with the expression ofthe cell cycle related biomarkers pi4ARF and pi6INK4Ain 
different groups of vulvar lesions may provide more insight into the pathways leading 
to vulvar carcinoma.
Materials and Methods
Sample selection
Seventy-three samples of different non- and (pre)neoplastic vulvar lesions were 
randomly selected from the archives of the Department of Pathology, Radboud 
University Nijmegen Medical Centre (Nijmegen,The Netherlands). All tissue specimens 
were collected between 1992 and 2000 and routinely fixed in 4% buffered formalin 
and paraffin embedded.The hematocylin and eosin-stained slides were re-examined 
blindly and independently by two consultant pathologists specialized in gynecological 
pathology (JG and JB) and diagnosed based on published histomorphologic criteria 
(classic VIN I, classic VIN II, classic VIN III, differentiated VIN III, squamous cell 
carcinoma, lichen sclerosus or chronic inflammation).28 Subsequently, divergently 
scored lesions were presented to a third gynecopathologist, who formulated a final 
diagnosis (which in all cases was identical to the consensus diagnosus reached by 
the 2 pathologists). In 66 of the 73 cases (90%) the independent diagnoses of the 
2 pathologists were identical. Altogether, the kappa value of was 0.94, indicating 
an excellent rate of interobserver reproducibility.29 All samples of squamous cell 
carcinoma were classified as being well, moderately or poorly differentiated (grade 
1-3, WHO classification).28
Thus, the final cases included in this study consisted of 10 samples of normal vulvar 
tissue with chronic inflammation, 10 samples of lichen sclerosus, 5 classic VIN I 
lesions, 7 classic VIN II lesions, 17 classic VIN III lesions, 8 differentiated VIN III lesions 
and 16 samples of squamous cell carcinoma (14 keratinizing and 2 non-keratinizing).
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The median age was 57 years (range, 8-91). Details o fthe different diagnostic groups 
are presented in Table 1.
Table i. Num bers o f sam ples in each diagnostic group and m edian age per group
Diagnostic group Final diag nosis
Initial diagnosis 
pathologist
: by
M edian age (yr)
JB JG
(m 1 n,m ax)
Classic VIN 1 5 4 5 48 (36:68)
Classic VIN II 7 9 9 54 (37:74)
Classic VIN III 17 15 14 48 (29:82)
Differentiated VIN III 8 8 9 66 (62;88)
Squamous cell carcinoma 16 (2) 15 16 71 (37;9l)
Well-differentiated 9 - - 62 (37:91)
Moderately differentiated 5 (1) - - 75 (44:87)
Poorly differentiated 2 (1) - - 87.5 (87:88)
Lichen sclerosus 10 10 9 57.5 ( 8;68)
Inflammation 10 10 10 32.5 (21:72)
Not conclusive 0 2 1 -
Total 73 73 73 57 (8:91)
Numbers in parenthesis in consensus diagnosis column = nu m bero f nonkeratinizing squamous 
cell carcinoma samples.
Immunohistochemistry
Four-micrometer-thick sections of the archival paraffin-embedded tissue samples 
were mounted onto polylysine-coated slides and dried overnight at 58°C. The 
sections were dewaxed in xylene and endogenous peroxidase was blocked using 
H20 2 in methanol for 15 minutes and the slides were rinsed three times in phosphate- 
buffered saline (PBS; pH 7.4) for 5 minutes. The slides were placed in a citrate buffer 
(0.01 M; pH 6.0), heated in a household microwave oven (3 minutes at 850 W until 
boiling; followed by 10 minutes at 180 W). The sections were allowed to cool down 
to room temperature (RT) and briefly washed in PBS (10 minutes). Subsequently the 
slides were pre-incubated with 20% normal goat serum and then incubated with 
primary antibodies p i6 INK4A (clone 16PO4, Neomarkers, Fermont, CA) diluted 1:500 in 
PBS with 1 % bovine serum album ine (BSA) (60 minutes, RT) and pi4ARF (clone 14PO2, 
Neomarkers) diluted 1:200 in PBS with 1% BSA (60 minutes, RT). Subsequently the 
slides were rinsed in PBS (10 minutes) and postantibody blocking was done for 15 
minutes (Powervision Plus, Dako SA, Glostrup, Denmark). This was followed by
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incubation with polymeric-horse-radish peroxidase-goat anti-m ouse/rabbit/rat 
IgG (30 min, RT). Staining was developed with diam inobenzidine (mixed with H20 2), 
counterstained with Mayer’s hematoxylin, dehydrated in ethanol and xylene and 
finally mounted. Negative controls (buffer only) and HPV-positive classic VIN III and 
CIN3 lesions served as p i6 INK4A and pi4ARF positive controls in each run.
Interpretation o fp i6INK4Aand pi4ARF
For pi6INK4A, nuclear and cytoplasmic staining was considered as a positive reaction. 
The results were reported in a semi-quantitative fashion: negative if <5% of the 
cells had nuclear or cytoplasmic staining, slightly positive (1+) if 5 to 25% o fth e  cells 
were stained, moderately positive (2+) if staining was present in 25 to 75% of the 
cells, and markedly positive (3+) if >75% of the cells showed nuclear or cytoplasmic 
staining.14'8^ 31
For pi4ARF, only nuclear or nucleolar staining was considered to be a positive reaction 
(no cytoplasmic staining was seen in any case). Because of a less extended expression 
pattern of pi4ARF, a different semi-quantitative scoring system was used: negative (-) if 
<1% of cells were stained, slightly positive (1+) if the percentage was in the range of 1 
to 5% and moderately positive (2+) if >5% o fthe cells were stained.l6;21
All stains were analyzed by one pathologist (HS).ln case of doubt a second pathologist 
(JB) was consulted.
HPV detection and genotyping
Four-micrometer-thick tissue sections of each archival sample were put into a reaction 
tube and incubated overnight at 56 °C in 200 |jl of 10 mM tris-HCL with 1 mM EDTA, 
0.2% Tween-20, and proteinase K (0.3 mg/ml). Proteinase K was inactivated by 10 min 
incubation at 100 °C.The sample was centrifuged for 10 min at 11.000 rpm and 10 |jl was 
directly used for PCR analysis. A water blank control was processed with each batch of 
ten samples. Broad-spectrum HPV DNA amplification was performed using a short PCR 
fragment (SPF-PCR) assay.The SPF-PCR system amplifies a 65 bp fragment ofthe Li open 
reading frame, allowing for the detection of at least 43 HPV types. Subsequent HPV 
genotyping was performed via a reverse hybridization line probe assay (LiPA), allowing 
for simultaneous typing of the following 25 HPV-genotypes: HPV 6,11,16,18,31,33,34,35, 
39,40,42,43,44,45,51,52,53,54,56,58,59,66,68,70 and 74.The combined SPF-PCR-LiPA 
system for detection and genotyping of HPV has been described in detail elsewhere.3*33
Statistical analysis
The interobserver variability was established by determining the kappa value. A 
kappa (k ) value of 1 indicates 100% interrater reliability. Generally, k  > 0.80 represents 
excellent agreement, 0.80 > k  > 0.60 represents substantial agreement, 0.60 > k  > 
0.40 represents moderate agreement; 0.40 > k  > 0.20 represents fairagreem ent, and 
k  ffi 0.20 represents slight or poor agreement.29
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Spearman’s rank correlation (Spearman’s p) was used to investigate the correlation 
between the expression of pi4ARF and p i6 INK4A and the grade of squamous cell 
carcinoma and the grade of dysplasia in classic VIN. To test whether the expression 
of pi4ARF and p i6 INK+A differed between cases infected and not infected with high-risk 
HPV, the non-parametric Mann-W hitney U test for unpaired observations was used.
To facilitate the statistical analysis o fth e  combined expression of pi4ARF and p i6 INK+A, 
the variables were converted to binary variables. For p i6INK4A, no staining (-) and slightly 
positive (+) immunohistochemical stainings were considered negative; moderately 
positive (++) and markedly positive (+++) immunohistochemical stainings were 
considered positive. Because ofthe less extended expression pattern and the absence 
of staining in the inflammed and lichen sclerosus samples, for pi4ARF, no staining (-) 
was considered negative and slightly (+) and moderately (++) stained samples were 
considered positive. The association between the presence of pi4ARF and p i6 INK4A 
expression was assessed by 2 x 2 contingency tables and using the Fisher exact test.34 
All analyzes were performed by using SPSS* version 12.0.1 software (SPSS Inc., Chicago, 
IL). A significance level of p<0.05 was considered to be significant.
Results
The immunohistochemical staining and HPV detection and typing results of all 73 
samples are presented in Table 2.
HPV detection and typing
No high-risk HPV DNA was detected in the VIN I lesions. High-risk HPV was detected 
in 3 o fthe 7 classic VIN II lesions (43%), and in 12 of the 17 classic VIN III lesions (71%). 
Only one of eight differentiated VIN III lesions contained high-risk HPV DNA (13%). In 
the 10 lesions with chronic inflammation, also 1 sample was found to be positive for 
high-risk HPV DNA (10%) and in none ofthe samples of squamous cell carcinoma and 
lichen sclerosus lesions high-risk HPV DNA was detected. Low-risk HPV was detected 
in two classic VIN I lesions and in two classic VIN II lesions (all HPV6).
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Tablel 2. Analysis of HPV, p i6 INK4A and pi4ARF in 73 vulvar lesions
Case HPV p i4ARF p i6 INK4A
1 classic VIN 1 - - +++
2 classic VIN 1 - - -
3 classic VIN 1 - - -
4 classicV IN  1 6 - +
5 classic VIN 1 6 - +
6 classic VIN II - - -
7classicV IN  II - - -
8 classic VIN II 16 + +++
9 classic VIN II 16 ++ +++
io  classic VIN II Bi + +++
n classic VIN II 6 - ++
12 classic VIN II 6 + +++
13 classic VIN III - ++ +++
i4classicV IN  III - ++ -
15 classic VIN III - ++ -
ïö cla ssicV IN  III - ++ +++
17 classic VIN III - - +++
18 classic VIN III 16 ++ +++
19 classic VIN III 16 ++ +++
20 classic VIN III 16 ++ +++
21 classic VIN III 16 + +++
22 classic VIN III 16 + +++
23 classic VIN III 16 - +++
24 classic VIN III 16 ++ +++
25 classic VIN III 16 - +++
26 classic VIN III 16 + +++
27 classic VIN III 33 ++ + ++
28 classic VIN III 16 ++ +++
29 classic VIN III 31 ++ + ++
30 differentiated VIN III - - -
31 differentiated VIN III - - -
32 differentiated VIN III - - -
33 differentiated VIN III - - +
34 differentiated VIN III - - +
35 differentiated VIN III - - -
36 differentiated VIN III - - -
37 differentiated VIN III 16 - -
38 SCC well differentiated - ++ + ++
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39 SCC well differentiated - - -
40 SCC well differentiated - ++ +
41 SCC well differentiated - ++ ++
42 SCC well differentiated - - -
43 SCC well differentiated - - -
44 SCC well differentiated - + -
45 SCC well differentiated - - -
46 SCC well differentiated - - -
47 SCC moderately differentiated - - -
48 SCC moderately differentiated - + -
49 SCC moderately differentiated - + -
50 SCC moderately differentiated - ++ -
51 SCC moderately differentiated (NK) - ++ +++
52 SCC poorly differentiated - ++ -
53 SCC poorly differentiated (NK) - ++ -
54 Lichen Sclerosus - - -
55 Lichen Sclerosus - - -
56 Lichen Sclerosus - - +
57 Lichen Sclerosus - - +
58 Lichen Sclerosus - - +
59 Lichen Sclerosus - - -
60 Lichen Sclerosus - - -
61 Lichen Sclerosus - - -
62 Lichen Sclerosus - - -
63 Lichen Sclerosus - - +
64 Inflammation - - -
65 Inflammation - - -
66 Inflammation - - -
67 Inflammation - - -
68 Inflammation - - -
69 Inflammation - - -
70 Inflammation - - -
71 Inflammation - - -
72 Inflammation - - -
73 Inflammation 16 - -
(-) negative; (+) slightly positive; (++) moderately positive; (+++) markedly positive; 
(SCC) squamous cell carcinoma; (NK) nonkeratinizing.
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pi4ARFexpression in vulvar lesions
Examples ofthe nuclear and nucleolar staining with pi4ARF in classic VIN III and vulvar 
squamous cell carcinoma is shown in the figures iA  and B, respectively. No cytoplasmic 
staining was observed. The level of pi4ARF expression increased with the degree of 
dysplasia in the classic VIN lesions (Spearman’s p=o.63; p<o.ooi): no expression in 
classic VIN I lesions, 57% (4/7) was slightly to moderately positive in the classic VIN II 
lesions and the majority ofthe classic VIN III lesions were slightly (18%) or moderately 
(65%) positive (3/17 and 11/17 respectively). In the diagnostic groups of differentiated 
VIN III, lichen sclerosus and chronic inflammation no pi4ARF expression was found. 
Expression of pi4ARF in vulvar carcinoma samples was heterogeneous: 38% (6/16) of 
the samples showed no expression; 19 % (3/16) o fth e  samples were slightly positive 
and the remaining 44% (7/16) were moderately positive. There was no statistically 
significant correlation between the expression of pi4ARF and the grade of squamous 
cell carcinoma (Spearman’s p=o.4; p=o.i).
p 1giNK4A expression in vulvar lesions
In the classic VIN lesions the level of expression of p i6 INK+A increased with the degree 
of the VIN (Spearman’s p=o.5; p=o.oos): in the classic VIN I lesions 60% (3/5) of the 
samples were slightly to markedly positive for p i6INK4A; in the classic VIN II lesions 
there was moderate to marked expression in 71% (5/7) ofthe samples and 88% (15/17) 
o fthe classic VIN III lesion samples were markedly positive for p i6 INK+A. Figure iC is an 
example of nuclear and cytoplasmic staining for p i6INK4A in a classic VIN III lesion. In 
classic VIN l-lll lesions, the positivity for p i6 INK4A parallels the presence of atypical cells 
at different levels within the epithelium (Fig.iC and D).
Seventy-five percent (12/16) o fth e  vulvar carcinoma samples showed no expression 
of p i6 INK+A; in one sample (6%) there was slight (5-25%) staining and 19% (3/16) ofthe 
samples were moderately to markedly positive for p i6INK4A. No statistically significant 
correlation between the expression of p i6INK4A and the grade of differentiation ofthe 
squamous cell carcinoma was found (Spearman’s p=-o.2i; p=o.43).
None of the inflammatory lesions showed any expression of p i6 INK4\  Six lichen 
sclerosus samples were negative and the other four were slightly positive (nuclear or 
cytoplasmic staining in 5-25% of the cells). Two of eight differentiated VIN III lesions 
were slightly positive for p i6INK4A.
Combined results of HPV detection and pi4ARF /  pi&NK4A expression
Sixty-eight percent (19/28) of the pi4ARF positive vulvar lesions simultaneously 
expressed p i6 INK4A and from the p i6 INK4A positive lesions, 79% (19/24) had a concordant 
expression of pi4ARF. In the classic VIN lesions the expression of pi4ARF and p i6 INK4A was 
significantly associated (Fisher exact test, p=0.028);f0rthe squamous cell carcinomas 
there was no significant association (Fisher exact test, p=o.2s). All high-risk HPV 
positive classic VIN lesions were accompanied by the expression of p i6INK4A and 13 of
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15 had a concordant expression of pi4ARF (87%). The two other high-risk HPV positive 
lesions (a differentiated VIN III lesion and a sample of inflammation) were negativefor 
p i6INK4A and pi4ARF.The expression of pi4ARF and pi6INK4A in classic VIN lesions was more 
frequently observed in the presence of high-risk HPV (Mann-Whitney U test=57-5; 
p=0.037 and Mann-W hitney U test=37-5; p=o.oo2 respectively). The simultaneous 
expression of pi4ARF and pi6INK4A in squamous cell carcinoma lesions was 19% (3/16), of 
which all were negative for high-risk HPV.The differentiated VIN III lesions showed no 
simultaneous expression for pi4ARF and pi6INK4\
Discussion
This article provides further evidence that vulvar squamous cell carcinoma and the 
preneoplastic precursor lesions may develop following two different pathways: HPV- 
dependent and HPV-independent pathway.The mechanistic aspects leadingto these 
different pathways will be discussed.
Development of vulvar squamous cell carcinoma: HPV-dependent pathway
The presence of high-risk HPV DNA in classic VIN lesions has been described to vary 
from o to 90%, depending on the stage of dysplasia (higher VIN lesions are more 
often positive for HPV DNA), type of HPV, and sensitivity of the method of HPV 
detection.5®1*3536 The HPV genotypes in this study correspond to the types that 
have been described in the literature: generally HPV 16 is considered to be the most 
common genotype in vulvar lesions although HPV type 18, type 31, type 33 and type 45 
also have been reported. Low-risk HPV types can also be found, being predominantly 
HPV type 6 and type 11.
In classic VIN lesions, the percentages of both pi4ARF- and pi6INK4A-expressing cells 
increased with the degree of dysplasia and the simultaneous expression was 
associated with the presence of hr-HPV DNA. Eighty-seven percent (13/15) of the 
hr-HPV positive classic VIN lesions expressed both pi4ARF and pi6INK4A. There is a 
remarkable resemblance with CIN lesions, where the expression of pi4ARF and p i6 INK4A 
has also been reported to be associated, with a close relation to the presence of high- 
risk HPV.16;27 pi6INK4A expression in vulvar lesions has also been described by Chan et al., 
who found a comparable increase of p i6 INK+A expression with the increase in the grade 
ofVIN lesions.30 The HPV status, however, was not assessed. The expression of pi4ARF in 
vulvar lesions has not been published.
The nonkeratinizing carcinoma is considered to be the endpoint ofthe HPV-dependent 
pathway leading to vulvar carcinoma. The nonkeratinizing vulvar carcinomas in this 
study were negative for HPV DNA, whereas others reported a presence of hr-HPV in 
these lesions from 69 to io o % .14 A possible explanation for the negative results might
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be the subset of HPV types that was tested for was not extensive enough; we only 
tested for 25 types of HPV. In cervical cancer studies the HPV types 16,18, 31, 33, 35,
39. 45. 51. 52. 56. 58, 59 68, 73 and 82 have been classified as high-risk and the HPV 
types 26, 53, and 66 as probable high-risk types of HPV. The HPV types 6,11, 34, 40, 
42,43,44, 54, 61,70,72, 81 and CP6108 have been classified as low-risk types.17;33;37 The 
detected HPV types were classified accordingly for the vulvar lesions in this study. It 
might be possible that there are unidentified high-risk vulvar HPV types. One of the 
nonkeratinizing HPV-negative squamous cell carcinomas and two HPV DNA negative 
classic VIN III lesions were positive for p i6 INK4A and pi4ARF, supporting this possibility, 
because the simultaneous expression of p i6INK4Aand pi4ARF was highly associated with 
the presence of hr-HPV DNA.
Unfortunately, there were only two nonkeratinizing vulvar carcinomas in this study, 
which makes it difficult to compare the results with other studies.The small amount of 
non keratinizing squamous cell carcinomas in the randomly selected group of samples 
in this study, might be explained by the hypothesis that the easier to recognize classic 
VIN lesions, which proceed to nonkeratinizing squamous cell carcinomas, have a 
long transition period before they develop into squamous cell carcinoma and thus 
HPV-related VIN lesions are surgically removed in an early stage. The more difficult 
to diagnose and identify differentiated VIN III lesions (probably the precursor of the 
keratinizing squamous cell carcinoma) is assumed to have a short existence period 
with rapid progression into carcinoma.
Development of vulvar squamous cell carcinoma: HPV-independent pathway
Our results support the hypothesis that, next to an HPV-dependent pathway, a 
second HPV-independent pathway leading to vulvar squamous cell carcinoma exists. 
All keratinizing squamous cell carcinomas in this study were hr-HPV negative which 
is in accordance with the results of others.3;4;11;3S Furthermore, seven of eight (88%) 
differentiated VIN III lesions also were hr-HPV negative.The median age of the women 
with differentiated VIN III lesions and squamous cell carcinomas is comparable and 
remarkably higher than the median age in the group of HPV-dependent classic VIN 
lesions.Also, only 14% (3/22) ofthe presumed HPV-independent lesions (differentiated 
VIN III and keratinizing squamous cell carcinomas) show simultaneous expression of 
pi4ARF and pi6INK4A. The absence of hr-HPV, the low presence of combined expression 
of pi4ARF and p i6 INK4A, and the high median age in both groups of differentiated VIN 
III and keratinizing squamous cell carcinoma, make it likely that differentiated VIN III 
precedes vulvar keratinizing squamous cell carcinoma.The heterogeneous expression 
patterns for either pi4ARF or p i6INK4A can not be explained by the presence or absence 
of hr-HPV. Perhaps pi4ARF and p i6 INK4A expression in vulvar squamous neoplasms are 
more complicated than the cervical counterparts.
The absence of pi4ARF-expression in lichen sclerosus, inflammation and differentiated 
VIN III lesions and the presence of pi4ARF-expression in 57% o fth e  squamous cell
62
Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways
carcinomas (8/14) suggests that (over)expression of pi4ARF is associated with tumor 
progression. However, the role of pi4ARF in vulvar lesions in general cannot be entirely 
explained in this way, as there was considerable pi4ARF expression in the classic VIN 
lesions, which are by definition non-invasive. Possibly, pi4ARF is activated differently 
in both pathways; through E6 and/or E7 in the HPV-dependent pathway and through 
otherfactors in the HPV-independent pathway (e.g., c-myc or ras). It has been suggested 
that an alteration in the P53 gene is important in the genesis of differentiated VIN III 
and the development of vulvar carcinoma in the absence of HPV.11;39;4°
The International Society for the Study of Vulvovaginal Disease (ISSVD), which 
recently proposed a modified terminology for vulvar lesions, emphasizes that there is 
no evidence that the VIN 1 to 3 morphologic spectrum reflects a biologic continuum. 
They also state that VIN I is no cancer precursor; the fact that we only found Ir-HPV 
and limited expression of p i6INK4A might support this. Further research on both 
keratinizing and nonkeratinizing vulvar squamous cell carcinomas with other P53/ 
mdm 2/pi4ARF-pathway- and pRb/cyclinDi/pi6INK4A-pathway-related biomarkers is 
needed to gain further insight in mechanisms taking place in the pathways that lead 
to invasive vulvar squamous cell carcinoma and to investigate the parallels with CIN 
that have been drawn.
Lichen sclerosus and inflammation
Women with lichen sclerosus are reported to have an increased risk of developing 
squamous cell carcinoma, although still the vast majority of women with lichen 
sclerosus do not develop vulvar cancer.8™41 In this study 40% of the lichen sclerosus 
lesions were slightly positive for p i6INK4A and consistently negative for pi4ARF, which 
is comparable to the expression in differentiated VIN III lesions. These results are 
comparable to other studies on lichen sclerosus and pi6INK4A expression: Riethdorf et 
a l.14 found lichen sclerosus to contain focal and heterogeneous pi6INK4A expression in 
42%, with little to no expression in other benign vulvar lesions and normal skin. From 
the seven benign lesions studied by Chan et a I., six were positive for p i6INK4A,w ith <25% 
ofthe cells showing nuclear staining.30 There was no expression for pi4ARF or p i6INK4Ain 
the group of inflammation. Neither pi4ARF nor p i6INK4A can be helpful in distinguishing 
inflammation or normal vulvar epithelium from differentiated VIN III lesions.
In conclusion, the results of this study are in agreement with the existence of two 
distinct pathways leading to vulvar cancer. The HPV-dependent pathway resembles 
the pathway leading to the development of cervical cancer and seems to result in 
predominantly nonkeratinizing vulvar cancer. The mechanism(s) involved in the HPV- 
independent pathway presumably leading to keratinizing vulvar carcinomas, as yet, 
remains unclear and further investigations are needed to determine the position of 
differentiated VIN III lesions and lichen sclerosus in this pathway.
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Figure i
Hematoxylin and eosin and indirect immunohistochemical staining o f 4-|jm paraffin 
sections o f a classic VIN III lesion and a squamous cell carcinoma. The peroxidase-labeled 
immunohistochemical complexes were visualized with diaminobenzodine (DAB) (brown-black).
A. pi4ARF-stained slide, showing a basal part of the epithelium of a classic VIN III lesion with 
speckled positive nuclei and/or nucleoli.
B. Squamous cell carcinoma stained with pi4ARF: positive nuclei (speckled) can be seen especially 
at the invasive border o fth e  lesion.
C. In a classic VIN III lesion p i6 INK4A-positive cells (nuclei and cytoplasm) can be seen in all layers 
o fth e  epithelium.
D. Hematocylin and eosin-stained section of the classic VIN III lesion, showing atypical cells 
throughout the whole thickness o fth e  epithelium.
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Abstract
Two pathways leading to vulvar squamous cell carcinoma (SCC) exist.The expression 
of proliferation- and cell-cycle-related biomarkers and the presence of high-risk (hr) 
HPV might be helpful to distinguish the premalignancies in both pathways. Seventy- 
five differentiated VIN-lesions with adjacent SCC and 45 usual VIN-lesions (32 solitary 
and 13 with adjacent SCC) were selected, and tested for hr-HPV DNA, using a broad- 
spectrum HPVdetection/genotyping assay (SPFio-LiPA),and the immunohistochemical 
expression of MIB1, p i6INK4A and P53. All differentiated VIN-lesions were hr-HPV- and 
pi6-negative and in 96% MIBi-expression was confined to the parabasal layers. 
Eighty-four percent exhibited high P53 labeling indices, sometimes with parabasal 
extension. Eighty percent of all usual VIN-lesions were hr-HPV-positive, pi6-positive, 
Ml Bi-positive and p53-negative. Five (of seven) HPV-negative usual VIN lesions, had 
an expression pattern like the other HPV-positive usual VIN lesions. In conclusion, 
both pathways leading to vulvar SCC have their own immunohistochemical profile, 
which can be used to distinguish the two types ofVIN, but cannot explain differences 
in malignant potential.
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Introduction
Vulvar squamous cell carcinoma (SCC) accounts for 3-4% of all female genital cancers. 
There are two types of vulvar SCC that have different clinical and pathological 
features.1;2 Both types of vulvar cancer are preceded by their own type of vulvar intra- 
epithelial neoplasia (VIN). Based on histopathological characteristics, VIN lesions can 
be divided into usual VIN (also known as Bowenoid or classic VIN, basaloid or warty 
subtype) and differentiated VIN (formerly named simplex VIN or well-differentiated 
VIN).3 Recently,the International Societyfor Vulvovaginal Disease (ISSVD) has proposed 
a revised nomenclature for vulvar lesions.*3
The majority of vulvar SCCs occur in elderly patients with lichen sclerosus and develop 
following an human papillomavirus (HPV)-negative pathway.45 Its premalignancy, 
differentiated VIN, can be difficult to distinguish from a benign vulvar lesion (e.g. 
chronic inflammation) or normal epithelium .56 It is assumed that differentiated VIN is 
highly proliferative and might rapidly progress into an invasive neoplasm, because it is 
seldom found without (micro-invasive) vulvar carcinoma and often adjacent to HPV- 
negative vulvar SCC.2;5;6 Since differentiated VIN is often unifocal and the amount of 
skin involved is limited, surgical treatment by means of a wide local excision probably 
reduces the risk of progression to invasive carcinoma.7
Usual VIN is often multifocal, occurs in younger women and is associated with 
smoking and HPV, predominantly HPV16 and -18, and can lead to HPV-positive vulvar 
SCC.8 One third of all vulvar SCCs is associated with HPV.9 The risk of malignant 
transformation of usual VIN to an invasive carcinoma appears to be 3-4%. The viral 
gene products E6 and E7 interfere with two pathways of cell cycle regulation. HPV E6 
can interact with P53, leading to P53 dysfunction, which allows for an absence of cell 
cycle arrest.16:10 HPV E7 can inactivate pRb which can result in an over-expression of 
p i6INK4A and hyperproliferation.11;12
Proliferative activity in tissues can be visualized using MIB1, a proliferation marker 
which is a monoclonal antibody against the Ki-67 nuclear antigen, present in human 
proliferating cells in all stages o fth e  cell cycle besides the Go phase.13 In several (pre- 
) malignant lesions, MIBi-expression can be used for grading, estimating prognosis, 
and prediction of biological behaviour.14'18 The tumor suppressor P53 detects genetic 
alterations in cells in G^phase, resulting in cell cycle arrest or apoptosis. It frequently 
is mutated in HPV-negative vulvar SCC.19 Immunohistochemically, P53 is detected 
frequently in vulvar SCC and differentiated VIN, most likely because of cellular 
accumulation o fthe mutated abnormal protein.6
The lack of knowledge about the oncogenesis of vulvar SCC and the malignant 
potential of VIN lesions result in the absence of an evidence based protocol for the 
optimal treatment and follow-up for patients with VIN. The aim of the present study
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was to investigate the patterns of MIBi, p i6 INK4A and p53-expression and the presence 
of HPV in VIN lesions and adjacent SCCs to gain insight in the oncogenesis of vulvar 
squamous cell carcinoma, and test whether these parameters can be helpful to 
distinguish the two types ofVIN lesions.
Materials and methods
Patients and histopathology
All patients with a histological diagnosis ofVIN  with or without concurrent primary 
vulvar carcinoma between 1990 and 2002, with available microscopic slides and 
paraffin blocks, were selected from the database of the Department of Pathology 
of the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 
(n=i62). No recurrent vulvar carcinomas were selected. When a patient had a VIN 
lesion preceding or after the diagnosis of vulvar carcinoma, only the carcinoma and 
the adjacent VIN lesion were used for analysis. This led to a reduction with 25 cases. 
Another seventeen patients were excluded because o fth e  absence ofVIN  according 
to current criteria, in which VINi is no longer considered to be a premalignancy.3
All original hematoxylin-and-eosin-stained slides were reviewed by one pathologist 
with special expertise in gynecopathology [J B]. The histological diagnosis ofthe vulvar 
lesion was based on Kurman etal..Sideri etal. and Wilkinson et al..3;20;21The differentiation 
grade of vulvar SCCs was determined according to WHO criteria. In figure 2A, 2E-inset, 
3A, and 3A-inset, H&E stained sections of respectively solitary usual VIN, SCC associated 
with usual VIN, and differentiated VIN with adjacent SCC are shown.
After revision, a total number of 120 patients with a VIN lesion were eligible for 
analyses. Eighty-eight patients had an associated primary vulvar carcinoma and 
32 patients did not have nor developed a vulvar carcinoma (last date of follow-up 
December 2006). No patients with differentiated type VIN without a previous or 
subsequent vulvar SCC were diagnosed and therefore this entity was not present in 
this study. Of the 88 patients with an associated vulvar carcinoma, 13 had a concurrent 
usual VIN lesion and in 75 patients the carcinoma was adjacent to a differentiated VIN 
lesion. Representative sections for each case were selected for immunohistochemical 
analysis. A minimum distance of 0.5 cm between differentiated VIN and SCC in the 
same slide was required. When normal vulvar epithelium was available in the tissue 
sample, a site most distant from the (pre-) malignant vulvar lesion was selected for 
analysis of one or more immunohistochemical parameters (n=62; 40 patients with 
a differentiated VIN lesion with associated SCC, nine patients with usual VIN with 
associated SCC and 13 patients with a solitary usual VIN lesion).
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Material of 32 patients was also used in previous studies by the same group; mostly 
providing lichen sclerosus and normal vulvar epithelium (not in investigation in this 
paper).9;22 When the use ofVIN and/or SCC was duplicated, new H&E staining as well 
as immunohistochemical- and HPV-analysis was performed.
Recently, a patient with a solitary dVIN lesion was treated at our hospital. She had 
lichen sclerosus and five years ago she underwent a hemivulvectomy with bilateral 
inguinofemoral lymph node dissection because of a multifocal, macro-invasive 
squamous cell carcinoma ofthe vulva. Afterwards she received radiotherapy because 
of two positive lymphnodes in the left groin.
HPV DNA detection
Four micrometer thick tissue sections of each archival sample were put into a reaction 
tube and incubated overnight at s6°C in 200 |jl of 10 mM tris-HCL with 1 mM EDTA,
0.2% Tween-20, and proteinase K (0.3 mg/ml). If the VIN lesion and vulvar carcinoma 
were not available in the same archival tissue sample, two tissue sections (placed in 
one reaction tube) were used for HPV analysis. Proteinase K was inactivated by 10 
min incubation at ioo°C. The sample was centrifuged for 10 min at 11.000 rpm and 
10 |jl was directly used for PCR analysis. A water blank control was processed with 
each batch o ften  samples. Broad-spectrum HPV DNA amplification was performed 
using a short PCR fragment (SPF-PCR) assay. The SPF-PCR system amplifies a 65 bp 
fragment o fthe Li open reading frame, allowing for the detection of at least 43 HPV 
genotypes. Subsequent HPV genotyping was performed via a reverse hybridization 
line probe assay (HPV SPFio Line BLOT 25, LABO Bio-Medical products B.V., Rijswijk, The 
Netherlands), allowing for simultaneous typing of the following 25 HPV-genotypes: 
HPV 6,11,16,18,31,33,34,35,39,40,42,43,44,45,51,52,53,54,56,58,59, 66, 68,70 and 
74.The combined SPF-PCR-LiPA system for detection and genotyping of HPV has been 
described in detail elsewhere and is considered highly sensitive.2*24 In cervical cancer 
studies the HPV types 16,18, 31,33, 35, 39,45, 51, 52,56, 58, 59, 68,73 and 82 have been 
classified as high-risk and the HPV types 26,53, and 66 as probable high-risk types of 
HPV.12;25The HPV types detected in this study were classified accordingly.
Immunohistochemistry
Serial tissue sections (4-|-im thick) of formalin-fixed and paraffin-embedded blocks 
were cut with the first and the last sections hematoxylin and eosin-stained for 
control. After deparaffinizing and hydration, endogene peroxidase was blocked by 
an incubation in 1,5% H20 2 in phospate-buffered saline (PBS) for 15 minutes. Antigen 
retrieval was performed by microwave heat induction.The slides were pre-incubated 
with 20% normal goat serum (10 min) and then incubated with primary antibodies 
P53 (clone DO7, Dakocytomation, Denmark) 1:400, p i6INK4A (clone 16PO4, Neomarkers, 
Fermont, CA, USA) 1:500, and MIBi (clone MIBi, Dakocytomation, Denmark) 1:200, 
all suspended in 1 % bovine serum albumine (BSA)/PBS (60 min, RT). Subsequently, 
post-antibody blocking was done for 15 min (powervision plus). This was followed by
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incubation with polymeric-horse-radish peroxidase-goat anti-m ouse/rabbit/rat IgG 
(30 min, RT). The slides were developed with diaminobenzidine (mixed with H20 2) 
and the p53 and p i6 INK4A slides were rinsed in CuS0 4 for amplification; all slides were 
counterstained with Mayer’s hematoxylin (30 sec), dehydrated and finally mounted. 
All incubation steps were followed by three washes in PBS. Titration experiments 
were performed to determine the aforementioned optimal dilutions for the primary 
antibodies and in each series a positive control was included (CIN3 lesion).
Quantification o f immunohistochemical results
The immunoreactivity of p i6INK4A in the VIN lesion (and, when present, in their 
adjacent vulvar carcinoma and normal tissue) was scored based on the localization 
and extent o fth e  p i6 INK4A-immunoreactivity within the epithelium. Three categories 
were discerned: (1) no p i6 INK4A-positivity, (2) focal p i6INK4A-positivity, and (3) diffuse, 
transepidermal positive p i6 INK4A-staining.26'28 For statistical purposes, focal p i6 INK4A- 
staining was considered 'negative’.
For MIBi, the localization ofthe immunoreactivity w ithin the epithelium was assessed, 
and four categories were discerned: (1) basal or parabasal staining, (2) positivity 
confined to cells in the lower one third of the epithelium, (3) staining of cells in the 
lower two thirds ofthe epithelium, or (4) diffuse, transepithelial positive staining.9 For 
statistical purposes, M IBi-staining in the (para)basal layers or in the lower one-third 
o fth e  epithelium was considered 'low ’ and M IBi-staining in the lower two-thirds or 
the entire epithelium was considered 'high’.
For P53, cells were considered to be positive in case of nuclear staining.The extent of P53- 
positivity was evaluated by determining the percentage of p53-positivity in basal layer 
cells after counting 200 consecutive cells (labeling index (Ll)).The pattern of p53-staining 
was assessed by recordingthe location ofthe positive cells in the levels ofthe epithelium. 
The term “suprabasal extension" was used when p53-positive cells were found in both 
the basal layer and in higher layers ofthe epithelium.5 In carcinomas, the percentage of 
p53-positive cells was estimated after evaluation ofthe entire lesion present in the slide.
When the carcinoma was micro-invasive (n=6,four adjacent to usual VIN,two adjacent 
to differentiated VIN) no immunohistochemical staining results could be scored.
Statistics
On the basis ofthe histological diagnosis, patients were divided in three groups (usual 
VIN with SCC, usual VIN without SCC and differentiated VIN with SCC).The difference 
in age was tested using the non-parametric Kruskal-Wallis test. Differences in 
presence of HPV, p i6INK4A-expression and MIBi-localisation were tested using the chi- 
square test. The differences in P53-U in VIN lesions and p53-positivity in SCCs between 
groups were tested using the non-parametric Mann-Whiney-U test. For all analyses a 
p-value of <0.05 was considered to be statistically significant.
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Results
Patients with a vulvar carcinoma adjacent to usual type VIN had a lower median age 
(52 years, SD 13.4 years) compared to patients with differentiated VIN with associated 
carcinoma (74 years, SD 12.5 years). Patients with usual VIN without an associated 
vulvar carcinoma had a median age of 36 years (SD10.8 years) at the time of diagnosis. 
The differences in age at the time of diagnosis were highly statistically significant 
(Kruskal-Wallis Test, p<o.ooi). In sixty percent o fth e  patients with differentiated VIN 
a (clinical and/or histological) diagnosis of LS was noted in the patient chart; in this 
study no examination for LS on the histology specimen was performed.
The FIGO and TNM stages o fthe vulvar carcinomas in both groups were comparable: 
64% ofthe dVIN associated carcinomas were FIGO stage I or II vs. 75% ofthe usual VIN 
related carcinomas. Ninety-three percent ofthe dVIN-associated carcinomas were T i/ 
T2 and 63% were No vs. 83% and 75% o fthe usual VIN related carcinomas.
In Figure 1, the combined results ofthe presence of HPV and the expression of p i6INK4A, 
MIBi and P53 are summarized in a flow-chart.
Figure i: Flow diagram  show ing sim ultaneous HPV-positivity, p i6 INK4A-expression and P53-LI in
m issing
the 120 lesions.
uVIN = usual VIN
dVIN = differentiated VIN
A P53-LI > 0.5 was considered p53-positive (p53+)
MIB low : M IBi-positive cells in the (para)basal layers or the lower one third o fth e  epithelium  
MIB high: M IBi-positive cells in the lower two thirds o fth e  epithelium  or the entire epithelium
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HPV
Usual VIN was significantly more often hr-HPV positive than differentiated VIN; 38 
of 45 cases of usual VIN were hr-HPV positive (84%); all cases of differentiated VIN 
were hr-HPV-negative (chi-square, p<o.ooi). Usual VIN without associated carcinoma 
showed comparable percentages of positivity for hr-HPV with usual VIN with 
associated carcinoma; 26 of 32 cases (81%) and 12 of 13 cases (92%) respectively (data 
not shown, chi-square, p>o.os). One usual VIN lesion without associated SCC was 
positive for low-risk HPV (HPV 6). All hr-HPV-positive usual VIN lesions were diffusely 
positive for p i6INK4A and had MIBi-expression up to high in the epithelium. Ninety-five 
percent (36/38) had a P53 Ll of ffio.5.
prfMW
The staining pattern of p i6INK4A in usual VIN was cytoplasmic and nuclear, with more 
nuclear than cytoplasmic staining (see Figure 2B). Irrespective ofthe type of adjacent 
lesion, normal tissue showed no or minimal im m unostainingfor p i6INK4A.
The pi6INK4A immunoreactivity in vulvar carcinomas showed similarities with the 
P-iö 'nk+a immunoreactivity in its associated VIN lesion: all usual VIN lesions were 
positive for p i6INK4A, whereas in differentiated VIN, all 75 lesions were negative for 
p i6 INK4A. All usual VIN lesions without SCC were positive for p i6INK4A. In the group of 
differentiated VIN lesions, only one case was positive for p i6INK4A. The difference in 
p i6 INK4A-positivity in the carcinomas adjacent to differentiated VIN (3/73: 4%) and 
usual VIN (8/9: 89%) was significant (data not shown, chi-square, p<o.ooi).
MIBi
A uniformly nuclear and mostly very strong M IBi-staining was seen in all types 
of vulvar lesions, with no cytoplasmic staining (see Figures 2C, 2E and 3B). MIBi 
immunoreactivity in normal epithelium (irrespective of the type of adjacent VIN 
lesion) was parabasal with a negative basal cell layer in all cases.
In SCC adjacent to differentiated VIN the median estimated positivity for MIBi was 
70% (range 10-100%) whereas in SCC adjacent to usual VIN the median estimated 
MIBi-positivity was 80% (range 50-100) (Mann-Whitney-U, p=o.o6). There was a 
significant difference in the localization of M IBi-staining between the two types of 
VIN lesions (chi-square, p<o.ooi); usual VIN lesions showed MIBi staining up to high 
in the epidermis in 44 of 45 of cases (98%), in contrast to the M IBi-staining confined 
to the lower layers ofthe epithelium in differentiated VIN in 72 of 75 cases (96%).
PS3
Analyzing the p53-expression patterns in VIN lesions, two distinct patterns became 
apparent. In differentiated VIN lesions, the basal cell layer often was positive for P53, 
and in most lesions there was “suprabasal extension” as can be seen in Figure 3C. In 
usual VIN lesions less cells o fth e  basal layer were positive.The suprabasal positivity
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in usual VIN, occasionally showed a distinct clustered pattern, in which central parts 
o fth e  epithelial rete ridges were positive for p53 whereas the rest o fth e  epithelium 
was negative for p53 as can be seen in Figure 2D. In normal vulvar epithelium no 
p53-expression was found. The expression of P53 in the two types of carcinoma can 
be found in Figure iF (carcinoma adjacent to usual VIN) and Figure 3D (carcinoma 
adjacent to differentiated VIN).
The median Lis and the percentages of p53-positivity in the carcinomas are shown in 
Table 1. Analyzing the P53 Lis revealed that the P53 Ll in differentiated VIN adjacent 
to VC was significantly higher than the P53 Ll in usual VIN adjacent to VC (Mann- 
Whitney-U, p<o.ooi).The difference in P53 Lis between usual VIN with and without 
VC was not significant (Mann-Whitney-U, p<o.o8). The median percentages of P53- 
positivity in vulvar carcinoma adjacent to differentiated VIN were significantly higher 
than in vulvar carcinoma adjacent to usual VIN (Mann-Whitney-U, p=o.oo8).
Discussion
Two separate pathways lead to the development of vulvar SCC, which have 
their own precursor lesions, with a unique immunohistochemical profile that 
corresponds with the profile in the adjacent carcinoma. We believe that the use of 
this immunohistochemical profile can be of particular help in the correct and tim ely 
diagnosis of VIN.
In VIN lesions asw ell asthe adjacent carcinomas, the expression of p i6 INK4Awas highly 
associated with the presence of HPV.This close relation has already been demonstrated 
in the vulva9;29;3°,the cervix31, the head and neck region3*33, the skin34, and the anorectal 
region.35 In the oral cavity, immunohistochemical p i6INK4A detection has proven to be 
fully equivalent to HPV detection.36 Others have shown that clinically meaningful viral 
HPV infections can be reliably measured with an algorithm of pi 6INK4Aimmu nostaining 
followed by PCR on pi6INK4A-positive cases.33 In this study, the use of p i6 INK4A alone was 
sufficient to identify all usual VIN lesions, and the immunohistochemical profiles 
of five o fth e  seven HPV-negative usual VIN lesions (see Figure 1) suggest that even 
though we used a highly sensitive and accurate HPV detection method24, the results 
in at least five usual VIN lesions were false-negative.
High-HPV DNA was found in only 12/88 (14%) of all the vulvar SCCs in this study, all 
adjacent to a usual VIN lesion and HPV16 was, as in earlier publications on HPV in the 
genital area, most prevalent.8;37 Previous studies on vulvar carcinomas have reported 
hr-HPV infection in 0-57% o fthe cases, depending on the HPV detection method and 
the types of SCC that were analyzed.9;19;3S'4°
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Figure 2: solitary usual VIN lesion (A-D) and squam ous cell carcinom a adjacent to a usual VIN  
lesion (E-F)
A. H&E stained slide o f a usual VIN lesion w ithout adjacent squam ous cell carcinom a; atypical 
nuclei can be found throughout the entire epithelium .
B. the entire epithelium  is positive for p i6 INK4A.
C. M IBi-positive cells can be found in at least the lower 2/3 o fth e  epithelium  in usual VIN.
D. Clusters o f p53-positive cells can be found in the epithelium  o f a usual VIN lesion.
E. M IBi-postive nests in vulvar squam ous cell carcinom a. On the H&E photo in the inlay, mitotic 
figures and atypia can be seen.
F. in the carcinom a adjacent to usual VIN, around 25% o fth e  cells are positive for P53.
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Figure 3: differentiated VIN lesion w ith adjacent squam ous cell carcinom a
A. H&E stained slides o f a differentiated VIN lesion (adjacent to squam ous cell carcinom a). Nu­
clear atypia and the presence o f mitotic figures in the differentiated VIN lesion is confined  
to the basal cell layers. Hyperkeratosis and dyskeratosis are present and the rete ridges are 
elongated.
B. In differentiated VIN, M IB i-positivity is confined to the basal and parabasal layers o f the 
epithelium .
C. In differentiated VIN, P53-posititivity is most prominent in the basal cell layers with suprabasal 
extension.
D. Around 90%  o fth e  cells o fth e  invasive nests o fth e  squam ous cell carcinom a adjacent to dif­
ferentiated VIN are positive for P53.
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Similar to the previously published series of Yang and Hart, the differentiated VIN- 
lesions adjacent to SCC showed a high p53 Ll and a comparable expression-pattern with 
suprabasal extension.5 Usual hr-HPV-positiveVIN lesions, however showed a much lower 
P53 Ll and the lower percentage in the HPV-positive carcinomas in our study, has also 
been described by others.41'43 As previously described by Santos et al., in HPV-positive 
SCCs, pi6INK4A and p53 tended to be mutually exclusive.30 Nogueira et al. described 
comparable results for VIN in women younger vs. older than 55 years of age, without 
testing for HPV.44 It is likely that the group of women younger that 55 years consisted 
of mainly high grade, HPV-positive, usual VIN lesions whereas the group of women 
over 55 years probably mainly consisted of HPV-negative, differentiated VIN lesions.The 
clustered positivity in the epithelium of usual VIN has never been described.
In normal vulvar tissue, irrespective o fth e  adjacent type ofVIN, no expression of P53 
and pi6INK4A was found and MIBi-expression in normal vulvar tissue was confined to 
the lower one-third o fth e  epithelium. As was shown in a recent publication, MIBi 
can be used to distinguish normal vulvar epithelium from differentiated VIN and 
other premalignancies because of a MIBi-negative basal cell layer in normal vulvar 
epithelium.22 This feature combined with the absence of expression o fth e  cell cycle 
related proteins investigated in this study, can improve the timely recognition of 
differentiated VIN as it is often overlooked or mistaken for a benign dermatose such as 
pseudoepitheliomatous hyperplasia and lichen simplex chronicus.4546 The differences 
in age ofthe two groups ofVIN lesions were highly statistically significant. This fits the 
epidemiological data known from literature; usual VIN occurs in younger women and 
LS associated differentiated VIN and keratinizing vulvar SCC occurs at a higher age.
The fact that no isolated, solitary differentiated VIN lesions have been found in this 
study supports the idea that differentiated VIN is a lesion with a short intra-epithelial 
phase that rapidly progresses to vulvar SCC.6;7 This is supported by the fact that in 
this study all differentiated VIN lesions presented adjacent to vulvar SCC, and mostly 
had a size of more than 1 cm. We strongly believe in the high malignant potential 
of differentiated VIN. Incidental cases of differentiated VIN occurred in our hospital, 
but all after a patient had been treated for vulvar SCC. We also found some cases of 
differentiated VIN on biopsy, and invasive carcinoma in the subsequent vulvectomy 
or excision (performed w ithin two weeks of diagnosis). Nevertheless, there is 
controversy regarding the actual role of differentiated VIN in the development of 
vulvar SCC. It has also been described as the in-situ carcinoma component adjacent 
to the invasive carcinoma47, and our results cannot confirm nor reject this hypothesis. 
Furthermore, differentiated VIN can be difficult to diagnose, both clinically and 
histopathologically.42:454648 When differentiated VIN is found in the surgical margins of 
an excision, this might have consequences for the further treatment and follow-up of 
the patient. Better recognition and uniform use of nomenclature will facilitate future 
research and the comparison of published results. The changes in nomenclature of 
squamous vulvar lesions proposed by the ISSVD are not yet uniformly used.3
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In conclusion, both pathways leading to vulvar SCC have their own molecular 
background. Future studies should focus on the exact role of p53 in the development 
of HPV-negative vulvar squamous cell carcinoma and the malignant potential of 
differentiated VIN. Using a robust immunohistochemical panel with the proteins 
pi6'NK4A, p53,and MIBi, the two types of VIN lesions can be accurately distinguished and 
recognized. Timely diagnosis and thus early recognition of differentiated VIN lesions 
should lead to a more extensive treatment strategy for this kind ofVIN lesion.
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Table i: pss Lis and range in vulvar carcinom a and VIN
m edian range
Vulvar carcinom a (74*) % <min-max>
adjacent to differentiated VIN (66) 67,5 % < o-95>
adjacent to high-grade VIN(8) 30,0 % <15- 6o >
VIN (114') Ll
differentiated type (69) 0.85 <o.i6-i.oo>
high-grade VIN, adjacent to VC (13) 0.025 < 0 .0 0 -0 .1 2 >
h igh-grade VIN, w ithout VC (32) 0.058 <o.oo-o.55>
# W hen the carcinom a was m icro-invasive (n=6) p53 positivity could not be estimated and in 8 
cases there was no carcinom a left in the p53 slide (but was present in H&E), therefore the total 
num ber o f carcinom as in this table is less than 88.
* In 6 cases there w as no VIN lesion left in the p53 slide (but was present in H&E), therefore the 
total num ber ofV IN  lesions is less than 120.
VC= vulvar carcinom a
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MIBi-expression in basal cell-layer: 
a diagnostic tool to identify 
premalignancies of the vulva
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Abstract
Lichen sclerosus, high-grade usual vulvar intraepithelial neoplasia (VIN) and differ­
entiated VIN have a different malignant potential. The objective of this study was to 
quantify the proliferative activity in the basal region o fth e  epithelium of vulvar pre­
malignancies. Furthermore, we investigated whether MIBi expression in the basal re­
gion of vulvar epithelium can be helpful in diagnosing differentiated VIN, which may 
be hard to discern from normal epithelium. MIBi was used to immunohistochemically 
visualise proliferating cells within formalin-fixed, paraffin-embedded, archival tissue 
sections of different vulvar premalignancies (N=48) and normal vulvar epithelium 
(N =i6). Automatic digital image analysis software was developed to quantify the pro­
liferating fraction in different parts of the epithelium (MIBi positivity index). MIBi 
expression differed among the various vulvar premalignancies; a MIBi-negative basal 
cell layer was a distinct feature of normal vulvar epithelium. No MIBi-negative basal 
cell layer was noted in differentiated VIN or other vulvar premalignancies. Owing to 
this negative cell layer, the MIBi proliferation index in normal vulvar epithelium was 
significantly lower than in vulvar premalignancies. In conclusion, MIBi expression can 
be a helpful tool in diagnosinga premalignancy and has additional value especially to 
distinguish differentiated VIN neoplasia from normal vulvar epithelium, but cannot 
explain the differences in malignant potential.
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Introduction
Vulvar cancer is the fourth most common gynaecologic cancer and comprises 5 per­
cent of all malignancies ofthe female genital tract. Based on clinical and pathological 
features, vulvar squamous cell carcinoma can be subdivided into two different types, 
which seem to develop from their own associated premalignancies.
The most frequent type of vulvar carcinoma occurs mainly as a unifocal lesion in el­
derly women and is related to lichen sclerosus and/or differentiated vulvar intraepi­
thelial neoplasia (VIN). This type of tum our is probably not associated with human 
papillomavirus (HPV) infection.1'4 The less common type, accounting for about one- 
third of all vulvar squamous cell carcinomas, is associated with HPV, predominantly 
HPV-types 16 and 18. This type of tum our often occurs as a multifocal lesion in rela­
tively young women and is usually preceded by high-grade usual VIN lesions (also 
referred to as classic VIN lesions).3;5;6 Recently, the International Society for the Study 
of Vulvovaginal Disease (ISSVD) has proposed a new nomenclature for premalignant 
vulvar lesions (see Table 1).7
In usual VIN, the epithelium is thickened and accompanied by hyperkeratosis and/or 
parakeratosis. Although a spectrum of architectural abnormalities may be seen, the 
lesion is readily recognizable as an intraepithelial neoplasm by the pathologist due 
to cytological abnormalities o fth e  epithelial cells throughout the whole thickness 
of the epithelium.8 Differentiated VIN is clinically and pathologically more difficult 
to recognize.There is little or no atypia above the basal or parabasal layers and it has 
a high degree of cellular differentiation, which combined with an absence of w ide­
spread architectural disarray hinders recognition.2*9 Differentiated VIN is relatively 
infrequently diagnosed in its pure form and is often seen adjacent to lichen sclerosus 
and/or rapidly growing invasive vulvar squamous cell carcinoma.3*10 Besides the dif­
ficulties in clinical and histological recognition of differentiated VIN, it is suggested 
that this form ofVIN is highly proliferative and might be more likely to progress to an 
invasive neoplasm than lichen sclerosus and HPV-related VIN lesions.2*11 Currently, no 
biomarker or diagnostic tool to predict possible invasive behaviour of premalignant 
vulvar lesions is available. Because o fth e  risk of malignant progression it is current 
practice that all patients with vulvar premalignancies undergo regular check-ups. 
However, there is no evidence that this follow-up prevents the development of cancer 
or results in earlier detection of a malignancy.12
Proliferative activity in tissues can be visualized using a proliferation marker like MIBi, 
which is a monoclonal antibody against the Ki-67 antigen, a nuclear antigen present 
in human proliferating cells in all stages ofthe cell cycle, but not in the Go phase.1*14 In 
many (pre)malignant lesions qualitative MIBi-expression is used for grading and es­
tim ating prognosis.10;15'18 Bulten et al. used a method in which epithelial MIBi-expres- 
sion patterns in cervical lesions were digitally quantified.The method proved to be an
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objective, reproducible and reliable method of classification for dysplastic changes 
in cervical epithelium.15 Systematic quantitative evaluation of MIBi-expression in the 
basal region of premalignant vulvar lesions has not yet been performed.10;19'23
The primary objective of this study was to quantify the proliferative activity in the epi­
thelial cell layers in differentiated VIN and othervulvar premalignancies with the aim 
to find an explanation for the differences in malignant progression. Furthermore, we 
investigated whether MIBi-expression in the basal regions o fth e  vulvar epithelium 
may be helpful in diagnosing differentiated VIN.
Materials and Methods
Specimens
Sixty-four specimens from vulvar biopsies, vulvar excisions or vulvectomies, diagnosed 
as non- or premalignant vulvar lesions between 1992 and 2002, were retrospectively 
obtained from the archives ofthe Department of Pathology at the Radboud University 
Nijmegen Medical Centre (Nijmegen, the Netherlands). All specimens were routinely 
fixed (4% buffered formalin) and paraffin embedded. Standard 4 |jm thick haematoxy- 
lin and eosin-stained sections were used for the classification of the lesions. Two ex- 
pert-pathologists [JB and JMMG], specialised in gynaecological pathology, blindly and 
independently re-examined the slides and classified them according to current WHO 
criteria and the recent modification ofthe ISSVD.7;24They agreed on all diagnoses.
The 64 tissue specimens in this study consisted of: 22 usual type VIN lesions, 14 dif­
ferentiated VIN lesions, 12 lesions with lichen sclerosus and 16 normal epithelium 
samples (10 patients with vulvodynia who were treated with a partial resection of 
the vulvar vestibule and six normal epithelium samples from free tum our margins in 
vulvectomy specimens of patients treated for vulvar cancer).
Immunohistochemistry
Four-micrometer thick paraffin sections were mounted onto polylysine-coated slides 
and dried overnight at s8°C. The sections were dewaxed in xylene and endogenous 
peroxidase was blocked using H20 2 in methanol for 15 minutes and the slides were 
rinsed three times in phosphate-buffered saline (PBS; pH 7,4) for 5 minutes.The slides 
were placed in a citrate buffer (0,01 M; pH 6,0) and heated in a household microwave 
oven (3 min at 850 W until boiling; followed by 10 min at 180 W). The sections were 
allowed to cool down to room temperature (RT) and were briefly washed in PBS (10 
min). Subsequently, the slides were pre-incubated with 20% normal goat serum and 
incubated with the primary antibody Ki-67 (clone MIBi, Dakocytomation, Denmark) 
1:100 in PBS with 1% BSA (60 min, RT). Subsequently, the slides were rinsed in PBS (10 
min) and post-antibody blocking was done for 15 min (powervision plus). This was
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followed by incubation with polymeric-horse-radish peroxidase-goat anti-m ouse/ 
rabbit/rat IgG (30 min, RT).The slides were developed with diaminobenzidine (mixed 
with H20 2), counterstained with Mayer’s haematoxylin, dehydrated in ethanol and xy­
lene and finally mounted. In each run a buffer only and a vulvar squamous cell carci­
noma served as negative and positive controls.
Quantification o f immunohistochemical staining /  Image analysis
Quantitative analysis of MIBi staining was achieved using digital image analysis of 
microscopic images. Image acquisition was performed using a 3CCD colour video 
camera (Sony DXC-950P, Sony Corp, Japan) mounted on a conventional light micro­
scope (Axioskop 2 plus, Carl Zeiss AG, Germany) and attached to a personal computer 
with frame grabber card (Matrox Meteor-ll M ultichannel, Matrox Imaging, Dorval, 
Canada). Images were acquired using a 20X objective (Plan Neofluar, NA=o.5, result­
ing specimen level pixel size 0.39 |-im2). Prior to analysis ofthe immunohistochemical 
staining, an image of an empty microscopic field was acquired, which was used for 
correction for unequal illumination. In each tissue section we aimed to measure 8 mi­
croscopic fields, representative ofthe lesion. Image acquisition and analysis were per­
formed using a custom written macro in KS400 image analysis software (Carl Zeiss 
AG, Germany). For each digitised red green blue (RGB) image, the following proce­
dure was performed.The operator interactively defined the location ofthe basement 
membrane by drawing a line with a mouse cursor. From this line, 20 strata of each 5 
|jm thickness were autom atically determined, covering the basal region of the epi­
thelium. Within these areas, pixels with a ratio between the red and green RGB com­
ponent of more than 1.03 and a red intensity under 180 were labelled as belonging to 
MIBi positive nuclei. In the same way, pixels with a ratio between blue and green in­
tensity over 1.07 and red camera channel under 210 were labelled as belonging to hae­
matoxylin stained, MIBi negative nuclei. See figure iA  and iB fo r the different steps in 
the process.Thresholds were determined from a set of training slides and were found 
adequatefor almost all slides analysed in this study.When the initial thresholds led to 
unrealistic patterns, adjustment was performed by the operator (data not shown).
For each measured field, the total area of positive nuclei per stratum of 5 |jm and the 
total area of all nuclei per stratum was automatically recorded. For each stratum, the 
ratio between the MIBi positive nuclear area and total nuclear area was calculated 
(single layer). This ratio, xioo% , was used as a measure of MIBi positivity: the MIBi 
positivity index. In addition, the cumulative MIBi positivity indices were calculated by 
dividing the sum ofthe MIBi positive nuclear area in multiple strata by the sum ofthe 
total nuclear area in the same strata (xioo%).
In normal vulvar epithelium, the presence or absence of inflammatory cells directly 
underlyingthe basement membrane was recorded for each measured field.
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Statistical analysis
All measured fields were averaged to calculate mean values per patient.These values 
were used to calculate mean values per type of lesion.
All analyses were performed using SPSS 12.0.1 software (SPSS Inc, Chicago, Illinois, USA). 
To test whether the positivity index in the lowest 5 |jm of normal vulvar epithelium 
differed between the fields with and without inflammatory cells underneath the basal 
membrane, the non-parametric Mann-Whitney-U-test for unpaired observations was 
used. The Kruskal-Wallis one-way analysis of varia nee by ranks was used totest w heth­
er the different positivity indices were different for at least one ofthe four diagnostic 
groups. When a significant difference was found, distribution-free all-treatments m ul­
tiple comparisons based on pairwise rankings with correction for tied observations 
were used to disclose which ofthe diagnostic groups differed significantly.25
Results
Pathology
In figure iC, iE and iG, H&E stained sections of differentiated VIN, usual VIN and lichen 
sclerosus are shown.
The epithelial cells of usual VIN (figure iC) have a high nuclear:cytoplasmic ratio and 
lack cytoplasmic maturation above the basal and parabasal layers. Mitotic activity 
is present above the basal layer with mitotic figures that are often abnormal in ap­
pearance and reach the upper cell layers. Multinucleation and dyskeratosis, including 
formation of intraepithelial squamous pearls, may be seen. Nuclear pleomorphism 
and hyperchromasia are present; however, nucleoli are uncommon.
The atypia in differentiated VIN lesions (figure iE) is strictly confined to the basal and 
parabasal layers ofthe epithelium, where the cells have abundant cytoplasm and form 
abortive pearls.The nuclei are relatively uniform in size and contain coarse chromatin 
and prominent nucleoli leading to paradoxical maturation abutting on the epithelial- 
stromal junction.The superficial layers o fth e  epithelium have a normal maturation, 
exhibit hyperkeratosis and do not show koilocytosis.24 Furthermore, in differentiated 
VIN the epithelium exhibits elongation of rete pegs.
In lichen sclerosus (figure iG) the loss of rete ridges is clearly visible.There is little or no 
cellular or nuclear atypia. A zone of homogeneous collagenised subepithelial oedema 
of variable thickness is present as is a band of lymphocytic infiltration beneath this 
zone.The epithelium is flattened and/or thinned, and mild hyperkeratosis is present.
MIBi expression pattern
In all lesions, MIBi staining was present in the basal and/or parabasal regions o fthe 
epithelium and the basal membrane was always clearly identifiable. As can be seen 
in figure 1 (D, F and G), MIBi expression varied in the different vulvar premalignan­
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cies. In usual VIN all cell-layers were positive for MIBi (see figure iD). In differentiated 
VIN (figure iF) the majority o fth e  epithelium was MIBi-negative with a thin layer 
of MIBi positive cells parabasally. MIBi positivity was restricted to the lower 1/3 of 
the epithelium in lichen sclerosus (figure iH). Furthermore, normal epithelium had a 
distinct MIBi expression pattern. Like in lichen sclerosus, the lower 1/3 o fth e  normal 
vulvar epithelium was MIBi positive, but a MIBi negative cell layer directly above the 
basement membrane was visible (figure i A-B). A simplified schematic representation 
ofthe different expression patterns is depicted in figure 2.
MIBi positivity index
In figure 3, an overview o fthe single (figure 3A) and cumulative (figure 3B) MIBi posi­
tivity indices in different areas o fthe epithelium are shown.The thick line represents 
the median positivity index, boxes represent quartiles and the lines indicate extreme 
values. The MIBi positivity indices per patient were based on a median number of 6 
(range 4-10) measurements. In normal epithelium, there was no statistically significant 
difference in MIBi positivity index in the lowest 5 |jm o fth e  epithelium between the 
measured fields with or without inflammatory cells underneath the basal membrane 
(data not shown, Mann-Whitney-U-test, p>o.os).The MIBi positivity indices in normal 
epithelium from vulvar vestibulitis patients and from patients with a carcinoma did 
not differ from one other (data not shown, Mann-Whitney-U-test, all p-values>o.os)
In table 2, an overview of p-values (distribution-free all-treatments multiple comparisons 
based on pairwise rankings with correction fortied observations) can be found,comparing 
cumulative and single layer MIBi positivity indices between the four diagnostic groups.
In normal vulvar epithelium, the lowest 10 |jm of the epithelium was almost negative 
for M IBi.The cumulative MIBi positivity indices at 5 and 10 |jm in normal epithelium 
were significantly lower than the corresponding areas in any ofthe other lesion types 
(all p-values <0.001). In the higher strata, single layer MIBi positivity indices in normal 
vulvar epithelium were comparable to the single layer MIBi positivity indices in dif­
ferentiated VIN. Due to the big difference in the lowest two layers, the difference be­
tween the cumulative MIBi positivity indices remained statistically significant. Com­
paring the MIBi positivity indices between lichen sclerosus and normal vulvar tissue 
revealed differences in only the layers up to 15 |jm.
In usual VIN lesions, a MIBi positivity index of almost 40% or more was observed in all 
layers o fthe epithelium, causing the cumulative MIBi positivity indices to be around 
the same values. In none o fthe other epithelia, single layer MIBi positivity indices (at 
55 |jm or higher) were as high as those in usual VIN (all p-values < 0.001). Comparing 
the cumulative MIBi positivity indices of usual VIN with the other lesions gave the 
same results (all p-values < 0.05).The differences with normal epithelium were most 
striking, as all cumulative and single layer MIBi positivity indices were significantly 
higher in usual VIN.
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The cumulative MIBi positivity indices up to 10 |jm in lichen sclerosus were signifi­
cantly lower than these strata in differentiated VIN.The single and cumulative MIBi 
positivity indices higher in the epithelium were not significantly different and the 
pattern was comparable (see figure 2 and figure 3).
Discussion
In general, it is suggested that differentiated VIN has a higher malignant potential 
than other vulvar premalignancies.8;26This is not explained by our quantitative analy­
sis of proliferative activity. The MIBi positivity indices in the epithelium of differenti­
ated VIN were not statistically different from the MIBi positivity indices in well estab­
lished other precursors of vulvar carcinoma, i.e. usual VIN. The proliferative activity 
in the lower strata was comparable whereas the MIBi positivity indices covering a 
higher part ofthe epithelium were significantly higher in usual VIN, which is thought 
to be of lesser malignant potential. Several other investigators calculated a MIBi posi­
tivity or labelling index, measuring the entire thickness o fthe epithelium or only the 
basal cell layer, but none o fth e  groups used digital quantitative image analysis and 
mostly no distinction was made between differentiated and usual VIN, or only usual 
VIN was analysed.27 Only scoring the Ml Bi-pattern or using a semi-quantitative scor­
ing method is less accurate. Due to deep rete pegs the measurement of the entire 
epithelium, as previously published by Bulten et al for cervical lesions, is technically 
not possible in differentiated VIN lesions.15 We calculated the MIBi positivity index 
by dividing the measured MIBi positive nuclear area by the total nuclear area. In this 
manner, the thickness of the epithelium that can be highly variable amongst differ­
ent vulvar premalignancies and amongst different patients was no confounder in the 
measurements. When it would be possible to measure the entire epithelium, the dif­
ferences in cumulative MIBi positivity indices between differentiated VIN and usual 
VIN would probably be more prominent.
We noticed a remarkable difference in the MIBi staining pattern of vulvar premalig­
nancies versus normal vulvar epithelium. In normal vulvar epithelium, a MIBi-negative 
cell layer above the basal membrane was observed, which was absent in differenti­
ated VIN. There was no MIBi-negative cell layer in other vulvar premalignancies and 
therefore the presence of a negative MIBi layer seems to be a characteristic of normal 
vulvar epithelium and the absence of such a layer above the basal membrane, indi­
cates the presence of a premalignancy. Scurry et al. describe similar results in their 
qualitative analysis of Ki-67 of lichen sclerosus and normal epithelium.21 Although they 
did not digitally quantify their measurements and did not specifically mention a MIBi- 
negative basal cell layer, they describe that the MIBi staining in normal epithelium 
was localized more parabasally and in lichen sclerosus more basally.The lack of effect 
of inflammatory cells beneath normal vulvar epithelium on the presence of a MIB1-
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negative basal cell layer and the absence of a MIBi-negative basal cell layer in vulvar 
premalignancies can be seen as disturbance of cell growth in vulvar premalignancies.
Lichen sclerosus and usual VIN lesions are readily recognizable as they have distinct 
characteristics at histopathological examination. Differentiated VIN is often very dif­
ficult to recognize and sometimes hard to discern from normal epithelium.2*9 Using 
MIBi-expression to detect a proliferating basal cell layer in combination with the 
characteristic MIBi staining pattern with only positive cells in the rete pegs and little 
positivity in the upper layers o fth e  epithelium, might improve the early recognition 
of differentiated VIN. A simplified schematic representation of the different expres­
sion patterns is depicted in figure 2. Further investigations have to provide evidence 
whether this feature of MIBi is applicable in daily practice.
Despite its atrophic clinical aspect, lichen sclerosus has a relatively high proliferative 
activity, which was significantly higher than in normal vulvar tissue, which might be 
responsible for its malignant potential. This is in contrast with Tan et al., who found 
a lower MIBi positivity index in vulvar lichen sclerosus compared to normal controls. 
However, they did not use digital imaging techniques to quantify MIBi-positivity and 
only counted the basal and suprabasal cell layers.29 Lichen sclerosus and differentiated 
VIN showed comparable patterns of MIBi positivity indices, both single and cumulative. 
This attributes to the assumption that lichen sclerosus and differentiated VIN belong to 
the same entity that might proceed to HPV-negative vulvar carcinoma.1'3*0 Differenti­
ated VIN might develop from lichen sclerosus and/or squamous hyperplasia, through 
loss of apoptosis regulation, like the development of squamous cell carcinoma in oral 
lichen planus lesions.31 The role ofthe regulator of apoptosis, P53, and its mutations, in 
differentiated VIN and HPV-negative vulvar carcinoma remainsto be elucidated.8;32'34
In conclusion, the use of MIBi in the diagnosis of premalignant vulvar lesions might 
prove helpful, especially to discern differentiated VIN from normal vulvar epithelium. 
In all vulvar premalignancies the relationship between basal and parabasal cel I-I ayers 
seems to be disturbed. However, the MIBi positivity index was not higher in differen­
tiated VIN lesions, which are presumed to be more likely to become invasive, than in 
usual VIN lesions.
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Figure 1
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A-B. Photos o f M IBi-staining and the digital image analysis process in normal vulvar epithelium.
A. A red line under the basem ent membrane, drawn by the operator.
B. An io o |jm  wide area covering part o fth e  epithelium  was identified. 20 strata o f each 5|jm  
width, in which M IBi-negative (green) and M IBi-positive (blue) nuclei are shown. Note the 
negative M IBi cell layer above the basem ent membrane.
C-H. H&E and M IBi-staining o f 4 |jm paraffin sections o f a usual VIN lesion, differentiated  
VIN and lichen sclerosus. The peroxidase-labelled im m unohistochem ical com plexes were 
visualized with diam inobenzodine (DAB) (brown-black).
C. H&E-stained section o f a usual VIN lesion, show ing atypical cells throughout the whole  
thickness o fth e  epithelium .
D. In usual VIN M IBi-positive cells can be seen in all layers o fth e  epithelium .
E-i. An abortive pearl that can be found in differentiated VIN.
E-inset The atypia in differentiated VIN is confined to the basal layers o fth e  epithelium .
F. In differentiated VIN the M IBi-positive cells are confined to the basal layers.
G. In lichen sclerosus little atypia can be seen.
H. In lichen sclerosus the M IBi-positive cells are confined to the basal layers.
Original m agnifications: (A, B) X20; (C, D, E-i, F, G, H) xio; (E-inset) X5
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Figure 2
Simplified schem atic representation o fth e  M IBi-expression in
A. normal vulvar epithelium ,
B. lichen sclerosus,
C. differentiated VIN and
D. usual VIN.
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Figure 3
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Table 1. Old and new  nom encla tu re  fo r vu lva r lesions7
Old nom enclature New nom enclature
VI Ni No cancer precursor
(Classic) VIN2/3 High-grade VIN, usual type /  usual VIN
(W ell-)Differentiated VIN(3) /  VIN sim plex Differentiated VIN
TOO
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Table 2. Com parisons of single layer and cum ulative M IB i positivity indices
Lesion types com ­ p-value single layer p-value cum ulative
pared M IB i positivity indices M IB i positivity indices
o-5|jm P < 0.001 5M m P < 0.001
5-io|jm P < 0.01 lom u P < 0.001
normal io -i5 |jm NS i5|jm P < 0.01
vs i5-20|jm NS 20|jm NS
lichen sclerosus 55-6o|jm NS 6o|jm NS
70 -75(jm NS 75Mm NS
9 5 -io o |jm NS io o |jm NS
o-5|jm P < 0.001 5M m P < 0.001
5-io|jm NS lom u P < 0.001
normal io -i5 |jm NS i5|jm P < 0.001
vs i5-20|jm NS 20|jm P < 0.001
differentiated VIN 55-6o|jm NS 6o|jm P < 0.01
70 -75(jm NS 75Mm P < 0.01
9 5 -io o |jm NS io o |jm P < 0.05
o-5|jm P < 0.001 5M m P < 0.001
5-io|jm P < 0.001 lom u P < 0.001
normal io -i5 |jm P < 0.05 i5|jm P < 0.001
vs i5-20|jm P < 0.01 20|jm P < 0.001
usual VIN 55-6o|jm P < 0.001 6o|jm P < 0.001
70 -75(jm P < 0.001 75Mm P < 0.001
9 5 -io o |jm P < 0.001 io o |jm P < 0.001
o-5|jm P < 0.05 5M m P < 0.05
5-io|jm NS lom u P < 0.05
lichen sclerosus io -i5 |jm NS i5|jm NS
vs i5-20|jm NS 20|jm NS
differentiated VIN 55-6o|jm NS 6o|jm NS
70 -75(jm NS 75Mm NS
9 5 -io o |jm NS io o |jm NS
o-5|jm NS 5M m NS
5-io|jm NS lom u NS
lichen sclerosus io -i5 |jm P < 0.05 i5|jm NS
vs i5-20|jm P < 0.001 20|jm NS
usual VIN 55-6o|jm P < 0.001 6o|jm P < 0.001
70 -75(jm P < 0.001 75M m P < 0.001
9 5 -io o |jm P < 0.001 io o |jm P < 0.001
o-5|jm NS 5M m NS
5-io|jm NS lom u NS
differentiated VIN io -i5 |jm NS i5|jm NS
vs i5-20|jm P < 0.05 20|jm NS
usual VIN 55-6o|jm P < 0.001 6o|jm P < 0.05
70 -75(jm P < 0.001 75M m P < 0.05
9 5 -io o |jm P < 0.001 io o |jm P < 0.01
NS = not significant (p>o.os)
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Abstract
Objective: To compare the treatment and followup of patients with lichen sclerosus 
(LS) at the departments of Gynaecology and Dermatology at the Radboud University 
Nijmegen Medical Centre (RUNMC), Nijmegen, the Netherlands, to evaluate the need 
for a m ultidisciplinary vulvar clinic.
Materials and Methods: Treatment and follow-up data of all women with histologi­
cally proven (between January 1995 and January 2001) anogenital LS visiting the out­
patient clinics o fth e  departments of Obstetrics & Gynaecology and Dermatology 
were collected (last date of follow-up: January 2008).
Results: Eighty-four patients with LS were included in this study; ten patients (12%) 
were treated by both specialties. At the Gynaecology-department, LS patients more 
often received surgical treatment, topical estrogens and lidocaine ointment, whereas 
at the Dermatology-department local class ll/lll corticosteroids were more often pre­
scribed. Follow-up frequencies were similar in both specialties and took place at 3-4 
visits in the first year, and at least once a year afterwards. One patient developed vul­
var squamous cell carcinoma (SCC).This patient had withdrawn from follow-up and 
was diagnosed with carcinoma 74 months after the LS had been diagnosed.
Conclusions: Although no hospital guidelines existed, management of patients with 
LS agreed with current recommendations in the literature, although differences in 
secondary and supportive therapy existed, due to differences in expertise. The rela­
tively high percentage of patients treated by both specialties with a high frequency of 
visits emphasizes the need for a m ultidisciplinary clinic for vulvar disease.
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Introduction
Lichen sclerosus (LS) is an idiopathic chronic inflammatory dermatose with an inci­
dence between 1:300 and in o o o .1 Most cases occur in postmenopausal women and 
approximately 7-15% appear in prepubertal girls. Hormonal factors, autoimmune dis­
orders, association with HLA class II antigens, infectious causes, as well as a genetic 
influence have been associated with LS.1
In a series of LS patients that underwent long-time follow-up, 2-6% developed vulvar 
SCC.2 Because o fthe risk of malignant progression, lifelong surveillance of all women 
with LS is considered essential.3 No evidence exists that regular check-ups reduce the 
risk of malignant progression. Malignant progression has never been evaluated in re­
lation to treated versus non-treated disease, or the length of time the disease has 
been present.4
Pruritus is the most common complaint among women with LS. Others may present 
with pain, a burning sensation, an altered appearance ofthe vulva, irritation, soreness, 
dyspareunia or dysuria. A considerable number of patients (33%) are asymptomatic, but 
do have clinical signs of LS upon physical examination.5 There is often a considerable 
delay in diagnosis, which may be due to patient’s embarrassment and reluctance of 
the physician to fully evaluate the symptoms as well as unfamiliarity with this disease. 
A wide variety of healthcare providers, including gynaecologists, dermatologists and 
general practitioners may treat the disease. The heterogeneity of medical specialties 
involved in the management of LS probably reflects the lack of a uniform approach to 
this disease. In LS, the cornerstone of treatment is the use of high-potent dermatocor- 
ticosteroid creams.6 Surgery is considered to be a last resort to treat complications sec­
ondary to the LS.7
At the departments of Gynaecology and Dermatology o fth e  Radboud University Ni­
jmegen Medical Centre (RUNMC), Nijmegen, the Netherlands, no guidelines concern­
ing the treatment and follow-up of LS existed. This study was designed to compare 
the treatment and follow-up of LS at the departments of Gynaecology and Dermatol­
ogy, and to evaluate the need for a multidisciplinary vulvar clinic.
Materials and Methods
Study population
All consecutive patients who were histologically diagnosed with anogenital LS be­
tween January 1995 and January 2001 at the outpatient clinics ofthe departments of 
Gynaecology and Dermatology by means o fth e  PALGA-registry (Pathologisch-Anat- 
omisch Landelijk Geautomatiseerd Archief: the nationwide network and registry of
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histo- and cytopathology in the Netherlands) o fth e  department of Pathology (RUN­
MC). After exclusion of all women with a previous vulvar SCC or vulvar SCC at the first 
histopathology specimen, 84 patients were eligible for analysis.
Patient characteristics, lesion characteristics, methods of treatment and follow-up 
data were obtained from the gynaecological and dermatological records and anon­
ymously stored in an SPSS database. Medical treatment was divided into topical 
treatment and systemic therapy and the type of treatment was recorded. Surgical 
treatment was subdivided in local excision, extensive excision/vulvectomy and laser 
vaporisation. Information was retrieved up to the last follow-up in the RUNMC or to 
date (until 1 January 2008).
The study was carried out in accordance with the applicable rules concerning the re­
view of research ethics committees and informed consent.
Statistics
All analyses were performed using SPSS® version 15.0.1 Software (SPSS Inc, Chicago, 
IL, USA). Differences in the use of medical treatment modalities between the 2 de­
partments were tested for significance using a Fisher exact probability test.The Chi- 
square test was used to calculate differences between the follow-up frequencies of 
the different departments. A p-value <0,05 was considered statistically significant.
Results
Patient characteristics
O fth e  84 women that were diagnosed with histologically proven LS between 1995 
and 2001,42 women (50%) had been referred to the department of Gynaecology and 
42 women (50%) to the department of Dermatology. Forty-eight patients (57%) had 
been referred bytheir GP,i8 (21 %) by a general gynaecologist, 13 (15%) by a dermatolo­
gist, one by a urologist, one by a specialist in internal medicine, and three patients 
(4%) visited the gynaecologist in the RUNMC for a different benign gynaecological 
problem (see Table 1). Most patients at the department of Gynaecology were referred 
by their G P. Both departments received approximately a quarter of their patients from 
a referring department in their own specialty.
At the first visit to our hospital the mean duration of symptoms was 3.3 months 
(range 0.2-21 months). The symptoms at the first consult were pruritus in 63 women 
(75%), dyspareunia in 40 women (48%), pain in 26 women (31%), dysuria in 11 women 
(13%), architectural changes in seven women (8%), and problems with defecation in 
four women (5%). One woman (1%) experienced no symptoms. At the first visit, the 
clinical examination o fthe vulva was suspicious for LS in 69 women (82%).
110
Treatment and follow-up of patients with lichen sclerosus
at the departments of Gynaecology and Dermatology
Treatment
Of all 84 women referred to the RUNMC, 38 (42%) were treated at the department of 
Gynaecology, 36 (46%) at the department of Dermatology and 10 (12%) by both spe­
cialties (referred to one department with internal consultation at the other). The dif­
ferent treatment modalities used by gynaecologists and/or dermatologists and the 
statistical significance o fthe differences are shown in Table 2.
The patients treated with class III and IV corticosteroids had an average of 2 exacerba­
tions per year; patients treated with other medication, had more exacerbations: 2.5/ 
year. The mean time to exacerbation of LS after vulvectomy was 15 months. Ranges 
can be found in Table 3.
Follow-up
Of all women with LS, 70 (83%) were followed for at least one year; 29 patients (32.2%) 
at the department of Gynaecology, 32 patients (40%) at the department of Derma­
tology and 9 patients (10%) by both specialties. The median time of follow-up of all 
patients was 58 months (range o -137 months).
The mean numbers of visits per year during the first five years after the first consult 
are shown in Figure 1. The follow-up frequency was equal at the two departments. 
Patients visiting both departments had a significantly higher frequency of follow-up 
(Chi square, p<o.os).
Four patients (5%) did not show up for follow-up and were considered lost to follow- 
up. Thirty-five patients (42%) are still followed at the RUNMC to date. For unclear rea­
sons, in at least 32 patients (38%) it was decided to stop further follow-up (after a 
mean follow-up time of 36 months).The remaining 13 patients (15%) were referred to 
their general practitioner (GP) or referring specialist for further follow-up.
Malignant progression
One patient (1.2%) o fth e  cohort developed vulvar SCC. This healthy, premenopausal 
woman was originally referred to the department of Gynaecology at the RUNMC be­
cause of menorragia at the age of 54. During clinical examination LS was diagnosed 
and confirmed by a biopsy. After 89 months, with no follow-up, she visited the RUN­
MC again because of a suspicious vulvar lesion. This lesion was locally excised with 
adequate margins (>8mm), and histopathological examination showed SCC with an 
invasion of 2-3 mm. Regular follow-up, 2-4 times a year, takes place at the department 
of Gynaecology (RUNMC). In the years after her primary tumor, seven recurrences of 
SCC occurred at 15,24,41,50,58,63 and 67 months after the primary tumor. At the mo­
ment she is in good clinical condition.
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Discussion
This retrospective study evaluates the treatment and follow-up of LS in two specialties 
(Gynaecology and Dermatology), which to our knowledge has never been described in 
detail so far.8 The data of our study show that in the majority of patients with LSa regular 
long-term follow-up takes place. There was no difference in frequency of follow-up be­
tween the departments of Gynaecology and Dermatology. A variable number of follow- 
up visits took place in the year after diagnosis and at least once yearly in the following 
years. Reasons for the relatively high number of visits in the first year of follow-up are the 
taking of another biopsy and the start and evaluation of (new) therapy.
Currently, the guideline o fth e  British Association of Dermatologists (BAD) regarding 
LS advocates life long follow up for LS that continues to be poorly controlled and for 
patients that have persistent disease with history of a previous vulvar SCC. Difficult 
cases with complications may be best managed in a vulval clinic with a m ultidisci­
plinary team, including a dermatologist and a gynaecologist.9 In a consensus docu­
ment prepared at a workshop at the ISSVD World Conference (2006), follow-up in 
specialist clinics is also recommended when the pathologist expresses concern and 
is unable to make a definitive diagnosis of differentiated vulvar intra-epithelial neo­
plasia (dVIN), when difficulty exists with symptom control or when there is clinical 
evidence of localized skin thickening.4 The American College of Obstetricians and 
Gynaecologists (ACOG) suggests annual examinations for patients whose LS is well 
controlled, and more frequent visits for those with poorly controlled disease.10 In gen­
eral, the BAD as well as the ACOG advise at least 2 follow up visits after the initial 
consultation: (i) at 3 months to assess response to treatment and (ii) 6 months later 
to ensure that the patient is confident in treating their problem, before discharge to 
the care ofthe primary physician (GP). If patients continue steroids, the BAD suggests 
yearly visits to a primary care physician.
All three published reports on the management of LS, indicate moderate to strong 
topical steroids as the treatment option of choice.49'10 The BAD guideline recommends 
clobetasol propionate initially once a night for 4 weeks, then on alternate nights for 4 
weeks and for the final third month, twice weekly.9 Topical steroid therapy is not w ith­
out complications, including the possibility of contact sensitization, skin changes, and 
secondary infection. In the RUNMC, all patients with clinically active LS, even when as­
ymptomatic, are treated to possibly prevent anatomical changes and exacerbations of 
LS symptoms. In both specialties, class IV corticosteroids were the most frequently used 
treatment for patients with LS. Whether the long-term topical treatment with a potent 
steroid cream can reduce the risk of malignant evolution remains unclear.10
In the Netherlands no guidelines directed by the Dermatology or Gynaecology Society 
regarding the treatment of LS exist. Considering the treatment of patients with LS, we 
noted a remarkable difference between the departments of Gynaecology and Derma­
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tology. Surgical treatments were exclusively performed by gynaecologists, especially 
in the past, and topical estrogen and lidocaine ointments were significantly more of­
ten prescribed by gynaecologist, whereas dermatologists prescribed class II and class 
III corticosteroids, antim alarials and retinoids significantly more often. These differ­
ences, however, are inherent to the different specialties: in The Netherlands, derma­
tologists are not trained to perform vulvar surgery and have experience with a much 
greater scale of medical therapies for dermatoses than gynaecologists. This empha­
sizes the importance of a m ultidisciplinary approach.
It is remarkable that in a substantial part o fthe patients with LS.for unclear reasons, 
no further follow-up took place in the RUNMC. However, we did not have information 
on the follow-up at general practioners. We believe that, because progression to SCC 
may occur at any time after the diagnosis of LS,n lifelong follow-up is essential. Un­
complicated cases of LS could very well be followed by fam ily physicians with enough 
experience in vulvar disease. Patients should be well educated about alarm signs and 
symptoms, and be instructed to visit their GP in case of persistent ulceration or new 
growth. During follow-up, biopsy taking of all suspicious lesions (mapping) plays an 
essential role in the early diagnosis of SCC.
There is an underreporting of young patients in this study as we have only included 
biopsy proven LS in our study and usually biopsy is not performed in pre-pubertal girls. 
The patients presenting with defecation problems were 8,50, 50 and 73 years old at 
time of diagnosis; in pre-pubertal girls this symptom is usually reported more often.
Twelve percent of the patients with LS were treated by both departments. In this 
group much more treatment modalities were used and the frequency of follow-up 
was significantly higher than in the patients treated by specialists from a single 
department. Possibly this high frequency of follow-up is caused by more and more 
severe complaints and/or non-responsiveness to some treatment options. For these 
patients, referral to a multidisciplinary clinic for vulvar disease is advisable, because of 
the advantages for early diagnosis, the best possible treatment and interdisciplinary 
teaching.12 A m ultidisciplinary clinic for vulvar disease should at least have specialists 
for the departments of Dermatology and Gynaecology. In case of sexual dysfunction 
or psychological problems, referral to a (specialized) sexologist or psychologist should 
be offered.
At least 1 patient that had withdrawn from follow-up, developed SCC. Because o fthe 
low number of patients and the retrospective character of this study, no firm conclu­
sions regardingthe malignant potential of LS and the effect of follow-up can be drawn. 
Balasubramaniam and Lewis audited the rate of follow-up by general practitioners (GPs) 
after discharge from secondary care. Twenty-six percent of patients had not been seen 
for two years after discharge, and 38% had never seen their GP at all. Seventeen percent 
had seen their GP specifically about their LS but had not been examined. Interestingly,
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82% of patients were receiving ongoing therapy for their LS.13 A prospective study by 
Oonk et al. indicated that routinely scheduled follow-up meetings with patients with 
vulvar carcinoma resulted in the detection of smaller recurrences in a substantial pro­
portion of patients compared with self-reported recurrences.14 Further research is nec­
essary to show if this also applies for LS; a multidisciplinary vulvar clinic would be an 
excellent setting for this type of research.
In our hospital, a large number of patients with LS was treated with extensive excisions 
or even vulvectomy. There was a relatively short time to relapse of LS symptoms. These 
surgeries have all taken place in the beginning ofthe investigated period (late 1990s). Be­
cause ofthe mutilating effect, high rate of recurrence and possible initiations of new LS 
lesions, which are reported in literature,79 vulvectomies or large excisions are no longer 
considered a suitable treatment for LS. Surgical intervention in LS should not be aimed at 
removing the disease, but at resolving complications ofthe disease: to release a buried cli­
toris, to separate fused labia or to widen a narrowed introitus in case of complaints about 
clitoral symptoms (pain or sexual clitoral dysfunction).
The treatment of LS patients varies, due to the differences in the specialties.To optimise 
the management of patients with LS strict protocols are advisable. So far, biomarkers that 
can predict which lesions are at risk to become malignant are lacking. Future research 
should be aimed at exploring different follow-up schemes. A multidisciplinary approach 
at a vulvar clinic provides an excellent setting to conduct this kind of research.
Acknowledgements
The authors would like to thanks dr.J. Hendriks (department of Epidemiology and Bio­
statistics, Radboud University Nijmegen) for his advice on the database development 
and statistical analysis.
Table i: O verview  of referring specialists
Referring specialist Gynaecology Derm atology Total
General Practitioner BO 18 48
Gynaecology n ‘ 10 21
Dermatology 1 12* IB
Urology - 1 1
Internal M edicine - 1 1
Total 42 42 84
* Patients sent from gynaecology to gynaecology or derm atology to derm atology were referrals 
for a second opinion.
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Table 2: Overview of treatment of LS patients per specialty
Treatment
Gynaecology
(n=38)
Derm atology
(n=36)
Both specialties 
(N =io)
Local excision 5* 0* 0
Extensive excision /  vulvectom y 14* 0* 5
Laservaporisation 2 0 2
Corticosteroids class 1 0 2 0
Corticosteroids class II 0* 10* 1
Corticosteroids class III 3* 17* 6
Corticosteroids class IV BO 24 10
1 ntrales ion al corticosteroids 0 0 1
Estrogen local 10* 3* 5
Estrogen systemic 3 1 1
Testosterone local 8 4 4
Retinoids oral 0* 5* 3
Coal tar 0 1 1
Tacrolimus 0 1 3
Im iquim od 0 1 0
A ntim alarials 0* 5* 2
Lidocaine 3* 0* 3
Antidepressants 1 1 1
* Statistically significant difference(Fisher exact probability test; P<o.o5)
Table 3: Exacerbations o f LS after /  w ith treatm ent
Exacerbation 
(% patients)
M ean tim e to  
exacerbation
Exacerbation rate 
(mean)
Vu Ivectomy 
(n=ig)
60%
19 months 
(range 2-150) -
Class lll-IV
Corticosteroids
(n=3i)
4 9 % -
2/year 
(range 0.3-5)
M ultiple treatments* 
(n=28)
69% -
2.5/year 
(range 1-10)
Derived from patients that had a follow -up o f at least l year
* m edical treatm ents other than corticosteroids lll-IV, laservaporisation and/or local excision
115
M
ea
n 
nu
m
be
r 
of
 
vi
si
ts
Chapter 5
Figure i: Bar ch a rt o f  mean num ber o f  v is its  for LS per year
1 2 3 4 5
year
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The prognostic value of blood 
and lymph vessel parameters 
in lichen sclerosus for vulvar squamous 
cell carcinoma development: 
an immunohistochemical 
and electron microscopy study
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Abstract
Objective: The objective of the study was to quantify vessel type and -density in li­
chen sclerosus (LS) to find a marker for its malignant potential.
Study design: Quantitative analysis was performed on paraffin-embedded tissue sam­
ples of 28 patients with LS (7 adjacent to vulvar squamous cell carcinoma, 21 solitary), 
and immunohistochemical staining for CD34 (vascular and lymphangiogenic lymph 
endothelial cells), D2-40 (lymphatic-specific marker) and ct-SMA (pericyte marker). 
Electron microscopy was performed on fresh tissue.
Results: No significant differences in vessel density or other vessel parameters could 
be demonstrated between the 2 groups. In hyalinized lesions, vessel diameter and 
a-SMA positivity was reduced compared with nonhyalinized lesions. Electron micros­
copy revealed detachment of pericytes from vascular endothelial cells and increased 
thickening of basement membrane, while endothelial cell function did not appear 
strongly impaired.
Conclusion: Malignant potential of LS cannot be predicted by vessel characteristics. 
Hyalinization in LS is associated with pericyte detachment from the basal lamina of 
vascular endothelial cells.
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Introduction
Lichen sclerosus (LS) is a chronic inflammatory skin disease that may occur in any cu­
taneous surface, but has a distinct preference for the anogenital area. It is more com­
monly found in women than in men, and extragenital LS can be found in up to 20% of 
all women suffering from vulvar LS.1 The etiology of LS remains elusive.
Multiple associations with autoimmune disorders, sexual hormones, infection or re­
peated trauma (itch and scratch hypothesis/Koebner phenomenon)2 have been report­
ed and genetic as well as immunologic factors are thought to play a role.3 The classic 
histological features of lichen sclerosus are epidermal thinning, decreased rete ridge 
length, band-like dermal inflammation of varying intensity, with or without edema 
and/or hyalinization.4 LS is diagnosed in all age groups, including infancy, but is most 
prevalent in postmenopausal women. An incidence of 1:300-1000 in gynecological and 
dermatological female patients is estimated but the exact numbers are unknown.5
Women suffering from genital LS have a 4-6% risk of developing vulvar squamous 
cell carcinoma (SCC).57 Furthermore, in 20-60% o fth e  cases of vulvar SCC, LS can be 
found in adjacent areas.8'10 Because o fth e  risk of malignant progression, it is current 
practice that all patients with vulvar LS undergo regular check-ups, although there is 
no evidence that this follow-up prevents the development of vulvar SCC or results in 
earlier detection of a malignancy.
Until now, there is no biomarker available that can identify vulvar LS lesions in which 
SCCs are more likely to develop. Microvessel density (MVD) has been suggested to 
be of predictive value for tumor development and progression in skin tum ors11 and 
multiple types of gynecological tumors.12;13 The induction o fth e  angiogenic response 
is considered a key step in the transition from a premalignancy toward an invasive 
neoplasm14'16 and high MVD is related to poor survival in vulvar cancer patients.17 Fur­
thermore, Raspollini et al. suggested that MVD could identify those cases of LS that 
have the potential to evolve to vulvar SCC.18 In addition to vascular endothelial cells, 
pericyte number and function could have a prognostic value. Pericytes envelop micro- 
vascular endothelial blood vessels and are key regulators of vessel homeostasis.19;20 In 
bladder and colorectal tumors, loss of pericyte function is associated with poor prog­
nosis.21;22 Pericytes have not been studied in vulvar lesions.
Edema and hyalinization may be considered surrogate markers for the (dys)function- 
ing of microvasculature: edema and deposition of proteins (hyalinization) may be the 
results of leaky microvessels and/or inadequate drainage. Although edema and hy­
alinization are both manifestations of vascular malfunction, hyalinization is thought 
to occur after the edematous phase in LS.23;24
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The aim of this study was to analyze MVD and pericyte characteristics in vulvar LS 
associated with vulvar SCC and solitary vulvar LS in order to establish a possible diag­
nostic significance in the identification of malignant potential.
Materials and methods
Sample Selection
Paraffin-embedded tissue of 28 LS patients were selected from the archives ofthe De­
partment of Pathology, Radboud University Nijmegen Medical Centre (Nijmegen,The 
Netherlands). Two distinct groups of patients were distinguished: solitary LS (n=2i) 
and LS directly adjacent to vulvar squamous cell carcinoma (n=7). LS was considered 
to be solitary when the patient had no history of differentiated vulvar intraepithelial 
neoplasia (VIN) and/or vulvar SCC prior to or after the biopsy. All Hematoxylin and 
Eosin (H&E)-stained slides were re-examined by an expert gynecopathologist (JB). In 
each lesion, the presence of edema and hyalinization was scored.
Because the stored tissue samples were anonymously studied, this part o fth e  study 
was exempt from institutional review board approval.
For electron microscopy, fresh 4 mm biopsies of LS lesions were obtained and split in
2. H alfw as processed for H&E staining and the otherfixed in 2.5% glutaraldehyde dis­
solved in 0.1 M sodium cacodylate buffer (pH 7.4). Tissues were obtained according to 
local ethical guidelines and approved by the local regulatory committee.
Immunohistochemistry o f CD34, D2-40 and a-SMA
Paraffin sections (4|-im) were mounted onto Superfrost slides (Menzel-Gläser, Braunsch­
weig, Germany), and dried overnight at 37°C. Tissues were dewaxed in xylene, rehydrated 
through graded alcohol baths and rinsed three times in phosphate-buffered saline (PBS; 
pH 7.4) for 10 minutes. Following an antigen retrieval step (Sodium citrate (0.01 M; pH 6.0), 
95°C,io minutes), tissue sections were preincubated with 20% normal goat serum in PBS 
and subsequently incubated with the primary antibodies for CD34 (Dako, Glostrup, Den­
mark, 1:750), D2-40 (Dako,i:ioo) or a-SMA (NeoMarkers, Fremont, CA, USA, 1:15000), for 60 
minutes at RT. All antibodies were diluted in PBS containing 1% bovine serum albumin.
Slides were rinsed in PBS for 10 minutes and incubated with biotinylated anti-rabbit 
IgG (Vector Laboratories, Burlingame, CA) for 30 minutes at room temperature (RT). 
A biotin-avidin alkaline phosphatase complex was generated according to standard 
procedures (Vector Laboratories). Alkaline phosphatase was visualized with Fast blue 
(20 ml Tris HCl pH 8.2,4 mg Naphtol AS-MX, 4.8 mg Levamisole and 20 mg Fast Blue 
BB salt) and counterstained with Nuclear fast red (Vector Laboratories). Slides were 
mounted with Imsol (Klinipath, Duiven, The Netherlands) and subsequently with Per- 
mount (Fisher Scientific, Fairlawn, NJ, USA). Negative controls (buffer only) and posi­
tive controls (normal skin) were applied in each run.
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Quantification ofCDs4, D2-40 and a-SMA staining
Image acquisition was performed using a 3CCD color video camera (Sony DXC-950P, 
Sony Corp, Japan) mounted on a conventional light microscope (Axioskop 2 plus, Carl 
Zeiss AG, Germany) and attached to a personal computer with frame grabber card 
(Matrox Meteor-ll M ultichannel, Matrox Imaging, Dorval, Canada). Images were ac­
quired using a X20 objective (Plan Neofluar, NA=o.5, resulting in specimen level pixel 
size of 0.39 |-im2). Prior to analysis o fthe immunohistochemical staining, an image of 
an empty microscopic field was acquired, which was used for correction for unequal 
illumination. Image acquisition and analysis were performed using a custom written 
macro in KS400 image analysis software (Carl Zeiss).25
Thresholds were determined from a set of training slides and were found adequate 
for almost all slides analyzed in this study. When the initial thresholds led to unreal­
istic patterns, adjustment was performed by the operator (data not shown). For each 
patient, MVD, mean vessel area, and mean vessel perimeter in the lichenoid area be­
tween the band-like inflammatory infiltrate and epidermis was calculated per surface 
area in multiple non-overlapping images (range 3-13, mean 6.4).
Electron microscopy
Processing of tissue samples for electron microscopy was performed as described pre­
viously.26 After presence of LS was confirmed in H&E, the glutaraldehyde-fixed tissue 
fragments were postfixed in cacodylate-buffered 1% osmiumtetroxide containing 1% 
potassiumhexacyanoferrate(ll)for 1 h, dehydrated, and embedded in Epon 812 (Merck, 
Darmstadt, Germany). Ultrathin sections were cut on an ultratome (Leica, Reichert 
Ultracuts, Wien, Austria), and contrasted with 4% uranyl acetate for 45 min and sub­
sequently with lead citrate for 4 min at room temperature. Sections were examined 
in a Jeol 1200EX-II electron microscope (JEOL,Tokyo, Japan).
Statistical Analysis
Calculation of vessel parameters per patient was performed using Statistical Package 
for the Social Sciences (version 15.0.1; SPSS, Chicago, IL). Because the vessel variables 
were not normally distributed, the non-parametric Mann-W hitney U test was used 
to analyze differences between the groups. The relationship between the presence 
of edema or hyalinization in the two groups of LS was calculated according to the 
Fisher’s exact test. PC05 was considered to be statistically significant.
To test our hypothesis that no differences exists for MVD between SCC-associated 
and solitary lesions, and also between non-hyalinized and hyalinized lesions, equiv­
alence testing was used27 next to the commonly performed testing for differences 
between groups. The null hypothesis for equivalence testing is that the difference 
between the means of two groups exceeds a certain threshold e, w ith alternative 
hypothesis that no such difference exists. The critical t-value for rejecting the null 
hypothesis may be computed from the inverse non-central F-distribution, w ith non­
centrality parameter X=ni n2 e2/(n i+n2).27 In the present study, the constant e was
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fixed at a value of 20% o fth e  average MVD for the respective experiment, which we 
consider an appropriate threshold for a difference of physiological significance.
Results
Clinicopathological features
The histopathological analysis of all cases of LS showed hyperkeratosis, a thin epider­
mis and a variable chronic inflammatory cell infiltrate. The presence of edema and 
hyalinization was variable and recorded for each patient. We found no cases of edema 
without hyalinization and half of the cases showed hyalinization without edema, con­
firm ing that hyalinization occurs after the edema (Table i).The presence of hyaliniza­
tion was not related to the presence of SCC adjacent to the LS (Table 2; P=.673).
Immunohistochemistry
LS lesions were immunohistochemically stained for CD34, D2-40 and a-SMA (Figure 
1) on consecutive sections. In addition to vascular endothelial cells, CD34 also stains 
lymphangiogenic but not quiescent lymph vessels.28 We did not observe CD34-posi- 
tive vessels that were also positive for the specific lymph vessel marker D2-40 (Figure
1, B and C), which indicates that lymph vessel growth is not evident in these LS sam ­
ples. Subsequently, the respective vessels number, area and perimeter were quanti­
fied. No significant differences in the total number of CD34, D2-40 or a-SMA-positive 
vessels could be demonstrated between solitary LS and SCC-associated LS (Figure 2). 
In addition, no differences in CD34, a-SMA or D2-40-positive vessel area and vessel 
perimeter were observed in both LS groups (data not shown).
We found a significantly reduced number of a-SMA-positive vessels in hyalinized LS, 
whereas the number of CD34-positive and D2-40-positive vessels was not reduced in 
hyalinized LS (Figure 3). However, all vessels were significantly smaller in hyalinized LS 
(Figure 4). A trend towards smaller vessels and less SMA positivity in edematous lesions 
was observed, but these differences were not statistically significant (data not shown).
Electron microscopy
Loss of a-SMA expression suggested impaired pericyte function or even lack thereof. 
To further analyze pericyte characteristics in LS, transmission electron microscopy 
was performed on fresh LS specimens with and without hyalinization. Microvessels in 
LS are enveloped by pericytes in nonhyalinized LS (Figure 5, A and B), but are detached 
from the basal lamina of microvascular endothelial cells in hyalinized regions of LS 
(Figure 5, C and D). At higher magnification (Figure 5, E), thickening o fth e  basement 
membrane is evident. Furthermore, inter epithelial junctions (lEJs) are closed and ve- 
siculovacuolar organelles (VVOs) can be seen, which suggests that endothelial cell 
function is not strongly impaired.
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Comment
Our study shows that vessel parameters in LS are not associated with development 
of vulvar SCC. Neither did we find a correlation between edema or hyalinization and 
the presence of SCC adjacent to LS. However, vessels were significantly smaller in LS 
with hyalinization, and reduced a-SMA-positivity was observed. Electron microscopy 
revealed that pericytes are detached from the basal lamina, and thickening o fth e  
basement membrane in hyalinized regions of LS. Hyalinization was observed in both 
types of LS and we did not find a significant difference between hyalinization and 
tumor development (Table 2).Therefore, although pericyte detachment occurs in hy­
alinized LS, we propose that this does not increase risk for tumor development.
The role of angiogenesis in vulvar oncogenesis is still unclear and studies focusing 
on the different vulvar premalignancies give conflicting results. Raspollini et al. de­
scribed that expression of vascular endothelial growth factor (VEGF) was highest 
among the group of LS that evolved to vulvar SCC.18 However, Maclean et al. showed 
that VEGF was not expressed in normal vulva, solitary LS or in LS adjacent to SCC.29 
Likewise, Bamberger et al. could not demonstrate a predictive value of VEGF expres­
sion.30 Furthermore, it has been suggested that increased density of sub-epithelial 
CD34-positive micro-vessels could identify those LS that are at greater risk for SCC 
development.18
Our study does not corroborate these findings. We did not find differences in vessel 
density, area or perimeter, nor did we detect lymphangiogenesis as we have not ob­
served D2-40 positive vessels that also expressed CD34.28 Our data confirm a previous 
report that micro vessel density in LS does not predict its malignant potential.30
Unexpectedly, we found a correlation between pericyte coverage of vascular endothe­
lial cells and the presence of hyalinization: reduced a-SMA positivity and detachment 
of mural cells was observed in hyalinized lichenoid areas in both types of LS. Peri­
cytes are generally considered to be contractile cells that stabilize vessel walls and 
participate in the regulation of blood flow  in the microcirculation.31 Pericytes may 
also influence endothelial permeability, proliferation, survival, migration and matu­
ration.31 Regulation of blood vessel homeostasis and response to angiogenesis or 
vascular permeability-inducing stimuli involves a complex spatio-temporal regula­
tion through several molecules.32 This provides a balance between the activation of 
endothelial cells to expand the vasculature and the interaction of endothelial cells 
with pericytes to ensure a stable, functional vasculature.This interaction is in part un­
der control o fth e  vascular endothelial growth factor (VEGF)-VEGF receptor system.33 
Currently, we do not know whether VEGF receptor activity is altered in vessels with 
detached pericytes, which is subject of our future investigations. However, despite 
detachment of pericytes and loss of their a-SMA expression in hyalinized LS, these 
vascular endothelial tubes do not display w idening o fth e  inter-endothelial junction
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(IEJ). Vesicular-vacuolar organelles (VVOs) that are involved in transcellular transport 
from vessel lumen to the interstitium can be readily detected in these vessels. This 
suggests that vascular function might be still intact and that the thickening of the 
basement membrane prevents the vessels from leaking.
The probability that LS is a vulvar SCC precursor lesion is debatable. The number and 
dilation of vessels in solitary LS is identical to that in LS directly adjacent to SCC. In 
tumors, however, MVD is strongly increased (shown by Bancher-Todesca et al,34 and 
our unpublished results). Our data demonstrate the lack of an angiogenic switch in 
LS juxtaposed to SCC. Since the induction of an angiogenic program is considered to 
be required for progression of a premalignant lesion towards an invasive tumor, we 
argue that LS is not a vulvar SCC precursor lesion. However, it has to be noted that the 
number of patients included in this study may have been too small for this statement 
to be unequivocal. An a  priori power analysis using vessel density values (n, average, 
SD, a, ß) as input data indicates that at least 1400 samples need to be analyzed in or­
der to detect a significant difference. However, the opposite statistical approach (i.e. 
testing that absolute difference in blood vessel density in the two groups is less than 
20%) demonstrated no differences in the density of CD34 and aSMA-positive vessels 
in solitary and SCC-associated LS (P<o.os). However, due to the low number of D2-40 
positive vessels, we cannot exclude a difference in lymph vessel density.
It is tempting to speculate that HPV-negative differentiated vulvar intraepithelial 
neoplasia (dVIN), which can be found in the edges o fthe tum or is the true precursor. 
MVD has been reported to be of value for determining the potential malignant pro­
gression of HPV-associated usual VIN to SCC.34;35 Whether this also holds true for dVIN 
remains elusive and is subject of further studies.
Table i. Hyalinization vs edema
Edema No edema Total
Hyalinized 7 IB 20
Non-hyalinized 0 8 8
Total 7 21 28
Fisher’s exact test, P =  .065. In lichen sclerosus, edem a was found only in the hyalinized cases
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Table 2. Hyalinization vs association with carcinoma
Solitary LS SCC associated LS Total
Hyalinized 15 5 20
Non-hyalinized 6 2 8
Total 21 7 28
Fisher’s exact test, P= .673.
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A. H&E staining of LS with the typical features of LS: thinned epithelium , loss of rete ridges and a 
band-like inflam m atory infiltrate beneath a zone of variable degrees of edema and hyalinization.
B. D 2-40  is expressed by the basal cell layer and lym phatic vessels
C. CD34 stains blood vessels and lym phangiogenic endothelium . W e did not find overlap w ith
B. D 2-40  stain ing  indicating that lym phangiogenesis did not occur.The CD34 stain ing  intensity 
was com parable in
E. nonhyalinized as well as (G) hyalinized regions. In contrast,
D. a -S M A  expression was strong (arrow) to moderate (white arrowhead) in
F. non-hyalinized regions of LS, but moderate (white arrowhead) or very weak (black arrowhead) in 
H. hyalinized regions.
Scale bars: A -D ,io o |jm ; E and F: 30 |jm .
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Figure 3. a-SM A-positive MVD is reduced in hyalinized LS
MARKER
■ non-hyalinized lesions (n=8)
■ hyalinized lesions (n=20)
M ean of M VD (± 2SEM) for CD34, D 2-40  and a-S M A -po sitive  vessels in nonhyalinized LS (n= 
and hyalinized LS (n=2o).
Figure 4. Reduced mean vessel area in hyalinized LS
02-40
MARKER
■ non-hyalinized lesions (n=8)
■ hyalinized lesions (n=20)
M ean o f vessel area for CD34, D 2-4 0  and SMA in non-hyalinized (n=8) and hyalinized LS (n=2o)
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Figure 5. Representative electron-micrographs of micro vessels in lichen sclerosus
A and B. The m icrovascular endothelium  is closely covered by pericytes in nonhyalinized lichen 
sclerosus
C and D. M icrovessels in hyalinized zones of lichen sclerosus d isplay pericyte detachm ent (dou- 
ble-headed arrows) and th ickening o f t h e  basem ent m em brane. (E) At higher m agnification, 
closed endothelial fenestrae (black arrow) and vesiculovacuolar organelles (white arrowheads) 
are visible.
BM, basem ent m em brane ; f , endothelial cell; RBC, red blood cell; P, pericyte; VL, vascular lum en. 
Scale bars: 5|jm .
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Abstract
The m olecular pathogenesis of HPV-unrelated vulvar squam ous cell carcinoma 
(SCC) is not well known. W hether m alignant progression of lichen sclerosus (LS) 
and differentiated vulvar intraepithelial neoplasia (dVIN) to vulvar SCC could be 
accom panied by altered DNA content has not been studied extensively. DNA- 
content in isolated nuclei of microdissected normal vulvar epithelium  (n=2), lichen 
sclerosus (n=g), differentiated vulvar intraepithelial neoplasia (n=i3), and squam ous 
cell carcinoma (n=i7) from 22 patients w as measured via DNA im age cytometry. For 
additional analysis, 6 differentiated vulvar intraepithelial neoplasia lesions were 
selected, bringing the num ber of patients to 28. P53 expression was determined by 
im m unohistochem istry on consecutive tissue sections. Thirty-eight percent (5/13) of 
differentiated vulvar intraepithelial neoplasia lesions and 6 5 %  (11/17) ° f  squam ous 
cell carcinom as were DNA aneuploid or tetraploid. In lesions that contained 
differentiated vulvar intraepithelial neoplasia and adjacent squam ous cell carcinoma, 
the ploidy status of differentiated vulvar intraepithelial neoplasia did not exceed 
that of squam ous cell carcinom a. We observed a strong correlation between high P53 
expression and DNA aneuploidy. This relation w as also present at the level of single 
nuclei, measured by sequential im age cytom etry of P53 im m unohistochem istry 
followed by DNA im age cytom etry on form alin-fixed tissue sections. Sim ilarly, 
we found p53-positive nonproliferating cells w ith increased DNA content in the 
superficial com partm ent of 6 additional solitary differentiated vulvar intraepithelial 
neoplasia lesions that were not associated w ith squam ous cell carcinom a, indicating 
ascending aneuploid cells from the basal com partm ent. DNA ploidy m easurem ents 
suggest that differentiated vulvar intraepithelial neoplasia has a higher m alignant 
potential than lichen sclerosus, and thus is a more likely precursor of squam ous cell 
carcioma. Furthermore, high P53 expression correlates w ith increased DNA content 
and aneuploidy; but it requires further research to unveil a possible causal relation.
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Introduction
Vulvar cancer is the fourth most common gynecologic cancer and accounts for 
approxim ately five percent o fth e  m alignancies o fth e  fem ale genital tract.1 Based 
on etiological characteristics, 2 separate pathways that lead to vulvar squam ous 
cell carcinoma (SCC) can be distinguished.2 About a third of all vulvar SCCs develops 
through a h igh-risk hum an papillom a virus (HPV)-dependent pathw ay in w hich 
prem alignant stages of vulvar cancer are usual vulvar intraepithelial neoplasia (VIN)- 
lesions that m ain ly affect younger w om en. However, the m ajority of vulvar SCCs arise 
in the absence of HPV, predom inantly in older women w ith lichen sclerosus (LS). LS is a 
chronic inflam m atory disease of the vulvar skin and mucosa characterized by markedly 
thinned epithelium  w ith loss of rete ridges, culm inating in architectural changes of 
the vulva and can give rise to severe itching. Differentiated VIN (dVIN) is thought to 
play a role in th is HPV-independent pathw ay as a prem alignant lesion w ith a high 
m alignant potential although the m olecular pathogenesis rem ains elusive.2 Women 
w ith LS have a 2 %  to 6 %  lifetim e risk to develop vulvar SCC.3 dVIN is seen relatively 
infrequently in its pure form and is com m only identified as an ulcerative or verrucous 
lesion, adjacent to invasive SCC, often in a background of LS. dVIN can be a difficult 
histological diagnosis as the atypia is confined to the basal cell layers whereas the rest 
o fth e  epithelium  shows normal m aturation.4 The possible m alignant progression of 
LS via dVIN and subsequently rapidly to vulvar SCC, m ay be caused by m itotic defects 
and consequently chromosome m issegregation and instability.
DNA aneuploidy, a frequently identified genom ic abnorm ality, can occur in the earliest 
stages of m alignant tra nsformation, although it is unknown w hether DNA a neu ploidy 
is a cause or consequence of m alignant progression.5 Impaired functioning of cell 
cycle checkpoint proteins contributes to proliferation of cells w ith im paired genomic 
integrity.To prevent survival of aneuploid cells, cell cycle checkpoint proteins block cell 
proliferation after abnorm al d ivision6. In normal skin, only a sm all percentage of cells 
divides and has a tetraploid status. Due to increased proliferation, the percentage of 
tetraploid cells increases and m ay result in the development of aneuploid cells when 
loss of function of the cell cycle regulator proteins occurs.6 The tum or suppressor 
protein P53 is a key regulator of m aintain ing normal diploid status7 and halts cell 
division and/or elim inates cells that have acquired irreparable DNA dam age.8 A 
relationship between high P53 expression, morphological variab ility of nuclei and 
DNA aneuploidy in breast carcinom as w as demonstrated by Haroske and co-workers9 
more than a decade ago, but has not been studied in vulvar carcinom as and their 
precursor stages before.
In vulvar carcinomas, ploidy has been studied m ostly in relation to prognosis. It has 
been reported that aneuploidy in vulvar carcinom as varies from 13 %  to 8 3%, but no 
relation w ith prognosis has been described so far.1016 Aneuploidy in vulvar LS varies 
from 0 %  to 3 3 %  o fth e  cases.1416'18 The relation between the expression of cell cycle
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proteins and ploidy status of vulvar lesions has not been extensively studied. Lerma 
et al. concluded that p53 expression is a late event in m alignant progression as 7 2 %  of 
the m ain ly HPV-negative SCCs were aneuploid and only 5 6 %  o fth e  SCCs showed P53 
overexpression.14 Recently, high P53 expression in the basal cell layers of LS has been 
postulated as a marker for increased likelihood to progress to vulvar SCC.19
The aim  of this study w as to analyze ploidy in different groups of HPV-negative 
vulvar lesions to test the hypothesis that in LS, dVIN, and SCC, increased DNA 
content abnorm ality is associated w ith an increased m alignant potential of the 
histological entity. In addition, we evaluated the correlation between aneuploidy and 
the expression of P53 w ith the intention to shed light on the potential m alignant 
conversion of LS and dVIN toward SCC.
Methods
Sample Selection
Form alin-fixed and paraffin-em bedded tissue sections of 28 patients w ho underwent 
a local excision or (partial) vulvectom y because of a (pre)m alignancy o fth e  vulva 
were random ly selected from the archives o fth e  Departm ent of Pathology, Radboud 
University Nijm egen M edical Center. All tissue sections were collected between 1996 
and 2009. All original hem atoxylin and eosin (H&E)-stained slides were re-exam ined 
by an expert gynecopathologist (J.B.), and all lesions were classified according to 
World Health Organization criteria.4 Tissues were obtained according to local ethical 
guidelines and approved by the local regulatory committee.
The median age of all patients w as 71.5 years (range 37-90 years). From most patients, 
more than one type of lesion was present in the excised tissue; and the total number 
of lesions available for analysis w as 47:2 sam ples of normal epithelium , 9 LS lesions, 13 
dVIN lesions, and 17 sam ples with SCC. In addition, 6 solitary dVINs not associated with 
m icro- or m acro-invasive SCC were included in this study. See Table 1 for an overview 
o fth e  lesions and tissue com position. In the tissue sections w ith LS and dVIN, and 1 
dVIN lesion, m icro-invasive vulvar SCC was present in the tissue, but was too sm all for 
ploidy analysis (Table 1). All patients w ith SCC had LS in the excised m aterial; w hen it 
w as present in the sam e tissue block, both entities were analyzed.
Lesions were tested for h igh-risk HPV DNA using a broad-spectrum  HPV detection/ 
genotyping assay (SPFio-LiPA) and were all HPV-negative. The combined SPF-PCR- 
LiPA system for detection and genotyping of HPV has been described in detail 
elsewhere.20;21
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Table i. Number of patients and samples
Lesion No. of patients No. of samples
L So nly 1 1
dVIN  (adjacent to m icroinvasive SCC) 1 1
dVIN  (w ithout adjacent [micro] invasive SCC) 6 6
SCC only 5 5
LS+dVIN (all adjacent to [m icro]invasive SCC) 3 6
LS+SCC 2 4
LS+dVIN+SCC 3 9
d VIN +SCC 5 10
N+SCC 1 2
N +dVIN +SCC 1 3
Total 28 47
LS = lichen sclerosus (n=g)
SCC = squam ous cell carcinom a (n=i7) 
dVIN = differentiated V IN  (n=ig)
N = norm al epithelium  (n=2)
Tissue dissection and isolation of nuclei for Feulgen staining
From each paraffin-em bedded tissue block, a 5 0 -|jm -th ick  section w as cut and 
dewaxed through xylene and rehydrated through graded alcohol.The tissue sections 
were washed three tim es in dem ineralized water and phosphate-buffered saline (PBS) 
before microdissection o fth e  different epithelial lesions. Excised tissue w as digested 
w ith pepsine (Sigma Aldrich, Zw ijndrecht,The Netherlands, 2 mL o.5%[w t/vol], pHi.5) 
for 60 m inutes at 37°C. After complete tissue dissolution, 2 mL of PBS w as added to 
stop the reaction.The suspension was passed through a 5 0 -|jm  CelItrics filter (Partec 
Gm bH, Münster, Germany) and spinned down for 10 min at 15 0 g .The pellet of nuclei 
was collected and counted using a Coulter Counter (Beckman Coulter, Woerden, The 
Netherlands). Subsequently, the suspension w as centrifuged again; and the pellet was 
re-suspended in PBS to a dilution of 200 00 0  nuclei per m illiliter. A cytospin of 20 000 
nuclei w as prepared (100 |jL, 10 minutes, 100g), followed by fixation in Böhm fixative 
(60 min at room tem perature [RT]), rinsing w ith m ethanol and air-dryin. For ploidy 
m easurem ent, Schiff-Feulgen staining w as performed as described elsewhere.22
Ploidy examination with O-path DNA software
Image cytom etry w ith O-path DNA software (Leica Im aging Systems Ltd, Cam bridge, 
United Kingdom) w as performed to determ ine DNA ploidy of isolated nuclei. For 
each analysis DNA content of 4000 nuclei w as calculated autom atically. Images 
of overlapping nuclei were m anually excluded from the analysis. Ploidy status was
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determ ined a cco rd ingto the consensus criteria o fth e  European Society for Analytical 
Cellular Pathology (ESACP).23'25 In each sample, lym phocytes were identified by the the 
size and roundness and included as an internal control for true diploid status.
PS3 and MIBi immunohistochemistry 
P53
Four-m icrom eter-thick sections of form alin-fixed paraffin-embedded tissue blocks 
were mounted onto SuperFrost slides (Menzel Gläser, Braunschweig, Germany) and 
dried overnight at 37°C. The sections were dewaxed in xylene and rehydrated through 
graded alcohols. Following quenching of endogenous peroxidases, slides were rinsed 3 
tim es in PBS (pH 7.4) for 5 minutes; and antigen retrieval was performed w ith boiling 
sodiumcitrate (0.01 mol/L, pH 6.0,10 minutes). After cooling down to RT, tissue sections 
were rinsed in PBSforio m inutes and subsequently incubated w ith a primary monoclonal 
antibody toward P53 (clone DO-7 [Neomarkers, Labvision, Fremont, CA, USA], 1:1000 in 
PBS containing 1 %  [wt/vol] bovine serum albumin) for 1 hour at RT. Subsequently the 
slides were rinsed in PBS (10 minutes) and post-antibody blocking was performed for 15 
minutes (Powervision Plus;DakoSA,Glostrup,Denm ark).Thisw asfollow edbyincubation 
with polymeric horseradish peroxidase-conjugated goat anti-rabbit im m unoglobulin G 
(30 minutes, RT). Staining was developed w ith diam inobenzidine (DAB) in the presence 
of H2O2, counterstained w ith Mayer’s hematoxylin, dehydrated in ethanol and xylene, 
and finally mounted w ith Permount (Fisher Scientific, Fair Lawn, NJ, USA). Negative 
controls (buffer only) and positive controls were included in each analysis.
Because the atypical cells in dVI N are located in the basal parts ofthe epithelium , nuclear 
P53 positivity in the lower one-third ofthe epithelium  was estimated. In the SCCs and LS 
lesions, the percentage of p53-positive cells in the entire lesion was estimated.
MIBi
M IBi im m unohistochem istry was performed as has been described in detail 
elsewhere.26
Combined ps3 immunohistochemistry and DNA image cytometry
Tissue sections (7 |jm ) mounted on Superfrost slides were stained for P53 as described 
above, but developed w ith the w ater soluble 3-am ino-g-ethyl-carbazole instead of 
diam inobenzidine, and mounted w ith Imsol w ithout coverslips (Klinipath, Duiven, 
The Netherlands). Images of representative areas were digitized and stored in 24 bit 
RGB using a 3CCD camera (Sony 950P, Sony,Tokyo, Japan) attached to a Zeiss AxioPhot 
microscope (Carl Zeiss, Jena, Germ any) w ith 20X  objective (Plan Neofluar, NA=o.5; 
specimen level pixel size 0.64x0.64 |jm 2). Subsequently, p53-stained sections were 
washed in dem ineralized water (37°C, 1 hour), followed by an overnight w ash step 
in dem ineralized w ater to remove all traces of Imsol. After a brief third wash w ith 
dem ineralized water, tissue sections were submerged in Böhm fixative (60 minutes, 
RT), rinsed w ith m ethanol, a ir-dried; and Schiff-Feulgen staining w as performed.
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This procedure removes all p53 staining as well as the hem atoxylin counter staining. 
Contours of nuclei in stored p53 im ages were extracted and shown as an overlay in 
the live camera im age, to facilitate acquisition of exactly the same locations in the 
Feulgen-stained sections. Images of the Feulgen stained sections were acquired 
using the sam e camera and microscope setup, using a band pass filter (565.5 ± 20 
nm). Recognition of nuclei in im ages from Feulgen-stained specimens was in itia lly  
performed b yap p ly in g a region grow ing algorithm  on m anuallyind icated seed points. 
If required, results of region grow ing were interactively corrected. Integrated optical 
density (IOD) of both Feulgen and P53 staining were calculated for 500 to 10 0 0  nuclei 
in each specim en.To obtain an internal reference for diploid Feulgen IOD and for P53 
negativity, approxim ately 200 nuclei in the tissue stroma were measured in each 
specimen. W hen com paring the p53-negative basal regions w ith the superficial P53- 
positive regions, the operator m anually identified the basal and superficial regions.
Statistical analyses
To determ ine the correlation between D N A  ploidy and sem iquantitative scoring of 
P53 expression, x2 tests were performed. To compare ploidy status of p53-positive 
versus p53-negative cells, the I O D P53 and I O D FeLlig en distributions for these groups were 
compared using the 2-sam ple Kolmogorov-Smirnov test. Statistics were performed 
using SPSS software (SPSS Inc, Chicago, I L ) .
Table 2. Ploidy-status vs type of lesion
Hypoploid Diploid Aneuploid Tetraploid Total (ioo%)
LS 1 (11%) 8 (89 %) - - 9
dVIN - 8 (6 2%) 5 (38% ) - 13
SCC - 6 (35% ) 9 (53% ) 2 (12%) 17
N - 2 (10 0 % ) - - 2
Total î (2%) 24 (59%) 14 (34% ) 2(5%) 41
N: norm al epithelium  
LS: lichen sclerosus 
dVIN : differentiated VIN 
SCC: squam ous cell carcinom a
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Results
Ploidy Analysis
DNA content of various entities of vulvar (pre)m alignancies w as performed by DNA 
im age cytom etry on isolated nuclei from m icrodissected tissues (Figure i A-D). The 
ploidy status of all sam ples is sum m arized in Table 2. Both normal epithelium  samples 
were DNA diploid. DNA hypoploidy w as observed in 1 (11%) of 9 LS lesions, w hereas the 
other 8 LS sam ples were DNA diploid. Five (38%) o fth e  13 analyzed dVIN lesions were 
DNA aneuploid. From the 17 carcinomas, 9 (53%) were DNA aneuploid tum ors; and 
2 (12%) tum or sam ples were DNA tetraploid. The rem aining 6 (35%) tum or samples 
were DNA diploid. For lesions in w hich both dVIN and SCC were present, the ploidy 
status of dVIN never exceeded the ploidy status o fth e associated SCC.
PS3 expression
Subsequently, consecutive tissue slides of the sam ples described above were 
subjected to P53 expression analysis by im m unohistochem istry (Figure i E-G). Results 
are sum m arized in Table 3. In all 13 dVINs present in composite lesions, p53-positivity 
w as confined to the lower one-third o fth e  epithelium  (Figure 1E), som etim es w ith 
suprabasal extension. In the SCCs, P53 expression (Figure iF) varied from 5 %  to 9 5 %  
(median, 75% ) positive cells (Table 3). In LS, the percentage of p53-positive (Figure 
iG ) did not exceed 3 0 % . In the composite lesions that contained dVIN and SCC, the 
percentage of p53-expressing cells in dVIN w as less or comparable to P53 expression 
by the corresponding SCC in all but one case (ie patient XVII in Table 3).
PS3 expression and DNA ploidy
To determ ine a possible correlation between the percentage of p53-positive cells and 
DNA content in a tissue entity, both results were com bined.This revealed that the high 
percentage of p53-expressing cells in the lower one-third o fth e  epithelium  (dVIN) or 
the entire lesion (SCC, LS or normal tissue) significantly correlated w ith aneuploidy 
determ ined by Feulgen staining on isolated cells (Table 4, x2 = 27.6, P < .001). N inety- 
three percent (14/15) of all non-diploid lesions displayed more than 7 0 %  of P53- 
positive cells. In contrast, in 9 2 %  (22/24) o fth e DNA diploid cases, P53 expression was 
observed in less than 7 0 % . As such, we subjectively set the cut-off value for high P53 
expression at 7 0 % . Despite high P53 expression in two dVIN lesions adjacent to an 
aneuploid SCC (case XVI and XIX) DNA content w as determ ined to be diploid, whereas 
the H&E staining displayed the typical features of dVIN.4 Case XIX is shown in Figure
2. Collectively, these data suggest a positive correlation between high percentage of 
p53-positve cells and altered DNA content in tissue specimens.
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Aneuploid Aneuploid Diploid
Figure i.  Analysis of DNA ploidy and p53 expression in tissue containing LS, dVIN and SCC.
A. H&E stain ing o fth e  com posite lesion (constructed of three im ages, as shown by the dashed 
divid ing lines, orig inal m agnification 12.5X). The black rectangles represent the excised areas 
for ploidy analysis.
B. H&E stained detail of dVIN lesion w ith nuclear atypia and the presence of m itotic figures in 
the basal cell layers. Hyperkeratosis and dyskeratosis are present and rete ridges elongated.
C. H&E stained detail of SCC.
D. In the H&E stained section of LS, flattened and m ild ly hyperkeratotic epithelium  is present. 
Loss of rete ridges is clearly visib le. There is little cellu lar or nuclear atypia. A zone of hyalinized 
derm is and subepithelial edem a of variable thickness is present. The characteristic band-like 
infiltrate of lym phocytic cells is located beneath this zone.
E. Im m unohistochem istry revealed nuclear P 5 B -p o s it it iv ity  in dVIN , m ost prom inent in the basal 
cell layers w ith suprabasal extension. In this section, p53-postivity of the lower one-third o fth e  
epithelium  is estim ated at 8 0 % .
F. Approxim ately 7 5 %  o fth e  cells o fth e  invasive nests o fth e  SCC are positive for P53.
G. p53-negative LS lesion.
O riginal m agnification B -G :5 0 x
Each histogram  (H-J) displays the ploidy condition of the vulvar lesion beneath it. The x-axis 
in the ploidy histogram  represents the integrated optical density (IOD) of the nuclei popula­
tion, w hereas the y -a x is  identifies the num ber of nuclei in the specific population. dVIN (H) was 
aneuploid w ith a 2A-peak (aneuploid peak) shown next to a 2C -peak (diploid peak).Tetraploidy 
in an SCC lesion (I), identified w ith a 4C-p eak (tetraploid peak) higher than the 2C-peak. Diploid 
LS lesion (J).
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Combined ploidy analysis and immunohistochemistry
The above-described correlation was derived from 2 different approaches, w hich 
made it im possible to determ ine the relation between DNA-content aberration and 
P53 expression in individual cells. To overcome this problem, we subjected tissue 
sections to sequential P53 im m unohistochem istry and Feulgen DNA staining (Figure 
3AB), and measured the staining intensity in between these tw o staining methods. 
The IOD of P53 in p53-negative stromal nuclei reached a m axim um  value of 1.6. Visual 
inspection of P53 staining confirmed that higher values corresponded to p53-positive 
nuclei. Therefore, P53 positivity w as defined as IODP53 greater than 1.6. The mean 
value of lODpeuigen of p53-negative nuclei in each tum or specimen is presented as a 
dotted line (Figure 3C, top panels), w hich allows easy visualization o fth e  shift in the 
distribution of I O D FeLligen towards increased intensity in P53 expressing cells (Figure 3C, 
middle panels). Comparison o fth e  Feulgen IOD distribution of p53-negative versus 
p53-positive epithelial nuclei showed a significant difference for all patients assessed 
(P < .001). W hen all IOD values for P53 and Feulgen are presented as a scatter plot 
(Figure 3C, bottom panels), a positive trend between both lODs can be observed in all 
sam ples that display high levels of P53 expression (i, ii, and iii).Thus, compared with 
p53-negative nuclei, p53-positive nuclei displayed an increased DNA content.
DNA ploidy, ps3 expression and cell proliferation in solitary dVIN
Expression of P53 was not observed in the superficial layers of dVIN, w hich could 
im ply that aneuploidy is confined to the lower layers. We have therefore analyzed the 
relationship between DNA ploidy and P53 expression in single cells of 6 solitary dVIN 
sam ples in more detail and sum m arized the results in Table 5 .The frequency plot of 
sam ple 2 is shown in Figure 4. Compared w ith the DNA content of normal reference 
cells w ithin  the stroma (DNA Index [Dl]=i), the lower one-third component of dVIN 
(basal epithelium ) contains nuclei w ith increased DNA content (DI>i: 27.5%; Figure
4, lower left panel). Because o fth e  effect of truncation of nuclei w ithin  (relatively 
thin) tissue sections, ploidy patterns show asym m etric (right skewed) distribution. In 
contrast, the upper one-third component (superficial epithelium ) only contains 4 .7 %  
nuclei w ith a DI greater than 1. This indicates that the superficial component indeed 
contains a low percentage of cells w ith an abnorm al DNA content.
In all samples, the basal layers contained significantly more p53-positive cells (Table 
5A). Sim ilarly, DNA content was significantly higher in the basal component compared 
w ith the superficial component for all sam ples (Table 5A). Strongly increased DNA 
content in the superficial layer w as also observed in tw o o fth e  six sam ples analyzed 
(ie sam ples 1 and 5). W hen com paring DNA content between p53-negative and P53- 
positive cells in the basal compartment, for all cases a strongly significant increase 
w as observed for the num ber of cells w ith DI greater than 1 (Table 5B). W ith the 
exception of sam ple 3, such a relationship was not found for cells in the superficial 
component due to the low num ber of p53-postive cells.
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We have previously shown that the lower compartment of dVIN is highly proliferative26, 
which also contributes to increased DNA content in this study.Therefore, we have analyzed 
M IB-i expression in the 6 solitary dVIN lesions and found a mean percentage of positive 
cells of 43.1% (95% confidence intervfal [Cl], 18.1% - 68.1%) in the basal compartment 
compared with 2 .1%  (95% Cl, i .i % - 4.8%) in the superficial compartment. The low 
abundance of proliferative cells in relation to the percentage of cells with DI greater than 
1 %  in the superficial component indicates that DNA content is in part due to aneuploidy.
Discussion
In this study, we demonstrate that DNA aneuploidy in vulvar lesions correlates w ith 
high expression of P53 in tissue at the cellular level, w hich has not been described 
before. Based on a higher percentage of DNA aneuploid cases in dVIN than in LS, 
we believe that at least a subset of dVIN lesions is a prem alignancy w ith a higher 
m alignant potential compared w ith LS.
Our find ing of a lack of DNA a neu ploidy in LS is coherent w ith the results published by 
Scurry et o/.l6They performed cytom orphom etric analysis on 20 LS sam ples and found 
that 5 0 %  of those sam ples were diploid, and that the other 5 0 %  were hypoploid. 
The authors concluded that the occurrence of hypoploidy in LS reflects reduced 
mitotic activity that relates to a loss of DNA.16 We only found 1 of 9 LS lesions to be 
DNA hypoploid and have described previously that the proliferative activity in LS is 
comparable to that in other vulvar prem alignancies.26 However, the absence of DNA 
aneuploidy in all but 1 hypoploid LS in our study suggests that LS has less m alignant 
potential than dVIN. Recently, Raspollini et al. showed that high M IBi and P53 labeling 
indices in LS m ight identify those vulvar LS cases w ith a high likelihood of evolving into 
SCC.19 However, these h igh-risk LS lesions show histological features that resemble 
the criteria for dVIN.27 The results of our study suggest that these so called 'atypical 
LS’ m ight be non-diploid dVIN lesions.
The atypia in a dVIN lesion is confined to the lower one-third ofthe epithelium  (Figure 
1B).28 However, the entire epithelium  ofthe dVIN lesion was microdissected and used for 
DNA image cytometry.Therefore, samples were “contam inated” with p53-negative cells 
and could have resulted in an underestimation of DNAaneuploidy in dVIN.Furthermore, 
in situ quantification of DNA demonstrated that increased DNA content in the superficial 
layers was observed w hich cannot be explained by mitotic activity, as MIBi positivity in 
these layers was low .However.it is unlikely that all dVIN lesions would have been DNA 
aneuploid, as DNA diploid SCCs were found, and as there were no patients w ith a DNA 
aneuploid dVIN lesion next to a DNA diploid SCC. From these observations we conclude 
that aneuploid cells predominantly reside w ithin the basal compartment of dVIN, but 
that migration toward the superficial compartment can occur.
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Figure 2: dVIN of case XIX 
A
r,: v v  &  
M f  U ;FTB? - ■'■fc-
B
f î y  # / y  0 r i  ■ »
"  4  ' 1 1 * [ J  $  !  0  f
•j s *,,/* e t  # 1
• M ' K f ' i V Ï M K ï ' A 1
i  . i l#  7 ' ‘ i f i . 1 1 . ' f * /
h  4 S 0  ' *  ’ ’ i l  ' I K  "  U  * » ' * * * { ,
l | F ^  • :
• ; • ' .• - ■' « T .
D
. / » A , !  «
1 « ■ ' •  » { f  .
A  , '
*1
# > ,  m  ,  _ 4
4
•  • / 1  « i  y *  .  r
/  I
. ' W J
1 /  * ,  % /
. M  •  ^  -•  1  % « »*  # 7 *
/ . '  #
% •* » *^  •  « 7
0 # V / v  #  V ’ * V /  * A  *  ' #  /
/ •  | 4  #  
v V ;  ;
;  ;  
• ’  «  1
«1 /  f
* $ 8  .  > s .  '  ^  %  > ft #
v v  . « v  • *  ; ' 4
% * v :  y : ,  ï - r  • *  *
A. H&E s ta in in g  o f  a d ip lo id  dVIN lesion ad jacent to  an aneuplo id carcinom a w ith  e longated and 
b ridg ing  rete ridges. B) Detail o f th e  boxed area in A show ing  atyp ia in the  basal layer.
C. A consecutive tissue section stained fo r P53 expression dem onstra tes m ore than  70% o f  the 
cells w ith in  the  low er o ne -th ird  com ponen t positive fo r P53.
D. Deta il o f th e  boxed area in C. O rig inal m agn ifica tions: A and O 5 0 X , B and D:200x.
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Sequential stain ing for p53 (A) and DNA (B) was performed on tum or tissue and the respective 
IOD values determ ined on selected cells. Yellow  asterisks indicate the region of inflam m atory 
cells from w hich cells were selected to serve as a diploid and p53-negative internal control. The 
frequency d istribution (C) o f IODftUigen values o f p53-negative (IODP53o .6 , top panels) and p53 pos­
itive (IODP53>i .6, m iddle panels) nuclei from 4 different patients (i-iv) is presented as histogram s 
and dem onstrates a shift tow ards increased DNA content w hen P53 expression is increased. Dot­
ted line: mode IODFeuigen o f p53-negative nuclei. Scatterplots of IODFeuigen and IODP53 (IODai,>o, bot­
tom panels) reveal a s im ilar positive correlation between P53 stain ing intensity and DNA content 
in individual cells. O rig inal m agnification A and B:50x.
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It rem ains unclear how p53 could contribute to the development of vulvar SCC from 
dVIN.
Lerma et al. concluded that p53 expression is a late event in m alignant progression 
as 7 2 %  of their SCCs were DNA aneuploid and only 5 6 %  of the SCCs showed P53 
overexpression (which w as defined as > 10 %  of the tum or cells)14; but they do not 
provide sim ultaneous results on ploidy status and P53 expression in individual 
lesions. In vulvar carcinomas, ploidy has been studied m ostly in relation to prognosis 
and no results on ploidy status o fV IN  lesions exist. Despite the lim ited num ber of 
cases in our study, the percentage of DNA aneuploidy in vulvar SCC (9/17, 53%) is in 
line w ith the percentages found in previous reports of 13 %  to 8 3% .10'16 The causal 
relationship between high P53 expression in vulvar epithelium  and DNA aneuploidy 
rem ains elusive. Possibly, destabilization of chromosomes due to centrosome 
am plification contributes to the cancer susceptibility phenotype associated w ith 
m utation (resulting in over-accum ulation of P53) or stabilization of P53.6 In this study, 
im m unohistochem ical detection of P53 expression could not be correlated w ith P53 
m utation because no antibody can discrim inate between either forms.
Rolfe et al. found that p53 m utations develop in LS and squam ous hyperplasia, and are 
intrinsic to the clonal evolution that leads to vulvar SCC.29 Our im m unohistochem ical 
data support this hypothesis, although we were unable to directly correlate 
im m unohistochem ical detection of P53 w ith P53 m utational status due to insufficient 
h ig h-q uality DNA in the m icrodissected tissue. Further correlative studies of P53 
expression w ith m utational status in vulvar dVIN and SCC are w arranted.
It has been suggested that loss of function of cell cycle regulator genes influences 
chromosome segregation, leading to DNA aneuploidy.6* 30 The absence of p i6 INK4A 
in cells generates supernum erary centrosomes, w hich can eventually lead to the 
production of aneuploid daughter cells as a result of unequal segregation of the 
genom ic m aterial during m itosis.31 In our study, we were unable to correlate the role 
of p i6 INK4A and pi4ARF to DNA aneuploidy since the staining of p i6 INK4A-expression was 
not different in DNA diploid and DNA aneuploid cases (data not shown).
In conclusion, a high percentage of P53 expressing cel Is in vulvar lesions appears to be a 
surrogate marker for DNA aneuploidy. DNA aneuploidy w as observed in vulvar lesions 
in w hich more than 7 0 %  of the epithelial cells expressed P53. Furthermore, high levels 
of P53 expression correlate w ith increased DNA content in individual cells. For dVIN, 
both adjacent to vulvar SCC and solitary, increased P53 expression and DNA ploidy 
are found in the basal cells compared w ith the superficial com partm ent, although 
ascending aneuploid cells can also be detected. The observation that the degree of 
aneuploidy in dVIN is higher compared w ith LS, but less or equal compared w ith SCC, 
suggests that dVIN has a higher m alignant potential than LS. The m echanism  of 
oncogenesis and the progression of LS to dVIN rem ains elusive.
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DNA ploidy histogram s for one exam ple case (case 2). Upper panels show  data from  the superfi­
cial com partm ent; lower panels for the basal com partm ent. Panels on the left show  data for all 
cells, m iddle and right panels d istinguish between p53-negative and p53-positive cells, respec­
tively. The percentages shown inside individual graphs indicate the percentages o f cells w ith DI 
greater than 1 (indicative for aneuploidy).
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Table 3. Analysis of DNA ploidy and P53 expression in composite vulvar lesions
Patient Diagnosis Ploidy-status* P53-expression*
1 LS Diploid 10%
dVIN Diploid 10%
II LS Diploid 2%
dVIN Diploid 1%
III dVIN Diploid 10%
SCC Diploid 5%
IV LS Diploid 0%
dVIN Aneuploid NA
V LS Diploid 10%
SCC Aneuploid 75%
VI SCC Diploid 40%
VII dVIN Aneuploid 75%
SCC Aneuploid 80%
VIII dVIN Diploid 5%
IX SCC Diploid 0%
X LS Hypoploid 30%
XI SCC Diploid 30%
XII LS Diploid 2%
dVIN Aneuploid 80%
SCC Tetraploid 75%
XIII dVIN Diploid 25%
SCC Diploid 50%
XIV SCC Tetraploid 20%
XV LS Diploid 5%
dVIN Diploid 50%
SCC Aneuploid 80%
XVI N Diploid 0%
dVIN Diploid 80%
SCC Aneuploid 90%
XVII dVIN Aneuploid 100%
SCC Aneuploid 70%
XVlll LS Diploid 30%
dVIN Aneuploid 75%
SCC Aneuploid 85%
XIX dVIN Diploid 90%
SCC Aneuploid 95%
XX LS Diploid 20%
SCC Diploid 65%
XXI N Diploid 0%
SCC Aneuploid 95%
XXII SCC Aneuploid 95%
*P53-expression: in dVIN: percentage in low er one -th ird  o f t h e  e p ithe lium ; in LS and SCC the 
en tire  lesion was assessed 
NA: n o t available
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Table 4 Ploidy-status vs high p53-expression
P53<7° % P53a 7° % Total
D ip lo id  (DNA index 0.9 -1 .1) 22 2a 24
N on-d ip lo id  (aneuplo id or te trap lo id ) i b H 15*
Total 23 l 6 39
a both dVIN les ions,b SCC, * P c o o i (%2test)
Table 5 P53 positivity and DNA content in solitary dVIN (A) and DNA content in relation to P53 
expression and localization within dVIN (B)
A
Solitary P53-positive cells (%) Cells with DI > i a (%)
dVIN Basalb Superfic ia l1 P Basal Superficial P
1 20.0 9.8 .003 47-4 21.7 <.001
2 72.9 27.2 <.001 275 4-7 <.001
3 41.4 9-4 <.001 3-9 5-2 <.001
4 30.9 3-3 <.001 16.6 7.8 .003
5 4.1 0.6 <.001 20.7 10.6 <.001
6 34-9 12.9 <.001 26.4 8.7 <.001
B
Solitary
dVIN
Basal compartment Superficial compartment
Percentage cells w ith  DI > 1 Percentage cells w ith  DI > 1
P53- P53 + P P53- P53 + P
1 43-9 61.0 <.001 20.2 35-7 NS
2 4.8 35-9 <.001 3-5 7.8 NS
3 1.6 7-1 <.001 3-5 21.6 <.001
4 8.4 34-9 <.001 6.9 33-3 NS
5 19-7 44.0 <.001 10.7 0 NS
6 21.8 35.0 <.001 9-3 5.0 NS
a DI = l:  DNA c on ten t o f  norm al reference cells w ith in  the  strom a 
b Basal com partm en t: the  low er one -th ird  com ponen t o f  dVIN 
c Superfic ial com partm en t: the  upper o ne -th ird  com ponen t o f  dVIN
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In this thesis, clear evidence is presented that there are two separate pathways 
leading to vulvar squam ous cell carcinoma (SCC).1;2 Both pathways have their own 
prem alignancies and patient characteristics. In the HPV-associated pathway, 
oncogenesis resembles the development of cervical carcinom a. In the HPV-negative 
pathway, the m echanism  of cancer development is unclear. So far, differentiated VIN 
(dVIN) is the most likely candidate in the search for the true precursor lesion.
HPV-positive pathway
The development of vulvar SCC through the HPV-related pathw ay resembles the 
development of cervical cancer. As shown in the meta analysis by Sm ith etal. including 
44 studies, HPV16 is the most prevalent HPV type in both vulvar SCC (29.3%) and 
uVIN (71.2%). The next most common HPV type w as HPV18 in vulvar SCC (5.6%) and 
HPV33 in uVIN (7.7%). W hen HPV prevalence w as calculated a sth e  percentage of only 
H PV-positive invasive vulvar cancer cases, 75.5%  of HPV positivity w as attributable to 
HPVi6,follow ed by HPV18 (14.3%) and HPV56 (1.7%).3
A decrease in incidence of HPV related vulvar squam ous lesions is to be expected w ith 
the introduction o fth e  prophylactic HPV vaccine. Two commercial vaccines against 
HPV (Gardasil™ and Cervarix™) are currently available in m any countries w orldw ide. 
They have been found to be highly efficient in preventing persistent infections 
and lesions not only from the uterine cervix, but also from the anus, vagina, and 
vulva. Both vaccines have been shown to be generally safe in phase II and phase III 
randomized controlled trials. Gardasil™  is a quadrivalent recom binant vaccine that 
protects against HPV 6, HPV11, HPV16 and HPV18.4 Cervarix™ is a bivalent vaccine that 
protects against HPV16 and HPV18, and has been chosen by the Dutch government for 
the Dutch vaccination programme. Cross protection for HPV31, HPV33 and HPV45 for 
cervical lesions has been described, but has not been evaluated for vulvar lesions.5
W ith the introduction and effectuation of HPV vaccination, a decrease in the incidence 
of uVIN and associated vulvar SCCs is to be expected. Novel therapies and treatments 
might decrease the m orbidity and possibly m ortality of HPV-related vulvar squam ous 
(pre-)m alignancies.Severaltherapeuticvaccination strategies have beentested (m ainly 
for HPV16) and were found to be effective on im m unological, serological or clinical 
parameters.6'9. Recently, the im m unogenicity and efficacy of a synthetic long-peptide 
therapeutic vaccine was tested in wom en suffering from HPV16 positive uVIN.10 Clinical 
response (12 months post vaccination) was achieved in 7 9 % , and complete response 
appeared to be correlated w ith induction of H PVi6-specific im m unity.
Im iquim od, the im m unom odulator that has been proven to be effective in the 
treatm ent of uVIN11, seems to fail in patients that lack H PVi6-specific type 1 T-cell 
im m unity. This indicates that a com bination therapy, in w hich the HPVi6-specific
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T-cell response is induced or boosted by vaccination and the affected skin is treated 
w ith im iquim od, m ay increase the num ber of patients that benefit from treatm ent.12 
Currently the combined effect of Im iquim od and therapeutic vaccination is 
investigated.13 It has to be noted that data on Im iquim od is still lim ited, side-effects 
can be severe, and long-term  follow -up is unknown.
Altogether, HPV-positive vulvar SCCs account for less than 2 0 %  o fth e  total am ount 
of vulvar cancers.14 Preventive HPV-vaccination has o n ly ju st started, and therapeutic 
vaccines are currently not common practice and only carried out in trials. W hen 
these strategies prove to be effective, the percentage is HPV-related vulvar lesions 
is likely to decrease. Given the often m ulticentricity of HPV, cervical sm ears should 
be taken in all patients w ith HPV-related vulvar lesions.15 Special attention should be 
paid to im m une-com prom ised individuals (e.g. transplant recipients, auto-im m une 
disease patients treated w ith im m unosuppressants, and HIV infected w omen) w ho 
are at increased risk of both anogenital HPV infections and their associated (pre) 
m alignancies, and recurrence after treatm ent of uVIN.l6;17
Development of HPV-negative vulvar squamous cell carcinoma
The biggest challenge in the m anagem ent for vulvar cancer patients lays in unravelling 
the pathw ay leading to HPV-negative vulvar SCC. This type of cancer occurs m ain ly in 
elderly patients and has a worse prognosis than its HPV-related counterpart.14 In our 
aging population, the incidence is likely to increase. In the HPV-related pathway, the 
w ell-investigated cervical cancer development equivalent has led to understanding 
the HPV-related vulvar SCC oncogenesis.
Recently,for the development of penile SCC, a bimodal classification w ith tw o distinct 
prem alignancies has been described.l8;19 Next to the HPV-related precursor of penile 
SCC, called bowenoid penile intraepithelial neoplasia (PIN) (the penile counterpart of 
uVIN), non HPV-related differentiated PIN has been described.This lesion has sim ilar 
characteristics as dVIN: subtle m orphologic features and an association w ith LS. 
S im ilar to w hat we have described for HPV-negative vulvar SCC, in the HPV-unrelated 
penile SCC development, m utations o fth e p53-gene have been suggested.20
In SCCs o fth e head and neck (HNSCC), HPV-positive cancers, seem to differ from HPV- 
negative HNSCC. Patients w ith HPV-positive HNSCC tend to be younger and have a 
lower intake of tobacco and alcohol. In patients w ith oropharyngeal cancer, tum or 
HPV status is a strong and independent prognostic factor for survival.21 The concept of 
“field cancerization” is well accepted for patients frequently exposed to carcinogens 
(like alcohol and tobacco), suggesting that the entire oral mucosa is exposed to 
carcinogens and m ultiple foci of transformed tissue clones are expected in these 
patients at high risk for m alignancy2*23. In the HPV-negative HNSCCs no lesion sim ilar 
to dVIN has been described.
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The question remains w hy only the m inority of patients w ith LS develops SCC. It 
might be a coincidence (due to age factors) but that cannot explain the fact that LS 
is present in such a high percentage of vulvar SCC specimens. Differentiated VIN is 
most often observed in association with SCC in a background of LS, but solitary dVIN 
in a background of LS also occurs. Interestingly, most dVIN tissue samples also contain 
atypical LS that is characterised by a strong inflam m atory response directly underneath 
the epiderm al-derm al junction. It has been proposed by Regauer and co-workers24 that 
these LS lesions are in fact early LS w ith the capacity to revert to normal epithelium, but 
which can also progress towards irreversible, advanced LS w ith the typical deep dermal 
band-like infiltrate and hyalinated and edemic dermal zone. Possibly, the inflam m atory 
response and activated vasculature in early LS might also trigger the development of 
(pre)malignancies just like chronic inflam m ation is associated w ith carcinogenesis (e.g. 
Crohn’s disease and colorectal carcinoma, gastric ulcers and gastric adenocarcinomas).25 
Since inflam m ation has been suggested as a critical component in tum or progression,26 
further analysing the inflam m atory response, might help us understand vulvar cancer 
oncogenesis.The analysis of inflam m atory infiltrate of LS and dVIN shows a promising 
role of mast cells.27 When the features of LS that are related to an increased risk of dVIN 
and/or SCC development are known, care for LS patients may be improved. When it is 
possible to distinguish patients w ith a high risk of m alignancy from low-risk patients, 
studies should be carried out to investigate the effect of different screening intervals. 
Possibly, low-risk patients can be followed less frequently and preferably by their GP, 
whereas high-risk patients are better followed in a hospital setting at higher frequency.
Currently, most research is carried out on histological specimens, using 
im m unohistochem istry. Further im proving the care for LS patients, could be aim ed at 
non-invasive methods of diagnosing (an increased risk) of m alignant transform ation, 
possibly by new advances in vulvar cytology.
Differentiated VIN is a not yet universally accepted diagnosis. The histological 
features are w ell described, but its cellular differentiation and absence of widespread 
architectural disarray makes this type of VIN difficult to recognize. Expert 
gynaecopathologists, m ostly w orking in university hospitals, often do recognize dVIN 
lesions, as most patients w ith vulvar cancer are treated and followed in a university 
hospital in the Netherlands. Not all pathologists agree to the sam e features as part 
o fth e  diagnosis, and some believe the lesion as such does not exist and it represents 
an in-situ carcinoma component adjacent to an invasive SCC28. Several lesions have 
been described that could be interpreted as dVIN: squamous hyperplasia with atypia, 
atypical lichen sclerosus, hypertrophic lichen sclerosus with acanthosis, all m ostly 
related to LS. On the recent m eeting o fth e ISSVD (Edinburgh, UK, 2009) a focus group 
was formed, w orking on the criteria of dVIN in order to gain w idespread acceptance 
o fth e  nom enclature and diagnosis. Interobserver studies, co m paringthe histological 
analysis of different pathologists and their final diagnoses and nom enclature w ill 
provide insight in the reproducibility of features of dVIN.
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The low num ber of published solitary dVIN lesions in studies, m ight be explained by 
the hypothesis that dVIN has a short intra-epithelial phase that rapidly progresses into 
vulvar SCC.The lack of a universally accepted histological definition and the variety of 
descriptions and “nam es” possibly referring to the same entity, are also contributors 
to the underestim ated incidence of dVIN. Investigating biopsies of patients w ho 
developed a vulvar SCC after the diagnosis of LS w ill be helpful in unravelling the 
biological behaviour. It is likely that revision of the available pre-cancer biopsies 
w ill reveal additional cases of solitary dVIN am ong cases previously labelled as LS.29 
Assessm ent of biopsy intervals w ill also provide inform ation on the length o fth e  
intra-epithelial phase, w hich in the HPV-negative pathw ay is expected to be shorter 
than in u VIN .30 Another factor in the relative underreporting of dVIN m ight be the fact 
that, w hatever is causing dVIN, m ight not result in a clinical lesion that is likely to be 
biopsied.31 We believe that the reddish or ulcerative lesions in LS patients are potential 
dVIN lesions (see figure 5CD, Chapter 1), and should be biopsied. However, m apping 
biopsies in individual patients, show dVIN at clin ically “quiet” appearing LS changed 
vulvar skin (personal experience). Therefore, studies should be initiated correlating 
clinical lesions to the morphological and histological features in dVIN, like has been 
done in lichen sclerosus.32
In the past few  years, in the Netherlands, the care for patients w ith vulvar 
com plaints has become more centralized in special vulvar clinics. Mostly, th is is a 
collaboration between the departm ents of gynaecology and dermatology. Often, 
additional specialists (e.g. sexologist, physiotherapist) are available for quick referral. 
M ultid iscip linary vulvar clinics can provide specialized medical and supportive care for 
patients w ith extensive vulvar disease and/or com plaints. There is no evidence that 
routine follow -up of patients w ith vulvar prem alignancies w ill improve the prognosis 
of patients or change the risk of m alignant progression nor the prognosis in patients 
w ho develop vulvar SCC.
Besides improvement of care for a subgroup of patients w ith difficult to treat vulvar 
complaints, these specialized vulvar clinics provide an excellent population for 
observational and follow-up studies. Our retrospective chart study on vulvar lichen 
sclerosus patients showed a subgroup of patients w ith a lot of symptoms that will 
especially benefit from the care in a vulvar clinic.33 Currently, the vulvar clinic in Nijmegen is 
subject of investigation regarding the quality of care for vulvar patients.Sofar.no studies 
on the preferences of and quality of care for vulvar patients have been published.
As long as no uniform nom enclature and definitions are used, publications w ill be 
difficult to compare. Still, articles not taking the new accepted nom enclature of the 
ISSVD into account are being published.34 To facilitate future studies and to further 
unravel the pathw ay leading to HPV-negative vulvar SCC, all studies should ideally use 
the sam e nom enclature and include pathological review. Uniform nomenclature, as 
introduced by the ISSVD,35 is therefore essential and should be adopted worldw ide.
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Summary
Chapter i
Vulvar squam ous cell carcinoma (SCC) develops follow ing tw o different pathways, 
w hich have their own prem alignant lesions. In the absence of hum an papillom a virus 
(HPV), vulvar SCC can develop in a background of lichen sclerosus (LS), differentiated 
vulvar intraepithelial neoplasia (dVIN) or both. The other pathw ay leading to vulvar 
SCC is associated w ith HPV and the HPV-associated prem alignancy is usual VIN 
(uVIN). Improving the care for patients w ith vulvar (pre-)m alignancies requires 
further understanding of the oncogenesis of vulvar SCC. The aim  of this thesis is to 
gain insight in the oncogenesis of vulvar squam ous cell carcinom a. Both pathways 
leading to vulvar squam ous cell carcinoma were investigated.
This chapter reviewsthe history,epidemiology,aetiology, histology,clinical characteristics, 
treatment options, m alignant potential and prevention strategies of LS, uVIN and dVIN 
as an introduction to the experimental work in the rest of the thesis.
Chapter 2
To obtain more insight into the m echanism s underlying the two pathways leading 
to vulvar SCC, we determined the relationship between HPV DNA and the expression 
of cell cycle related biomarkers pi4ARF and p i6 INK4A in non- and (pre)malignant vulvar 
lesions. The prevalence of HPV increased w ith the severity of the classic VIN lesions 
and so did the expression of pi4ARF and p i6 INK4A.The sim ultaneous expression of pi4ARF 
and p i6 INK+A was h ighly associated w ith the presence of hr-H PV DNA. H r-H PV was 
detected in only a single case of dVIN, whereas no expression of pi4ARF was found and 
lô 'N ^ w a s present in only 2 cases. AI I sam ples ofvulvar SCC were hr-H PV DNA negative 
although in a substantial part pi4ARF and/or p i6 INK4A w as expressed. No relation was 
found between hr-HPV and the expression of pi4ARF and p i6 INK4A in the non-neoplastic 
vulvar lesions. These results provide further evidence that vulvar squam ous cell 
carcinoma is a m ultifactorial disease that develops from tw o different pathways.
Chapter 3
It is important to distinguish the two types of VIN because the both have their own type 
of treatment and a different m alignant potential. Therefor three groups of VIN lesions 
were investigated; seventy-five dVIN lesions with adjacent SCC and 45 usual VIN lesions: 
32 solitary and 13 w ith adjacent SCC. All were tested for hr-HPV DNA, using a broad- 
spectrum HPV detection/genotyping assay (SPF10-LiPA), and the im m unohistochem ical 
expression of MIB1, p i6 INK+A and P53. All dVIN-lesions were hr-HPV-negative and p i6 INK4A- 
negative and in nearly all, M lBi-expression was confined to the parabasal layers. 
Eighty-four percent exhibited high P53 labeling indices, sometimes with parabasal 
extension. Eighty percent of all usual VI N-lesions were hr-HPV-positive, p i6 INK+A-positive, 
Ml Bi-positive and p53-negative. Both pathways leading to vulvar SCC have their own 
im m unohistochem ical profile, w hich can be used to distinguish the two types of VIN, 
but cannot explain differences in m alignant potential.
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Chapter 4
Tofurther investigate the differences in m alignant potential in vulvar prem alignancies, 
the proliferative activity in the epithelial cell layers in different vulvar prem alignancies 
and normal skin w as quantified. In chapter 3, a distinct Ml Bi-expression pattern in 
dVIN lesions w as found. In this study, we tested w hether the expression of MIB1 in 
the basal regions of the vulvar epithelium  m ay be helpful in diagnosing dVIN and 
can explain the differences in m alignant potential. Autom atic digital im age analysis 
software w as developed to quantify the prolife rating fraction in different parts of the 
epithelium  (MIB1 positivity index). MIB1 expression differed am ong the various vulvar 
prem alignancies; a M IBi-negative basal cell layer w as a distinct feature of normal 
vulvar epithelium . No M IBi-negative basal cell layer was noted in dVIN or other vulvar 
prem alignancies. O w ing to this negative cell layer, the MIB1 proliferation index in 
normal vulvar epithelium  was significantly lower than in vulvar prem alignancies. 
MIB1 expression can be a helpful tool in diagnosing a prem alignancy and has 
additional value especially to distinguish dVIN from normal vulvar epithelium , but 
cannot explain the differences in m alignant potential.
Chapter 5
The m alignant potential of LS is believed to be low; 3 -5 %  of the patients develop vulvar 
SCC. Therefore, most guidelines recommend regular, low-frequency follow-up. In this 
chapter, we describe the follow-up of LS patients at the departments of Gynaecology 
and Dermatology in the Radboud University Nijmegen Medical Centre, where no 
guidelines concerning the treatment and follow-up of LS existed. By doing so, the need 
for a m ultidisciplinary vulvar clinic was evaluated. Treatment and follow-up data of all 
women with histologically proven (between January 1995 and January 2001) anogenital 
LS visiting the outpatient clinics of the departments of Obstetrics & Gynaecology and 
Dermatology were collected (last date of follow-up: January 2008).
Eighty-four patients with LS were included in this study; ten patients (12%) were treated by 
both specialties. At the department of Obstetrics & Gynaecology, LS patients more often 
received surgical treatment, topical estrogens and lidocaine ointment, whereas at the 
department of Dermatology local class ll/lll corticosteroids were more often prescribed. 
Follow-up frequencies were sim ilar in both specialties and took place at 3-4 visits in the 
first year, and at least once a year afterwards. One patient developed vulvar squamous cel I 
carcinoma (SCC). This patient had withdrawn from follow-up. M anagement of patients 
with LS, agreed with current recommendations in the literature. However, differences in 
secondary and supportive therapy existed, due to differences in expertise.The relatively 
high percentage of patients treated by both specialties with a high frequency of visits 
emphasizes the need for a m ultidisciplinary clinic for vulvar disease.
Chapter 6
Follow-up in LS patients could be improved when one is able to differentiate between 
LS lesions that w ill progress into dVIN and/or vulvar SCC and those that remain 
solitary LS. Vessel type and vessel density m ight be predictors of m alignant potential.
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Therefore vessel parameters and pericyte characteristics in vulvar LS associated with 
vulvar SCC and solitary vulvar LS lesions were compared.
Q uantitative analysis of im m unohistochem ical staining for CD34 (vascular and 
lym phangiogenic lymph endothelial cells), D 2-40 (lym phatic-specific marker) and 
ct-SMA (pericyte marker) w as performed on paraffin-em bedded tissue sam ples of 
28 patients w ith LS (7 adjacent to vulvar SCC, 21 solitary). Electron microscopy was 
performed on fresh tissue. No significant differences in vessel density or other vessel 
parameters could be demonstrated between the 2 groups. In hyalinized lesions, vessel 
diam eter and a -S M A  positivity w as reduced compared w ith nonhyalinized lesions. 
Electron m icroscopy revealed detachm ent of pericytes from vascular endothelial cells 
and increased thickening of basem ent membrane, w hile endothelial cell function did 
not appear strongly im paired. M alignant potential of LS cannot be predicted by vessel 
characteristics. Hyalinization in LS is associated w ith pericyte detachm ent from the 
basal lam ina of vascular endothelial cells.
Chapter 7
Chapter 7 describes the expression of P53 and DNA ploidy status in LS, dVIN and HPV- 
negative vulvar SCC. The goal of this study w as to investigate w hether the progression 
of LS towards dVIN and vulvar SCC is accompanied by an altered DNA content. Also, 
the expression of P53 was assessed to investigate the relationship between P53- 
expression and DNA ploidy.
Alm ost all LS lesions were diploid, im plicating normal DNA content. In lesions that 
contained both dVIN and vulvar SCC, the ploidy status of the dVIN never exceeded the 
ploidy status of the adjacent vulvar SCC.
We observed a strong correlation between high P53 expression and DNA aneuploidy. 
This relation w as also present at the level of single nuclei, measured by sequential 
im age cytom etry of P53 im m unohistochem istry followed by DNA im age cytom etry 
on form alin-fixed tissue sections. Sim ilarly, we found p53-positive nonproliferating 
cells w ith increased DNA content in the superficial com partm ent of solitary dVIN 
lesions that were not associated w ith SCC, indicating ascending aneuploid cells from 
the basal com partm ent. DNA ploidy m easurem ents suggest that dVIN has a higher 
m alignant potential than LS, and thus is a more likely precursor of SCC. Furthermore, 
high P53 expression correlates w ith increased DNA content and aneuploidy; but it 
requires further research to unveil a possible causal relation.
Chapter 8
In the final chapter, future studies and hypothesis based on the results of the 
abovementioned studies are proposed and discussed, in order to gain further insight 
in the development of HPV-negative vulvar SCC and to improve the care for patients 
w ith vulvar disease.
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Samenvatting
Hoofdstuk 1
Vulvair plaveiselcelcarcinoom  (PCC) kan ontstaan via 2 verschillende routes, elk 
met een eigen voorstadium  (prem aligniteit). Zonder de aanw ezigheid van hum aan 
papillom avirus (HPV) kan een vulvair PCC ontstaan in een gebied met lichen sclerosus 
(LS), gedifferentieerde vulvaire intraepitheliale neoplasie (dVIN) of beide. De andere 
route, die leidt tot een vulvair PCC is wel geassocieerd met HPV. De HPV-geassocieerde 
prem aligniteit is de zogenaam de usual VIN (uVIN). Het verbeteren van de zorg voor 
patiënten met een vulvaire (pre-)m aligniteit kan alleen, w anneer het onstaan van 
kanker (oncogenese) verder wordt doorgrond. Het doel van dit proefschrift is om 
inzicht te krijgen in de ontstaansw ijze van het vulvaire PCC. Beide routes die leiden 
tot het vulvair PCC werden onderzocht.
Het eerste hoofdstuk geeft een overzicht van de geschiedenis, epidemiologie, etiologie, 
histologie, klinische verschijnselen, behandelingsopties, ma ligne potentie en preventie­
strategie van LS, uVIN en dVIN. Het dient als introductie op het experimentele werk, 
dat wordt beschreven in de overige hoofdstukken van het proefschrift.
Hoofdstuk 2
Om meer inzicht te krijgen in de m echanism en, die ten grondslag liggen aan de 2 
routes, die leiden tot vulvair PCC, bepaalden we de relatie tussen de aanw ezigheid 
van HPV DNA en de aanw ezigheid van eiw itten die gerelateerd zijn aan de cel-cyclus 
(expressie van de de biomarkers pi4ARF en p i6 INK4A) in niet- en (pre-)m aligne vulvaire 
afw ijkingen. Het voorkomen van hoog-risico HPV (hr-HPV) nam toe met de ernst van 
de uVIN afw ijking; deze relatie w as ook aanw ezig voor de expressie van pi4ARF en 
p i6 INK4A. De gelijktijd ige expressie van pi4ARF en p i6 INK4A had een sterke relatie met de 
aanw ezigheid van hr-HPV DNA. H r-H PV werd slechts in 1 dVIN afw ijk ing aangetroffen, 
terw ijl er in deze groep geen expressie van pi4ARF kon worden aangetoond en p i6 INK4A- 
expressie slechts aanw ezig was bij 2 patiënten. Alle vulvaire PCCs waren hr-HPV DNA 
negatief, alhoewel in een deel pi4ARF en/o f p i6 INK4A wel tot expressie kwam. Er kon 
geen relatie worden aangetoond tussen hr-HPV en de expressie van pi4ARF en p i6 INK4A 
in de niet-prem aligne vulvaire afw ijkingen. Deze resultaten bevestigen, dat vulvair 
PCC een m ultifactoriële ziekte is, die kan ontstaan via twee verschillende routes: met 
en zonder de aanw ezigheid van hr-HPV.
Hoofdstuk 3
Het is van belang om onderscheid te maken tussen de twee types VIN vanwege 
verschil in enerzijds de behandeling en anderzijds de kans op m aligne ontaarding. 
In de zoektocht naar een betere herkenning van de twee types VIN en een verklaring 
voor het verschil in m aligne potentie zijn er drie groepen VIN afw ijkingen onderzocht: 
vijfenzeventig dVIN afw ijkingen met naastgelegen PCC en 45 uVIN afw ijkingen (32 
solitairen 13 met naastgelegen PCC). Er werd gekeken naar de aanw ezigheid van hr-HPV 
DNA met behulp van een breedspectrum HPV detectie-en genotypering-assay (SPF10-
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LiPA). Daarnaast werd ook gekeken naar de expressie van M IBi, p i6 INK4A en p53; dit zijn 
eiw itten die gerelateerd zijn aan de cel-cyclus en proliferatie. Alle dVIN afw ijkingen 
waren hr-H PV-negatief en p i6 INK4A-negatief en in vrijw el alle gevallen w as de expressie 
van M IBi alleen aanw ezig in de lagen net boven de basaalm em braan (parabasaal). 
V ierentachtig procent had een hoge p53 labelings index, soms met een uitbreiding 
richting het oppervlak.Tachtig procent van alle uVIN afw ijkingen was hr-HPV-positief, 
p i6 INK4A-positief, Ml Bi-positief en p53-negatief. De twee routes, die leiden n aarvulva ir 
PCC hebben hun eigen profiel van HPV en im m unohistochem ische expressie van 
eiw itten, dat gebruikt kan worden om de twee VIN types te onderscheiden, m aar dat 
profiel geeft geen verklaring voor het verschil in m aligne potentie.
Hoofdstuk 4
Om de verschillen in m aligne potentie van vulvaire voorstadia verder te onderzoeken, 
werd de m ogelijkheid tot groei (proliferatie) in de epitheliale cellagen in getal 
uitgedrukt voor verschillende vulvaire prem aligniteiten en norm ale vulvaire huid. 
In hoofdstuk 3 werd een opvallend expressie-patroon van MIB1 bij dVIN gevonden. 
In de studie beschreven in hoofdstuk 4 werd onderzocht of de expressie van MIB1 
in de basale cellagen van vulva-epitheel behulpzaam  kan zijn bij het stellen van de 
diagnose dVIN en of het de verschillen in m aligne potentie kan verklaren.
Speciaal voor de studie ontwikkelde, digitale beeldanalyse software werd gebruikt om de 
groeifractie in de verschillende delen van het epitheel te berekenen (MIB1 positiviteits- 
index). Het patroon van M IBi-expressie was verschillend in de diverse vulvaire weefsels: 
normaal vulva-epitheel had een M IBi-negatieve basale cellaag als uniek kenmerk. 
In dVIN of de andere premaligniteiten was deze M IBi-negatieve basale cellaag niet 
aanwezig. Dankzij deze negatieve cellaag was de M IBi-positiviteits-index in normaal 
vulvair epitheel significant lager dan in de vulvaire premaligniteiten. MIBi-expressie 
kan behulpzaam zijn bij het stellen van de diagnose van een vulvaire prem aligniteit 
en heeft toegevoegde waarde in het maken van onderscheid tussen dVIN en normaal 
vulva-epitheel, maar kan het verschil in maligne potentie niet verklaren.
Hoofdstuk 5
De m aligne potentie van LS wordt in de literatuur als laag ingeschat: 3 -5 %  van de 
vrouw elijke LS patiënten ontw ikkelt een vulvair PCC. De meeste richtlijnen adviseren 
regelm atige controles in een lage frequentie. In dit hoofdstuk wordt de follow -up van 
LS-patiënten bij de afdelingen Verloskunde & Gynaecologie en Derm atologie in het 
UMC St Radboud beschreven. Daarnaast vond ook evaluatie plaats van de behoefte 
aan een m ultidisciplinaire vulvapoli w aar gynaecologen en dermatologen samen 
patiënten zien met name met m oeilijk te behandelen klachten.
Van alle vrouwen met een histologisch bewezen anogenitale LS (tussen jan u ari 1995 
en jan u ari 2001), die de polikliniek van de afdeling Verloskunde & Gynaecologie en/of 
Derm atologie bezochten, werden gegevens over behandeling en follow -up verzameld 
(laatste follow -up: jan u ari 2008).
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Het beloop van 84 patiënten werd geanalyseerd; tien patiënten werden behandeld 
door beide specialism en. Op de afdeling Verloskunde & Gynaecologie werden LS 
patiënten vaker behandeld door middel van chirurgie, lokale oestrogeen-crèm es en 
lidocaïnezalf, terw ijl op de afdeling Derm atologie vaker klasse ll/ lll  corticosteroïden 
werden voorgeschreven. De follow -up frequentie w as gelijk op beide afdelingen: 3 tot 
4 bezoeken in het eerste jaar, en daarna ten m inste eenm aal per jaar. Eén patiënte 
ontwikkelde een vulvair PCC. Zij had zich onttrokken aan follow -up. De behandeling 
van patiënten met LS was in overeenstem m ing met de thans geldende richtlijnen 
in de literatuur. Er zijn wel verschillen ten aanzien van de therapie van tweede keus 
en ondersteunende therapie, door verschil in expertise. Het relatief hoge percentage 
patiënten, dat door beide specialisten wordt behandeld met een hoge frequentie van 
polibezoeken, onderschrijft de behoefte aan een m ultid iscip linaire vulvapoli.
Hoofdstuk 6
De follow -up van patiënten met LS kan verbeterd worden, w anneer het m ogelijk is 
onderscheid te maken tussen LS afw ijkingen, die zullen ontaarden in dVIN en/of 
PCC, en LS afw ijkingen, die dat niet zullen doen. Vaattype en vaatdichtheid zouden 
voorspellers van m aligne potentie kunnen zijn. Daarom werden vaat-param eters 
en eigenschappen van de cellen rondom bloedvaten (pericyten) in solitaire LS en LS 
geassocieerd met vulvair PCC vergeleken.
Kwantitatieve analyse van im m u nohistochem ische kleuringen voor CD34 (aan kleuring 
van vasculaire en lym fatische endotheel cellen), D2-40 (lym fvat-specifieke merker) en 
a -SM A  (pericyt merker) werd verricht op LS afw ijkingen naast een vulvair PCC en op 
solitaire LS afw ijkingen. Tussen de 2 groepen konden geen significante verschillen in 
vaatdichtheid of anderevaat-param eters worden aangetoond.Electronen microscopie 
van vers LS weefsel liet het loslaten van pericyten van het vasculaire endotheel 
zien, naast een toegenomen dikte van de basaalm em braan, terw ijl de endotheliale 
celfunctie niet leek te zijn aangedaan. De m aligne potentie van LS kan derhalve niet 
worden voorspeld met behulp van vaat-eigenschappen.
Hoofdstuk 7
In hoofdstuk 7 wordt beschreven w at de p53-expressie en ploïdie status is in LS, 
dVIN en het HPV negatieve vulvacarcinoom . Het doel van deze studie w as om te 
onderzoeken of de progressie van LS naar dVIN en het vulvacarcinoom  gepaard gaat 
met een andere DNA inhoud. Ook is onderzoek gedaan naar de p53-expressie van 
deze afw ijkingen om de relatie tussen p53-expressie en DNA inhoud te bestuderen. 
Bijna alle LS afw ijkingen waren diploïd, wat een normale DNA inhoud im pliceert. In 
afw ijkingen w aarin zowel dVIN als vulvacarcinoom  voorkwam, w as de DNA inhoud 
van dVIN nooit méér dan in het naastgelegen PCC. In de dVIN afw ijkingen w as de P53- 
expressie alleen in de basale en suprabasale lagen aanw ezig, soms met uitbereiding 
naar de hogere lagen. Er w as een positieve correlatie tussen hoge expressie van 
P53 en de aanwezigheid van DNA aneuploïdie. Deze relatie w as zowel aanw ezig op 
weefsel niveau als op het niveau van individuele cellen. In de oppervlakkige lagen
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van de solitaire dVIN afw ijkingen vonden we p53-positieve, niet-prolifererende cellen 
met een toegenom en DNA inhoud. Dit lijkt erop te w ijzen, dat aneuploïde cellen 
kunnen opstijgen vanaf het basale com partim ent. DNA ploïdie metingen suggereren, 
dat dVIN een hogere m aligne potentie heeft dan LS, en dus een meer w aarschijnlijke 
voorloper van PCC is. Er dient nog meer onderzoek te worden gedaan om de m ogelijk 
causale relatie tussen hoge p53-expressie en toegenomen DNA in houd en aneu ploïdie 
te onderzoeken.
Hoofdstuk 8
In het laatste hoofdstuk worden toekom stige studies en hypotheses, gebaseerd op de 
resultaten beschreven in dit proefschrift, voorgesteld en bediscussieerd. Genoemde 
studies zijn noodzakelijk om meer inzicht te krijgen in de ontw ikkeling van HPV- 
negatief vulvair PCC en om de zorg voor patiënten met vulvaire afw ijkingen te 
verbeteren.
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Dankwoord
Het zit erop! Een proefschrift is vaak heel lang “bijna a f”... Nu is het eindelijk zo ver. 
Zoals bij alle proefschriften zijn er veel mensen betrokken geweest bij de 
totstandkom ing en afronding; iedereen op een andere m anier en de één bijna net 
zo onm isbaar als de ander. Bij het schrijven van dit dankwoord vond ik dat heel veel 
mensen het verdienen om met name genoemd te worden:
Professor Massuger, beste Leon. Vanuit jo u w  kamer in de hoek van de kantoortuin 
heb je  een goed overzicht over de (wetenschappelijke) activiteiten in de tu in. Je 
overzichtelijke blik w as onm isbaar voor het onderzoek als geheel en ook voor de 
artikelen kon je  door helderheid te scheppen, weer veel nieuw e onderzoeksvragen 
genereren. Dank voor de tijd  die ik kreeg toen ik in Eindhoven zat, fijn dat je  op het 
eind met Joanne samen de duimschroeven hebt aangedraaid!
Doctor de Hullu, beste Joanne. Toen ik tijdens mijn co-schap aangaf dat ik geen 
w etenschappelijke stage meer hoefde te doen m aar wel “een case-report ofzo” zou 
w illen schrijven bij je, had ik niet kunnen vermoeden dat er nu een boekje ligt. Dank 
voor je  creatieve m anier van begeleiden; via de mail of telefoon, lekker in de voortuin, 
bij je  thuis met lekkere koffie en altijd tijd  makend tussen de patiëntenzorg door.
Doctor Bulten, beste Hans. Opeens werd er een klinische dokter aan je  voorgesteld, 
die (nog steeds) geen patholoog w il worden, m aar wel belangstelling heeft voor de 
lopende sam enw erking tussen de Gynaecologische Oncologie en de Pathologie en 
de plannen met het vulva-onderzoek. Dank voor je  zorgvuldige blik op alle coupes en 
kleuringen en de gesprekken over (ons) onderzoek en “het leven”.
Professor Sigrid Regauer. Together w ith Hans and Joanne, I had a w onderful tim e in 
Graz. Our lively discussions on the oncogenesis of vulvar squam ous cell carcinoma 
and your hospitality were great! It is an honour for me that you are attending the 
defence of my thesis.
Dit onderzoek werd voor een groot deel uitgevoerd op de afdeling Pathologie; veel 
medewerkers hebben m ij geholpen met het zoeken/snijden/plakken/kleuren/ 
analyseren van heel veel blokjes en coupes w aarvoor veel dank.
Peter de W ilde en Annem arie Grefte, dank voor ju llie  geduld en de vele discussie- 
en kijk-sessies bij de eerste hoofdstukken van dit proefschrift. De discussies in “de 
epitheel club” o.l.v. professor Slootweg, leidden vaak tot ideeën voor vervolgonderzoek 
of het aanscherpen van de conclusie van ons onderzoek. Jeroen van der Laak, jo uw  
beeldanalyse software en je  geduld om kleine en grotere problemen op te lossen 
hebben hoofdstuk 4, 6 en 7 naar een hoger plan getild. Irene Otte-Höller, jo u w  werk 
voor hoofdstuk 6 en 7 was onmisbaar. Professor van Krieken, dank voor het kritisch 
doorlezen van de m anuscripten en het contact leggen met professor Regauer.
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Léon van Kempen. Ik ken niem and anders die als niet-dokter, zo in staat is om vanuit 
een klinische blik, w etenschap te bedrijven. Helaas heb je  een transfer naar Canada 
gem aakt; ik hoop dat we in de toekom st nog van je  w etenschappelijke enthousiasm e 
mogen blijven genieten.
Dr. Melchers, beste W illem . Bij het begin van het onderzoek w as je  nauw  betrokken, 
later op de achtergrond aanw ezig. Je bent eerlijk, direct en een kei in het in zo w einig 
m ogelijk woorden zo veel m ogelijk zeggen (ook altijd handig voor een abstract dat 
ingekort moet worden). Dank.
De hulp van diverse stagiaires heeft de basis gelegd voor hoofdstuk 4, 5 , 6 en 7: Ard, 
Demia en Ella. Het voorwerk voor hoofdstuk 2 en 3 is verricht door Hebste Shirango en 
Brigiet Hoevenaars. Dank voor ju llie  inzet.
Eén stagiaire verdient een uitgebreidere verm elding: Hedw ig van de Nieuw enhof. Je 
begon als stagiaire, toen ik zelf ook nog niet zo lang bezig w as met onderzoek. Je 
verslag vorm t nu een van de hoofdstukken van je  eigen boekje. Toen mijn klinische 
tijd  w as begonnen, nam je  de vulvapoli vol enthousiasm e van me over. Je eindsprint 
bij het afronden van je  boekje was niet bij te houden (wat nou rustig aan doen als je  
zwanger bent..). Ik vind het leuk om na m ijn eigen promotie, als paranim f naast jou 
te mogen staan!
Alle (ex-)kantoortuin-bewoners, m inder of m inder perm anent en/o f prominent 
aanwezig: dank voor de gezellige onderzoekersweekenden, lunches, “wie 
publiceert-trakteert-taarten”, eerste-hulp-bij-com puter-stress-m om enten, onzin- 
em ails, congressen en andere gedeelde eerste en vervolgstappen in de grote 
wereld van de w etenschap. Charlotte Lenselink, het w as gezellig om je 
w egw ijs te maken in de kantoortuin en Nijm egen en fijn om (onderzoeks-) 
frustraties (ook per em ail) te kunnen delen met mijn overbuurvrouw. 
Loes, ik hoop op mooie resultaten van het voortzetten van het onderzoek. Heel veel 
succes! Ik kom nu echt heel snel de kast opruim en!
Dr. van Hamont, lieve Dennis, grote vriend, wat ben ik blij dat je  me bijstaat als 
paranimf. V anaf de co-schappen gingen we dezelfde kant op en deelden we (hotel) 
kamer, bureau en (weliswaar niet gelijktijd ig) perifere opleidingskliniek. Ik hoop dat 
onze vriendschap en sam enw erking nog lang duurt!
Collega Al OS in periferie en academie: vanuit de kantoortuin in opleiding, misschien niet 
de ideale start, maar dankzij ju llie  warme ontvangst heb ik het enorm naar mijn zin.
Alle gynaecologen in het Radboud, dank voor ju  Nie aanm oedigingen en belangstelling, 
ik leer veel van en bij ju llie . Ook dank aan alle verpleegkundigen, secretaresses en poli- 
medewerkers van de afdeling Verloskunde & Gynaecologie van het UMC St Radboud
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voor ju llie  hulp bij m ijn onderzoek en w erkzaam heden. Yvonne Lawson, dank voor al 
je  inspanningen ten behoeve van het sym posium .
Lenno Dukel, de vulvapoli ging van start en opeens werd je  opgescheept met een 
(onervaren) arts-onderzoeker. Doordat we elkaar al kenden vanuit de co-schappen, 
was het ijs snel gebroken. De poli’s met jou werden vaak afgesloten met een lunch 
inclusief gesprekken over kw aliteit van onderw ijs en (ver)huizen. Gezellig dat je  
m eeging met “de vulvaclub” naar M ünchen.
Door de vulvapoli kwam ook de sam enw erking met de afdeling Derm atologie tot 
stand: M ichelle van Rossum, Dick de Hoop en Carine van der Vleuten, ju llie  maakten 
regelm atig de overtocht voor een derm atologische blik op een casus of artikel. Mede 
nam ens alle patiënten: bedankt!
Alle gynaecologen van het Catharina Ziekenhuis: dr. Hasaart, dr. Van der Putten, dr. 
Kuppens, dr. Dietz, dr. Hermans, dr. Schoot, dr. Van Dop, dr. Roes, drs. Boll, dank voor de 
leerzame momenten in het eerste deel van mijn opleiding.Tot over 2 jaar!
De (oud-)assistenten in Eindhoven: Anika, René, Bianca, Marloes, Nienke, Ilse, 
Annem arie, Marieke, Anne, Dieter, Tjalina, Evelyne, Ellen en Shahed, w il ik bedanken 
voor de collegialiteit en gezelligheid. W anneer houden we een (kerst)diner-reünie?
Verloskundigen, verpleegkundigen en poli-m edew erksters CZE: Bedankt voor ju llie  
w arm e welkom en geduld. Ik kijk uit naar m ijn tweede ronde in ’t Catrien!
Uitleggen aan niet-medici wat voor onderzoekje doet, kan een uitdaging zijn. In mijn 
geval kun je  er hele treincoupés mee stilkrijgen... Ik beloof aan alle lieve vrienden, mijn 
oud-Ko-Raadbestuursgenoten Loes, Corinne, Jente en Niels, en fam ilie dat ik nu weer meer 
tijd heb voor gezellige borrels, etentjes en weekendjes w eg in Nijmegen en daarbuiten.
Lieve Ellen en Yvette, we kennen elkaar vanaf de eerste Nijm eegse studieweken; toen 
al waren onze levens verschillend en dat zijn ze gebleven... Gelukkig is daarin altijd 
plaats voor een dagje sauna, avondjes uit (eten) en natuurlijk Sinterklaas. We hebben 
veel leed m aar ook veel lief samen gedeeld de afgelopen jaren. Ik ben trots op onze 
vriendschap en blij met ju llie  steun en begrip!
Lieve Irene, Marieke, Sefke, Iris, Helga, Laura, Wendy, Susana, Maud, M arijke en alle
andere Circe-dam es: mogen ju llie  je  alweer voor m ij in ’t net h ijsen....Dit is (voorlopig)
de laatste keer hoor!
Joop en Henny, wat heb ik het met ju llie  getroffen. W eekendjes met of bij ju llie  zijn 
een heerlijk rustpunt. Esther en Saskia, ju llie  zijn de leukste schoonzussen die je  je  
m aar kan wensen, thuis en op vakantie.
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Lieve zusjes, Sylvia & Charlotte. “Nee, we zijn geen drieling...” en “Ja, dat is mijn zus...” 
antwoorden we alle drie regelm atig. Gelukkig hebben we behalve onze looks, ook een 
hele hoop andere dingen gemeen, daarom is het zo fijn met ju llie ! Ik denk dat we met 
z’n drieën voorlopig wel genoeg scripties hebben geschreven, zullen we papa nu maar 
aan het w erk zetten?
Lieve papa en m am a, er staat altijd een bed, glas w ijn  of gedekte tafel klaar, om (zelfs 
met een heel dispuut of 10 collega’s) te genieten van een goed gesprek, heerlijk eten 
en 'gewoon thuis z ijn ’. De van ju llie  geërfde liefde voor koken en mijn hotelschool 
am bities hebben het moeten afleggen tegen Geneeskunde; het tot 2 keer toe worden 
uitgeloot, heeft heel w at tranen en bekeuringen gekost, m aar het is toch gelukt. Dank 
voor ju llie  liefde en de ruim te om eigen keuzes te maken en het w arm e nest om af en 
toe in terug te keren.
M am, je  bent er a ltijd ! Je inbindkunsten worden nu ook al beroemd buiten Nijm egen 
en ik denk dat de verzoeken blijven binnenstrom en.
Papa, al voordat ik begon aan het onderzoek w ist ik dat als ik ooit ging promoveren, 
j i j  m ijn paranim f zou worden. Kan ik eindelijk weer eens zeggen: “boekje voorlezen 
papa”. Na een lange zoektocht tijdens mijn co-schappen naar het vak dat het beste bij 
m ij past, kwam ik toch steeds uit bij de gynaecologie. Ik weet d a tje  trots om me was 
geweest, w elk vak ik ook had gekozen, m aar ik vind het erg bijzonder om m ijn liefde 
voor ons vak met je  te kunnen delen.
Lieve oma, u bent als geen ander in staat om groots te genieten van kleine dingen. Ik 
ben er trots op dat u op de eerste rij zit 2 december!
Liefste Boudewijn, het boekje van je  meisje is af. Al meer dan 10 ja a r probeer je  de 
medische wereld w aarin ik me begeef te begrijpen: het is heerlijk om met jou te 
kunnen relativeren. Zonder jou w as het ECHT niet gelukt.
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Curriculum Vitae
Irene van der Avoort werd op 14 februari 1978 in Eindhoven op de wereld gezet door 
haar moeder met hulp van haar vader. Ze groeide op in Hardenberg en verhuisde op 
haar 17e ja a r naar Helm ond. Na haar eindexam en aan het Dr. Knippenbergcollege in 
Helmond, w as het tijd om te gaan studeren.
Toen ze w as uitgeloot voor Geneeskunde, werd ze nageplaatst voor Biomedische 
Gezondheidsw etenschappen (BGW) in N ijm egen. Tijdens haar studententijd was 
ze als lid actief bij Carolus M agnus en Dispuut Circe. Daarnaast w as ze lid van de 
Opleidingscom m issie en tijdens haar co-schappen secretaris van de KoRaad. Een 
stage bij professor Barker (Medical Research Council, Southam pton, UK) w as al 
gepland, toen ze bij de derde keer meeloten toch werd ingeloot voor Geneeskunde. 
Ze besloot om de studie BGW  eerst af te maken, voordat ze begon aan haar doctoraal 
Geneeskunde.Tijdens de afstudeerstage werkte ze mee aan het promotieonderzoek 
van Ron van Golde naar m annelijke subfertiliteit. Met de nodige vrijstellingen haalde 
ze in 2002 haar doctoraal geneeskunde en kon ze beginnen met haar co-schappen, die 
in augustus 2004 werden afgesloten met het artsexam en.
Direct daarna kon ze voor 4 m aanden aan de slag als zaalarts op de afdeling 
Gynaecologie in het UMC St Radboud te N ijm egen. Daarna startte ze als arts- 
onderzoeker en werd samen met Leon Massuger, Joanne de Hullu en Hans Bulten 
een interne AGIKO-subsidie verkregen, zodat het onderzoeksproject, dat heeft geleid 
tot dit proefschrift, kon worden voortgezet. Ze was betrokken bij de opzet van de 
vulvapoli in het UMC St Radboud en daarvan 2006 tot 2008 ook werkzaam .
Van april 2008 tot en met september 2009 volgde ze het eerste perifere deel van 
de opleiding tot gynaecoloog in het Catharina Ziekenhuis in Eindhoven (opleider 
dr. T.H.T. Hasaart). V anaf 1 oktober 2009 volgt ze in het UMC St Radboud het 
academ ische deel van de opleiding (opleider prof.dr. D.D.M. Braat).
Irene woont samen met Boudewijn de Boe in Nijm egen.
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